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Abstract 
 
Tumor protein D52 (TPD52) is known to be amplified and overexpressed in many 
cancer types. TPD52-amplified cancer cell lines may therefore be sensitive to 
reduced TPD52 expression and dependent on TPD52 for cell survival. Previously, 
TPD52 expression has been associated with ERBB2, suggesting that these 
oncogenes may be co-operating in cancer pathogenesis.  
 
We employed RNA interference approaches to characterise the effects of reducing 
TPD52 expression in breast cell lines according to their TPD52 and ERBB2 
amplification status. Firstly, a panel of 15 breast cell lines was selected based on 
their TPD52 amplification status. These cell lines were subjected to quantitative real-
time (RT-) PCR to determine relative TPD52 DNA copy number and RNA transcript 
levels, while TPD52 protein levels were analysed by Western blotting. The results 
confirmed SK-BR-3 as a TPD52-amplified and overexpressing cell line. Apoptotic 
assays conducted after 72 hours of TPD52 gene knock-down revealed that reduced 
TPD52 expression was associated with increased apoptosis in the TPD52-amplified 
cell line SK-BR-3, relative to non-amplified cell lines (MCF-7, MDA-MB-231, MCF-
10A). These results suggest that the TPD52-amplified cell line SK-BR-3 is most 
sensitive to reduced TPD52 expression.  
 
Next, the effects of TPD52 knock-down were compared with those of another 
oncogene ERBB2, which is amplified in both SK-BR-3 (TPD52 amplified) and BT-474 
(TPD52 non-amplified) cell lines. Apoptosis assay results revealed transiently 
reduced TPD52 expression decreased the survival of these two ERBB2-amplified 
breast cancer cell lines. BT-474 cells were more sensitive to reduced ERBB2 
expression, whereas SK-BR-3 cells were similarly sensitive to reduced TPD52 and 
reduced ERBB2 expression. In SK-BR-3 cells, knock-down of both ERBB2 and 
xii 
 
TPD52 genes led to increased apoptosis, relative to knock-down of either gene 
alone. 
 
We also generated SK-BR-3 cells in which TPD52 expression was stably reduced 
using human TPD52 shRNA vectors, to characterise for the first time the long-term 
consequences of reducing TPD52 expression in breast cancer cells. Reduced 
TPD52 protein expression in stably shRNA-transfected cell lines was confirmed using 
Western blot and immunofluorescence analyses, relative to non-targeting shRNA 
transfected cells. Results in stably TPD52-depleted SK-BR-3 cell lines showed 
increased pERBB2 and pAkt levels, while MTT assays showed no changes in 
proliferation, indicating compensatory effects towards increased ERBB2 signaling to 
ensure cell survival.  
 
In attempting to explain these findings further, we proposed a novel function of 
TPD52. Associations between TPD52 and ERBB2 expression, an oncogene 
promoting lipogenesis, led us to hypothesize that TPD52 expression may be 
associated with lipogenic phenotypes. Lipid droplet-associated proteins (perilipin, 
TIP47, adipophilin) play important roles in regulating the storage of intracellular lipid 
in lipid droplets. As protein-protein associations between TPD52 and both perilipin 
and TIP47 have been reported, we hypothesized that TPD52 overexpression might 
advantage cancer cells by increasing their lipid storage capacity.  
 
TPD52-transfected 3T3 fibroblast cell lines have been previously shown to 
demonstrate transformed phenotypes, relative to vector control cell lines. We 
examined whether TPD52 expression was associated with an increase in the number 
and/or size of lipid droplets in these cell lines, and whether this phenotype is an 
isoform-specific function of TPD52. Fluorescent staining (BODIPY 493/503) of 
TPD52-transfected 3T3 cell lines showed increased lipid droplet numbers and sizes 
xiii 
 
relative to vector control and parental cell lines, as measured by fluorescent intensity. 
Immunofluorescent staining demonstrated that whereas the PAT protein adipophilin 
showed a diffuse cytoplasmic distribution in 3T3 parental and vector control cell lines, 
this was clustered into cytoplasmic structures resembling lipid droplets in TPD52-
transfected 3T3 cell lines. In contrast, 3T3 cell lines expressing the related protein 
TPD2L1, which does not show the same oncogenic potential as TPD52, showed no 
alterations in lipid droplets, and similar adipophilin staining patterns as parent and 
vector controls. 
 
We also investigated TPD52-expressing 3T3 cells’ ability to store exogenous lipids 
by treating cells with oleic acid, a monounsaturated dietary fatty acid. Following oleic 
acid treatment, fluorescent BODIPY 493/503 staining revealed that TPD52-
expressing 3T3 cells formed more lipid droplets, relative to parental and vector 
control cells. However, parental and vector control cells showed greater relative 
increases in lipid droplet numbers, than TPD52-expressing 3T3 cells. Interestingly, 
immunofluorescent staining demonstrated TPD52 redistribution in some TPD52-
expressing 3T3 cells following oleic acid treatment, without affecting TPD52 levels as 
assessed by Western blot analyses. The mechanisms whereby TPD52 expressing 
cells accumulate more lipid droplets require further investigation. 
 
This study therefore identified TPD52 as a survival factor in ERBB2-amplified breast 
cancer cell lines. For the first time, we also provide direct evidence of TPD52 
involvement in regulating cellular lipid storage. TPD52 may therefore co-operate 
indirectly with ERBB2 by regulating lipid storage, possibly via associations with PAT 
proteins. This highlights TPD52 as a candidate therapeutic target in ERBB2-positive 
cancers, or cancers with a lipogenic phenotype. 
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1. Introduction 
 
This review will give a brief introduction to cancer to generate awareness of the rising 
numbers of cancer cases worldwide, hence the urgent need to understand how 
cancer develops. This will be followed by an introduction to oncogenes, and how 
these are involved in cancer formation. The “oncogene addiction” phenomenon will 
be defined and we will explain how this concept can be applied to the development of 
cancer treatments. The ERBB2/HER2 (Human epidermal growth factor receptor 2) 
oncogene will be used as an example of “oncogene addiction”, and we will describe 
how understanding its structure and function led to the development of the drug 
Herceptin for cancer treatment. We will also briefly discuss the significance of altered 
lipid metabolism in cancer pathogenesis, and ERBB2 will be used as an example of 
an oncogene which affects downstream lipid metabolism. Finally, the review will 
introduce the TPD52 (Tumor Protein D52) gene as the focus of this project, which is 
a potential oncogene identified through its overexpression in various types of 
cancers. It will be explained how the “oncogene addiction” concept could be applied 
to TPD52 in terms of developing a new anti-cancer drug specifically for TPD52 
overexpressing cancers.   
 
1.1 Cancer – A global burden of disease  
 
Cancer is considered as one of the leading causes of death worldwide (Mathers and 
Loncar, 2006). In 2008, cancer resulted in 7.6 million deaths, accounting for about 
13% of all human deaths worldwide (Ferlay et al., 2010). The total number of cancer 
cases globally is predicted to continue to rise, with WHO predicting ~13 million 
cancer deaths in 2030 (Ferlay et al., 2010). New cancer cases are estimated to rise 
to 21.4 million in 2030 compared to 12.7 million cases in 2008 (Ferlay et al., 2010). 
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WHO estimates that 84 million people will die of cancer between 2005 and 2015 
without intervention (www.who.int/). In 2003, through the Surveillance, Epidemiology 
and End Results (SEER) Program cancer statistics, Gloeckler Reis et al. reported 
that one of every two men and one of every three women will develop cancer during 
their lifetime (Gloeckler Ries et al., 2003). In Australia currently, the major cancer 
affecting males is prostate cancer and for females the major cancer is breast cancer, 
as reported by the Australian Institute of Health and Welfare (AIHW) and the 
Australasian Association of Cancer Registries (AACR) (AIHW and AACR 2012). The 
four most common cancers for both men and women are colorectal cancer, 
melanoma of the skin, lung cancer and lymphoma (AIHW and AACR 2012). 
Therefore, it is very important to understand the cellular and molecular basis of 
cancer, in order to find ways to either prevent cancer, or cure cancer in a highly 
specific and effective way, at low cost. The cost of treatment is important, as current 
cancer treatments such as chemotherapy are expensive and therefore not always 
available to people in underdeveloped countries (Hanna and Kangolle, 2010).  
 
Cancers detected early are generally associated with a better prognosis and, in many 
cases, can be cured (Kramer and Croswell, 2009; Peto et al., 2004). However, cures 
are not attempted in some advanced cancer cases, where palliative care provides 
better quality of life than aggressive treatment, particularly in the elderly or in patients 
with underlying comorbid disorders (Yancik and Ries, 2000). At present, the 
emerging number of cancer cases around the world is more than the number of 
people cured from cancer (Jemal et al., 2010). There are several factors which could 
improve this situation, such as generating more awareness amongst the general 
public as to the importance of cancer screening or vaccination (e.g. breast cancer, 
cervical cancer) and living a healthy lifestyle (e.g. smokers with lung cancer).  
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1.1.1 Causes of cancer – from alterations in a single cell to tumor formation 
 
There are many different types of cancers affecting different parts of the body. A 
cancer, or tumor, can occur in any organ or tissue of the human body (Weinberg, 
2007). All cancers result from mutations in cellular DNA (Weinberg, 2007). Cancers 
can be due to inherited factors (familial cancer) or can arise sporadically. 
Approximately 90-95% of all cancers are sporadic while the remaining 5-10% are 
familial. Such an example has been described for breast cancer, where family history 
is responsible for about 5 - 10% of breast cancers (De Greve et al., 2008).  
 
Age is a major factor to consider, as the incidence of cancer increases dramatically 
with increased age (Suen et al., 1974). In the United States, the incidence of cancer 
for those aged over 65 has been reported to be 10 times greater than that of people 
aged below 65 (Yancik and Ries, 2000). Furthermore, the cancer death rate was 16 
times greater in cancer patients over 65, compared with that of younger cancer 
patients (below 65) (Berger et al., 2006). More than 70% of the mortality associated 
with cancers including prostate, bladder, colon, uterus, pancreas, stomach, rectum 
and lung occurs in patients 65 and older (Yancik and Ries, 2000). A similar trend has 
also been observed in Australia, where the incidence rates of cancer and the risk of 
being diagnosed with cancer increases with age (Figure 1.1) (AIHW & AACR 2012). 
The association of cancer incidence and increased age is likely underpinned by the 
accumulation of genetic mutations over time, combined with the tendency for cellular 
repair mechanisms to be less effective as a person grows older (Rudolph et al., 
1999; Sharpless and DePinho, 2004). Therefore, while cancer affects people of all 
ages, the risk for most cancer types increases with age. 
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Figure 1.1 Estimated incidence rates of all cancers combined by age at 
diagnosis, Australia, 2012. The Y-axis represents incidence rates (per 100,000 
population) and the X-axis represents age group (in years). Reproduced from 
Australian Institute of Health and Welfare (AIHW) and Australasian Association of 
Cancer Registries (AACR), 2012. 
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Cancer has been regarded as a genetic disease, and as such, cancer-causing 
mutations alter the cell’s life cycle of growth, proliferation, DNA repair and death by 
altering the quantity or function of critical protein products (Ames et al., 1993; 
Bertram, 2000). This leads to the accumulation of more cancer cells and the 
development of a tumor mass. Mutations can arise from environmental or exogenous 
factors such as physical carcinogens (ionizing radiation, UV radiation), chemical 
carcinogens (asbestos, tobacco, aflatoxin, arsenic) or biological carcinogens 
(infections from viruses such as Hepatitis B virus (HBV), Hepatitis C virus (HPC), 
Human papilloma virus (HPV), bacteria or parasites) (Ames, 1984; Ames et al., 1993; 
Anand et al., 2008). Alternatively, DNA damage can also result from endogenous 
processes such as errors in DNA replication (Chen et al., 1999; Lavin and Khanna, 
1999; van Steeg and Kraemer, 1999), the intrinsic chemical instability of certain DNA 
bases, or from free radicals generated during metabolism (Halliwell, 1994; Jones et 
al., 1992; Malkin et al., 1990). The DNA mutation may be a single nucleotide change, 
or a deletion or duplication of longer DNA sequences.  A change in the genetic 
sequence can then lead to the production of a mutant protein. It is usually an 
accumulation of mutations in multiple genes that irreversibly transforms a normal cell 
into a cancerous one (Cahill et al., 1999; Cho and Vogelstein, 1992).  
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1.1.2 Cellular and molecular basis of cancer 
 
Cancer is a multistage process (Grivennikov et al., 2010) (Figure 1.2) involving 
changes to a number of key cellular processes, known as the hallmarks of cancer, 
which were initially proposed in 2000 (Hanahan and Weinberg, 2000). These key 
processes or hallmarks are self-sufficiency in growth signals, insensitivity to growth 
inhibitory signals, protection against programmed cell death or apoptosis, 
unregulated/uncontrolled growth (division beyond normal limits), sustained 
angiogenesis, local tissue invasion (intrusion on and destruction of adjacent tissues), 
and often metastasis (spread of cancer cells to other locations in the body via the 
lymphatic system or blood) (Hanahan and Weinberg, 2000) (Figure 1.3). Since then, 
the cellular changes depicting the hallmarks of cancer have been revisited and 
updated. A recent review included additional hallmarks of cancer that describe the 
stress phenotypes of cancer cells, namely metabolic stress, proteotoxic stress, 
mitotic stress, oxidative stress and DNA damage stress (Luo et al., 2009) (Figure 
1.3). Another hallmark has also been recently proposed, namely the evasion of 
immune surveillance (Kroemer and Pouyssegur, 2008). A detailed understanding of 
these hallmarks is important in order to develop new therapeutic strategies for 
treating cancer (Hanahan and Weinberg, 2011). 
 
Two main categories of mutated genes contribute towards tumor development, 
namely oncogenes and tumor suppressor genes (Hanahan and Weinberg, 2000). In 
many cases, oncogenes promote cell proliferation whereas tumor suppressor genes 
inhibit this, and the activities of these two gene classes are optimally balanced under 
physiological conditions. Most mutations in oncogenes contribute to cancer 
development by allowing dominant gains of function, whereas inactivation of most 
tumor suppressor genes occurs through recessive loss of function mutations. 
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Figure 1.2 Cancer initiation and progression, from changes in a single cell 
through to metastatic cancer. Reproduced from Grivennikov et al. (2010) 
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Figure 1.3 Hallmarks of cancer. The acquired properties of a tumor cell (shown on 
the outside of the circle) and their cellular consequences (shown on the inside of the 
circle). Reproduced from Luo et al. (2009) 
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1.2 Oncogenes  
 
Oncogenes are genes with the ability to induce tumor formation and malignancy 
when mutated or expressed at high levels (Adamson, 1987; Croce, 2008). They are 
the mutated forms of cellular proto-oncogenes, that encode proteins which regulate 
various aspects of normal cell growth and differentiation (Adamson, 1987). Proto-
oncogenes can be classified into groups, based upon their normal function within 
cells or based upon sequence homology to other known proteins. There are five 
broad types of proteins encoded by proto-oncogenes: growth factors, receptors for 
growth factors and hormones, intracellular signal transducers, nuclear transcription 
factors and cell-cycle control proteins (Croce, 2008).  
 
Oncogenes can usually act in a dominant fashion through gain of function and only 
one allele has to be altered for phenotypic consequences. Oncogenes can be 
activated via retroviral transduction or integration, point mutations (Konopka et al., 
1985; Rous, 1911; Stehelin et al., 1976), gene amplification (i.e, an increase in the 
number of copies of an otherwise normal gene) (Press et al., 1997; Schwab et al., 
1983) and/or chromosomal translocation (Finger et al., 1986; Tsujimoto et al., 1985). 
Activation of oncogenes may result in the direct and continuous stimulation of 
signaling pathways that control cellular growth and division, DNA repair, 
angiogenesis and other physiologic processes (Croce, 2008). Examples of well 
characterised oncogenes and their involvement in various types of cancers are 
shown in Table 1.1. As inhibiting the function of a mutant protein, or reducing the 
activity of a non-mutant protein is currently more feasible than restoring a function 
that has been lost, oncogenes are prime targets for anticancer therapies (Table 1.2). 
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Table 1.1 Examples of oncogenes involved in human cancers 
Gene 
name 
Protein function Examples of cancers 
involved 
Nature of 
dysregulation 
 
Bcl-2 
 
Apoptosis inhibitior 
 
B cell lymphomas 
 
Chromosomal 
translocation 
 
c-myc 
 
Transcription factor, 
Activates other growth 
promoting genes 
 
Leukemia, breast, 
stomach and lung 
cancers   
 
Chromosomal 
translocation/gene 
amplification 
 
K-ras 
 
Small GTPase,  
Involved in proliferation 
signaling pathways 
 
Lung, ovarian, colon and 
pancreatic cancers 
 
Gene mutation 
 
ERBB2/
Her2 
 
ligand-less receptor of 
the EGFR family  
 
Breast, salivary gland 
and ovarian cancers 
 
Gene amplification 
Adapted from Weinstein et al. (2006) 
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Table 1.2 Cancer therapies that target oncogenic proteins 
Anticancer Drug Types 
Name (Trade name, Company) 
Target(s) Approved cancer type(s) 
 
Monoclonal antibodies 
  
    Trastuzumab (Herceptin, Genentech) ERBB2 Breast 
    Cetuximab (Erbitux, ImClone) EGFR Colon 
    Bevacizumab (Avastin, Genentech) VEGF Colon, NSCLC 
 
Small molecules 
  
    Imatinib (Gleevec, Novartis) ABL, 
PDGFR, 
KIT 
Chronic myelogenous 
leukemia, gastrointestinal 
stromal tumors, chordoma 
    Gefitinib (Iressa, AstraZeneca) EGFR NSCLC 
    Erlotinib (Tarveca, Genentech) EGFR NSCLC 
    Sorafenib (Nexavar, Bayer/Onyx) VEGFR, 
PDGFR, 
FLT3 
Renal cell carcinoma 
    Sunitinib (Sutent, Pfizer) VEGFR, 
PDGFR, 
FLT3 
Gastrointestinal stromal 
tumors, renal cell 
carcinoma 
 
ABL/ABL1 = Abelson murine leukemia viral oncogene homolog 1; EGFR = Epidermal 
growth factor receptor; ERBB2/HER2 = Human epidermal growth factor receptor 2; 
FLT3 = FMS-like tyrosine kinase 3; PDGFR = platelet-derived growth factor receptor; 
VEGF = vascular endothelial growth factor; NSCLC = non-small cell lung cancer. 
Adapted from Croce et al. (2008) 
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1.2.1 The “oncogene addiction” concept 
 
Interestingly, some tumors have been shown to be physiologically dependent on 
(addicted to) the uninterrupted activity of a single mutated oncogene for maintaining 
tumor survival and proliferation (Weinstein, 2000). Disruption of the respective 
oncogene leads to apoptosis, selective growth arrest, and/or differentiation of the 
malignant cells. This important phenomenon, termed “oncogene addiction” 
(Weinstein, 2002), has been documented in multiple mouse tumor models, cell 
culture models, and human clinical trials involving specific molecularly targeted 
inhibitors (Weinstein, 2000; Weinstein and Joe, 2006). These addicted oncogenes 
and the cellular pathways hijacked by them make attractive therapeutic targets. An 
example is chronic myeloid leukemia and the selective tyrosine kinase inhibitor 
Gleevec that preferentially and dramatically acts on tumor cells addicted to the 
tyrosine kinase BCR-ABL, and causes rapid cancer regression with only limited side 
effects (Druker et al., 2001; Shah and Sawyers, 2003). This example indicated that 
tumor cells can default to an apoptotic outcome in response to oncogene inactivation, 
leading to complete tumor regression (Weinstein, 2000). However, the precise 
mechanism underlying how this phenomenon occurs is still unclear and requires 
further investigation. Oncogenes which are mutated or gene amplified, and not 
simply overexpressed are more likely targets for therapy, reflecting “hard-wiring” of 
cancer cells as opposed to epigenetic abnormalities (Weinstein and Joe, 2008). This 
“hard-wiring” reflects cancer cells being more dependent on these oncogenes for 
both maintaining the malignant phenotype, and for cancer cell survival.  
 
Another example to explain the rational of the oncogene addiction concept is the 
ERBB2 gene that has been shown to be amplified and overexpressed in breast 
cancer cell lines as well as in patients (Berger et al., 1988; Press et al., 1997) and 
which led to the development of trastuzumab/herceptin, a humanized monoclonal 
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antibody (Baselga et al., 1998; Harries and Smith, 2002; Hudis, 2007). The response 
of ERBB2 amplified breast cancers to Herceptin is further support for the oncogene 
addiction hypothesis. A better understanding of the basis of oncogene addiction is 
expected to identify critical predictive biomarkers for assessing patients’ suitability for 
therapy. Overall, a better understanding of oncogene addiction will contribute 
towards the development of new cancer treatments, and the best way to use these in 
the clinic. 
 
1.3 ERBB2: an example of the “oncogene addiction” phenomenon 
 
1.3.1 ERBB receptors: structure 
 
ERBB2 is part of a family consisting of 4 members, namley EGFR/HER1, 
ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4. These 4 belong to the subclass 1 
of the receptor tyrosine kinase (RTK) superfamily, according to their sequence 
homology and domain organization (Yarden and Sliwkowski, 2001) (Figure 1.4). 
They were named due to their homology to the viral ERBB (v-ERBB) oncogene 
(Schechter et al., 1984). These ERBB receptors share a common structure: an 
extracellular ligand-binding domain containing 4 subdomains, a transmembrane 
domain with a single hydrophobic anchor sequence and an intracellular region, with a 
catalytic tyrosine kinase domain. The tyrosine kinase domain is important for the 
activation/induction of intracellular signaling (Figure 1.4) (Yarden and Sliwkowski, 
2001). The ERBB family members show individual differences, such as the intrinsic 
tyrosine kinase activity for ERBB3 being impaired (Guy et al., 1994).  
 
ERBB2 or HER2 (Human Epidermal growth factor Receptor 2) was cloned by 
homology screening with v-ERBB, and its amino acid sequence was shown to be 
structurally homologous to that of EGFR (Coussens et al., 1985; Schechter et al., 
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1985). Neu, the rat homologue of ERBB2, was identified as a transforming gene 
activated in chemically induced rat neuroectodermal tumors (Shih et al., 1981). The 
ERBB2 proto-oncogene, located at chromosome 17q21-q22 (37.8 - 37.9 MB), 
encodes a protein of 185 kDa (Coussens et al., 1985; Schechter et al., 1984).  
 
 
 
Figure 1.4 ERBB family receptors and their cognate ligands. Each receptor 
consists of three domains: a ligand-binding extracellular domain containing two 
cysteine-rich regions (CR1 and CR2), a transmembrane domain, and an intracellular 
domain containing a tyrosine kinase region. Note that ERBB2/HER2 has no known 
ligands and that ERBB3/HER3 has no intrinsic tyrosine kinase activity. (EGF = 
epidermal growth factor; EGFR = EGF receptor; HER = human epidermal receptor; 
HB-EGF = heparin-binding EGF; NRG = neuregulin; TGF- = transforming growth 
factor-). Reproduced from Rowinsky et al. (2004) 
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1.3.2 ERBB receptors: signal transduction 
 
Signal transduction via the ERBB family receptors is initiated by ligand binding. Upon 
ligand binding, receptor homo/heterodomerisation occurs and each receptor subunit 
is activated by transphosphorylation of tyrosine residues in the receptor C-terminus 
(Ferguson, 2008) (Figure 1.5). Phosphorylated tyrosine residues serve as docking 
sites for a host of intracellular signaling molecules, leading to the activation of diverse 
signaling cascades such as the mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K) signaling pathways that mediate the physiological 
changes ascribed to ERBB receptors (Olayioye, 2001; Schlessinger, 2000) (Figure 
1.5). These changes include regulation of cell growth, differentiation, motility and 
inhibition of cell death (Rowinsky, 2004). Disruption of any pathway component such 
as ERBB ligands, receptors, downstream signaling molecules or transcriptional 
targets has been reported to have profound consequences for both normal 
development and malignant transformation in multiple tissues (Landis et al., 2005; 
Rowinsky, 2004). 
 
ERBB receptors are activated by members of the EGF family of ligands (Figure 1.4). 
These ligands contain an EGF-like domain comprised of a motif of ~50 amino acids, 
including 6 cysteine residues, with two stranded β-sheet structure (Yarden and 
Sliwkowski, 2001). Unlike other members of the ERBB family, ERBB2 has no known 
ligand and is therefore also known as an orphan receptor (Klapper et al., 1999; 
Rowinsky, 2004). For this reason, activation of ERBB2 is dependent on its 
association with other ERBB family members to form functional heterodimers (Figure 
1.5). Interestingly, ERBB2 has been found to be recruited as the preferred 
heterodimeric partner of ERBB3 (Graus-Porta et al., 1997; Karunagaran et al., 1996; 
Sliwkowski et al., 1994). Of all the ERBB heterodimers, ERBB2-ERBB3 heterodimers 
elicit the strongest signal (Alimandi et al., 1995; Graus-Porta et al., 1997; Pinkas-
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Kramarski et al., 1996; Stern, 2008). Removing ERBB3 from the cell has a drastic 
effect on ERBB2 mediated signaling and downstream effectors (Stern, 2008). ERBB2 
has been shown to also form heterodimers with EGFR and ERBB4 as well as other 
non-ERBB receptors, such as the gp130 subunits of the IL-6 receptor (Rowinsky, 
2004). In at least some cell types, the association between gp130 and ERBB2 is 
essential for ERBB2-ERBB3 phosphorylation and subsequent MAPK signaling (Grant 
et al., 2002). MAP kinases are important mediators of signal transduction, and 
activation of this pathway has been linked to cell proliferation and differentiation 
(Keshet and Seger, 2010). The EGFR-ERBB2 complex increases the signaling 
capacity of EGFR by increasing ligand affinity, as well as recycling of the heterodimer 
(Hendriks et al., 2003; Karunagaran et al., 1996; Wada et al., 1990). Extensive 
receptor–receptor interactions and the existence of numerous ligands (Figure 1.5) 
highlight the enormous potential for diversification of biological messages mediated 
by the ERBB family (Graus-Porta et al., 1997; Rowinsky, 2004). 
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Figure 1.5 An overview of ERBB signaling. ERBB2/HER2 receptor pairs with itself 
(homodimerization, when overexpressed) or with other epidermal growth factor 
receptors (EGFR/HER1, HER4, HER3) that have bound their respective ligands 
(heterodimerization), leading to activation of the intracellular tyrosine kinase domains. 
A phosphorylation (P) cascade is activated whereby key downstream effectors are 
recruited and this results in activation of multiple intracellular pathways, including 
mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K), 
which promote cell proliferation, survival, cycle progression and inhibit apoptosis. 
(Akt/PKB = Protein kinase B; MEK = MAPK kinase; RAS = rat sarcoma; RAF = 
Rapidly Accelerated Fibrosarcoma; SOS = son-of-sevenless guanine nucleotide 
exchange factor; VEGF = Vascular endothelial growth factor). Reproduced from 
Hudis (2007).  
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1.3.3 ERBB2 amplification and cancer 
 
ERBB2 is activated by gene amplification in some 15 - 30% of breast cancers and 
this is associated with increased ERBB2 protein expression (Berger et al., 1988; 
Slamon et al., 1987). ERBB2 gene amplification and overexpression were also found 
in other types of cancers including ovarian and stomach cancers (Berchuck et al., 
1990; Park et al., 1989; Slamon et al., 1989). Furthermore, ERBB2 overexpression 
was associated with increased disease recurrence and worse prognosis in breast 
cancer patients (Borg et al., 1991; Guerin et al., 1988; Slamon et al., 1987; Varley et 
al., 1987). This led to the suggestion that ERBB2 overexpression produced by gene 
amplification plays an important role in tumor development.  
 
ERBB2 overexpression is the predominant mechanism involved in cancer 
tumorigenesis, and it has been proposed that ERBB2 amplification overcomes 
repression of ERBB2 expression by sequence-specific transcription factors 
(Birnbaum et al., 2009). However ERBB2 mutations have been reported in breast, 
gastric, colorectal and lung cancers (Bekaii-Saab et al., 2006; Buttitta et al., 2006; 
Cohen et al., 2005; Kubo et al., 2009; Lee et al., 2006; Stephens et al., 2004). 
Overexpression of ERBB2 resulted in ligand-independent signaling in mouse 
fibroblasts and this was assumed to occur in human breast cancers as well (Hudziak 
et al., 1987). In vitro studies of ERBB2 overexpression showed that this produced 
increased cell motility, increased sensitivity to mitogenic stimuli, anchorage 
independence and cell transformation (Brandt et al., 1999; Chazin et al., 1992; 
Ignatoski et al., 1999; Spencer et al., 2000). Studies in vivo confirmed the oncogenic 
potential of ERBB2 in the mammary epithelia of transgenic mice (Bouchard et al., 
1989; Guy et al., 1996; Muller et al., 1988). Overexpression of the unactivated rat 
neu protein (neu proto-oncogene) in the mammary epithelium resulted in transgenic 
mice stochastically developing focal mammary tumors and pulmonary metastases 
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after a long latency (Guy et al., 1992). These findings all supported ERBB2 as an 
oncogene involved in the development of breast and other cancers.  
 
Identification of ERBB2 amplification and overexpression in cancer led to the 
development of the monoclonal antibody trastuzumab (HerceptinTM, manufactured by 
Roche-Genentech, CA, USA), that targets the extracellular domain of ERBB2 (Figure 
1.6). Trastuzumab is only effective in ERBB2-overexpressing cancers. Numerous 
human trial observations have shown trastuzumab to be an effective treatment for 
patients with ERBB2-overexpressing breast cancer (Hudis, 2007). The high success 
rate of trastuzumab in treating breast cancer patients with ERBB2 amplification 
validates the importance of this receptor in sustaining breast tumors (Piccart-Gebhart 
et al., 2005; Romond et al., 2005). Growing evidence showing ERBB2 amplification 
in other types of cancers, such as ovarian, stomach and uterine cancers (Lassus et 
al., 2004; Santin et al., 2005; Tanner et al., 2005), have led to trials examining 
whether trastuzumab could also be used to treat these cancers (Fleming et al., 2010; 
Gravalos and Jimeno, 2008). 
 
There have been numerous studies of the mechanism of action of trastuzumab, and 
even though it is still not completely known, several mechanisms have been 
proposed (Hudis, 2007) (Figure 1.6). This includes binding of trastuzumab to ERBB2 
inhibiting the cleavage of the ERBB2 extracellular domain (Molina et al., 2001), as 
well as interfering with ERBB2 dimerization with other ERBB receptors (Junttila et al., 
2009), and disrupting the activation of downstream signaling pathways. Increased 
endocytotic destruction of ERBB2 has also been observed in vitro (Raja et al., 2008) 
but this remains to be demonstrated in vivo (either in pre-clinical xenograft models or 
clinical studies) (Fiszman and Jasnis, 2011). Antibody-dependent immune 
menchanisms induced upon trastuzumab treatment have also been proposed. 
Studies using animals deficient in immune-cell-activating Fc receptors (on effector 
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cells) showed no response upon trastuzumab treatment, suggesting that trastuzumab 
recruits immune effector cells that are responsible for antibody-dependent cell-
mediated cytotoxicity (Clynes et al., 2000). Trastuzumab treatment was also reported 
to decrease vascular endothelial growth factor (VEGF) protein levels, which was 
proposed to be due to trastuzumab interfering with the dimerization between ERBB-
family receptors, but this was only shown in vitro (Izumi et al., 2002; Kumar and 
Yarmand-Bagheri, 2001). VEGF production activates angiogenesis, or the formation 
of new blood vessels, and is important for maintaining tumor growth (Hoeben et al., 
2004). Treatment with trastuzumab has been reported to affect cell cycle regulators 
such as p27, an inhibitor of cell proliferation, which was shown to be induced upon 
trastuzumab treatment through ERBB2 binding (Le et al., 2005).  
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Figure 1.6 HerceptinTM/Trastuzumab targeting of the ERBB2 receptor. (A) 
Trastuzumab is a humanized monoclonal antibody that binds to ERBB2/HER2 and 
inhibits tumor-cell growth through a variety of intracellular, and possibly extracellular, 
mechanisms. (B) Cleavage of the extracellular domain of HER2 leaves a membrane-
bound phosphorylated p95, that allows the activation of downstream signal-
transduction pathways. Binding of trastuzumab to a juxtamembrane domain of HER2 
reduces shedding of the extracellular domain, p95, thereby reducing signal 
activation. (C) Trastuzumab may also reduce HER2 signaling either by 
homodimerization, or heterodimerization inhibition between the ERBB receptors. (D) 
Trastuzumab may also induce tumor-cell death via activation of antibody-dependent 
cell-mediated cytotoxicity. (E) HER2 down-regulation upon trastuzumab binding 
through endocytosis has also been proposed. Reproduced from Hudis (2007). 
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1.4 Lipid metabolism 
 
1.4.1 Overview of biological functions of lipids in mammalian cells 
  
In order for an organism to function properly, a variety of nutrients are needed, 
including fats or lipids, carbohydrates, proteins, and vitamins that can be obtained 
from the diet. Proliferating cells require nutrients, energy, and biosynthetic activity to 
generate biomass (proteins, lipids, nucleic acids) for cell growth (DeBerardinis et al., 
2008).  
 
Lipids are a diverse and ubiquitous group of hydrophobic compounds which play 
important roles in numerous biological functions in humans and other organisms 
(Wenk, 2005). Cells require lipids as another source of energy in addition to 
carbohydrates, as secondary messengers in signaling pathways, and also for 
building cell membrane structures (Figure 1.7) (Wenk, 2010). Lipids are the primary 
structural components of all cell membranes. As cells die and are degraded, there is 
a continuous demand for lipids for cell maintenance and growth. Lipids are the major 
constituents of adipose tissue, which provides insulation against heat loss, and forms 
protective cushions surrounding major organs (Kremmyda et al., 2011). Dietary lipids 
are also important for facilitating the absorption of fat-soluble vitamins (A, D, E, and 
K) and carotenoids (Kremmyda et al., 2011). Lipids can either be obtained from the 
diet, or synthesized de novo (lipogenesis). At times where lipids are in excess, they 
are primarily stored in fat cells or adipocytes within the organelle known as the lipid 
body or lipid droplet. 
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Figure 1.7 The cellular compartments of common biological lipids. The lipid 
portion of biological membranes is made up to a large extent of phospholipids (e.g. 
glycerophospholipids), sterols, and sphingolipids (blue box, top left). Some 
organelles are enriched with particular lipids (examples, cardiolipin in mitochondria 
and lysobisphosphatidic acid/bis(monoacylglycero)phosphate in endosomes), and 
lateral distribution within membranes leads to functional domains. Metabolism of 
membrane lipids generates highly active signaling molecules (purple box, top right). 
Very nonpolar lipids, such as sterol-esters and triacylglycerides, are assembled in the 
endoplasmic reticulum and stored in lipid bodies/droplets within cells (green box, 
bottom right). Reproduced from Wenk (2010). 
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1.4.1.1 Fatty acids – structure, types and biological functions 
 
Many cellular lipids are built from fatty acids, which consist of a carboxyl head group 
followed by a hydrocarbon chain (Figure 1.8) (Evans and Hardy, 2010). Fatty acids 
can be saturated or unsaturated, depending on the structure of their hydrocarbon 
chains. Saturated fatty acids such as stearic acid and palmitic acid lack double C-C 
bonds, whereas unsaturated fatty acids have either one or two double bonds (Evans 
and Hardy, 2010) (Figure 1.8). The former cases are known as monounsaturated 
fatty acids (MUFA, one double bond), such as oleic acid, whereas the latter are 
known as polyunsaturated fatty acids (PUFA, two or more double bonds), such as 
linoleic (omega-6 PUFA) and linolenic (omega-3 PUFA) acids (Evans and Hardy, 
2010). PUFA are also known as essential fatty acids, because humans and other 
mammals are not able to synthesize PUFA, and therefore they can only be obtained 
from the diet (Evans and Hardy, 2010; Tvrzicka et al., 2011). PUFA are important 
biosynthetic precursors of arachidonic and eicosapentaenoic acids which are then 
precursors to eicosanoids (hormone-like lipid molecules), including prostaglandins, 
luekotrienes and thromboxanes (Evans and Hardy, 2010). Eicosanoids are known to 
be involved in regulating blood clotting, inflammatory response and the reproductive 
system (Evans and Hardy, 2010). 
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Figure 1.8 Fatty acid nomenclature. (A) Fatty acids are composed of a carboxyl 
head group followed by a hydrocarbon-like chain. The first carbon on the head group 
is known as the α-carbon, whereas the second is the -carbon, and so on. The final 
carbon is known as the ω-carbon. Unsaturated fatty acids are classified based on the 
position of the first double bond from the ω-carbon, and the number of double bonds 
present. B) Saturated fatty acids, such as stearate, have no double bonds. Stearate 
is also referred to as C18:0, as stearate has 18 carbon atoms in the hydrocarbon 
chain, and no double bonds. Monounsaturated fatty acids, such as oleate, have one 
double bond (hence C18:1), and polyunsaturated fatty acids such as linoleate 
(C18:2) have more than one double bond. Oleate is termed a ω-9 fatty acid, because 
the double bond occurs 9 carbons from the omega carbon. In contrasts, linoleate is 
an ω-6 fatty acid. Reproduced from Evans and Hardy (2010).  
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Lipid metabolism plays an important role in energy homeostasis, and involves the de 
novo synthesis of fatty acids (lipogenesis) and the degradation of stored lipid 
(lipolysis). These processes are described in detail in the following sections (Section 
1.4.2.1 and 1.4.2.2). Lipogenesis results in the production of various types of lipids, 
from basic lipids such as palmitic and stearate acids, to more complex lipids such as 
phospholipids and sphingolipids. Fatty acids obtained from the diet or synthesized de 
novo are then used as building-blocks for more structurally complex lipids. Free fatty 
acids (or unesterified fatty acids) are either oxidized immediately for energy 
consumption through the -oxidation pathway as an alternative pathway for energy 
production (Kunau et al., 1995), used as secondary messenger signaling molecules, 
or esterified/ re-esterified into diacylglycerides (DAGs, composed of 2 fatty acids and 
glycerol) or triacylglycerides (TAGs, composed of 3 fatty acids and glycerol), which 
are packaged into lipid droplets for energy storage (Evans and Hardy, 2010; Tvrzicka 
et al., 2011).  
 
Alternatively, organic or inorganic compounds can be added to the fatty acid and 
glycerol backbone such as in the formation of phosphoglycerides (PG) and 
cholesterol esters (CE) (Figure 1.7) (Wenk, 2010). Phosphoglycerides contain a 
phosphate group added to the fatty acid and glycerol backbone, and form a basic 
component of plasma membranes (Fahy et al., 2005). Sterols are composed of four 
fused carbon rings with a long hydrocarbon side chain, and an example is 
cholesterol, another essential component of mammalian cell membranes (Fahy et al., 
2005). Cholesterol is also a precursor of bile acids, Vitamin D and several steroid 
hormones such as corticosteroids, testosterones and oestrogens (Kremmyda et al., 
2011). These steroid hormones are critical as intercellular secondary messengers. 
Sphingolipids such as sphingomyelins are another important structural component of 
the cell membrane (Kremmyda et al., 2011). Phosphoglycerides, sphingolipids, and 
sterols are therefore essential structural components of mammalian cell membranes, 
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as well as being involved in intracellular signaling and hormonal regulation (Figure 
1.7) (Wenk, 2010). 
 
Saturated fatty acids have been connected to adverse health effects, whereas 
unsaturated fatty acids are thought to be more beneficial for human health. Excess 
saturated fatty acids (due to a diet high in saturated fatty acids) have been reported 
to be associated with diseases such as diabetes, obesity and cardiovascular related 
diseases (Kremmyda et al., 2011). It is notable that palmitic acid is both the first fatty 
acid product once synthesized de novo, and also the most abundant saturated fatty 
acid in the human diet. In contrast, unsaturated fatty acids such as eicosanoids 
derived from linolenic acids (PUFA) have been shown to have anti-inflammatory, 
anti-thrombotic and anti-tumorigenic effects (Evans and Hardy, 2010; Kremmyda et 
al., 2011). 
 
 
1.4.2 Lipid metabolism pathways 
 
1.4.2.1 Lipogenesis or de novo fatty acid synthesis 
 
Fatty acids can be obtained either exogenously from the diet (e.g. linoleate and 
linolenate) or endogenously de novo (e.g. palmitate). Lipogenesis mainly occurs in 
the liver and adipose tissue (Strable and Ntambi, 2010) or the lactating breast 
(Anderson et al., 2007). There are two main enzymes involved in de novo fatty acid 
synthesis or lipogenesis, acetyl-CoA carboxylase (ACC/ACACA) (Brownsey et al., 
2006) and fatty acid synthase (FASN) (Asturias et al., 2005; Chirala and Wakil, 2004) 
(Figure 1.9). ACC is the rate limiting enzyme that converts acetyl-CoA to malonyl-
CoA. Acetyl-CoA and NADPH are derived from glucose and glutamine metabolism 
respectively. FASN then catalyses fatty acid synthesis through condensation of 
acetyl-CoA (primer) and malonyl-CoA (carbon donor), in the presence of NADPH as 
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a reducing equivalent, to produce palmitate, a 16 carbon saturated fatty acid. Newly 
synthesized saturated fatty acids can be further modified to longer fatty acids by 
elongases, or unsaturated fatty acids by desaturases (e.g. stearoyl-CoA desaturases, 
such as SCD1). These processes will form more complex fatty acids such as 
diacylglycerides, phosphoglycerides, triacylglyerides and cholesterol esters. The 
elongation and desaturation of fatty acids occurs at the endoplasmic reticulum (ER) 
membrane (Cook and McMaster, 2002). These complex fatty acids such as 
phosphoglycerides, are important for maintaining the cell’s membrane structure and 
other cellular processes (as described in Section 1.4.1.1).  
 
Excess free fatty acids such as palmitate are toxic to cells, and induce a form of cell 
death known as lipotoxicity (Hardy et al., 2003; Hardy et al., 2000; Listenberger et al., 
2003). One possible explanation for this is that palmitate could be used to generate 
ceramide, a proapoptotic secondary messenger (Obeid et al., 1993). If there is an 
excess of free fatty acids (i.e. during excessive food intake), these will be esterified 
and converted into triacylglycerides and stored in lipid droplets in adipocytes. 
Previously considered to be an inert organelle, lipid droplets have multiple roles in 
balancing lipid turnover, membrane and lipid trafficking, protein storage and 
degradation, and the proliferation of pathogenic viruses (Walther and Farese, 2012). 
Lipid droplet biology will be discussed further in Chapter 4. Adipocytes are 
specialized cells which can store large amounts of excess lipid in lipid droplets, in 
contrast to non-adipocytes which have more limited lipid storage capacity 
(Brasaemle, 2007). Diseases associated with excess lipid accumulation in non-
adipose tissues include obesity, diabetes and cardiovascular-related diseases 
(Garbarino and Sturley, 2009).  
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Figure 1.9 Overview of the lipid metabolism pathway. Free fatty acids (FFA) are 
obtained either exogenously (i.e. dietary lipids, saturated or unsaturated) or 
synthesized de novo (lipogenesis) or through degradation of lipid stores/lipid droplets 
(lipolysis). Metabolism of both glutamine and glucose supplies citrate and supports 
the production of acetyl-CoA and NADPH (nicotinamide adenine dinucleotide 
phosphate-oxidase) needed for lipogenesis. Acetyl-CoA is the precursor for both fatty 
acid synthesis and cholesterol synthesis. Free fatty acids are processed into complex 
lipids which are then utilized for cell membrane formation (phospholipids, such as 
phosphatidylcholine (PC) and phosphatidylethonalomine (PE)) or stored as 
triacylglycerides (TAG) and cholesterol esters (CE) in lipid droplets. Free fatty acids 
are also used as an alternative source of energy through the -oxidation pathway in 
mitochondria when glucose stores are limited, such as during fasting. (ACC = acetyl-
CoA carboxylase, ACLY = ATP citrate lyase, FA = fatty acids, FASN = fatty acid 
synthase). Adapted from Kamili and Byrne (in press). 
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1.4.2.2 Lipolysis – degradation of lipids from lipid storage 
 
Lipolysis occurs at times of energy deprivation, such as exercise and fasting. 
Specifically, lipolysis is the process whereby triacylglycerides stored in lipid droplets 
are hydrolyzed by lipases, releasing fatty acids. These will either be used as energy 
substrates through the -oxidation pathway, or re-esterified as essential precursors 
for lipid and membrane synthesis, or as mediators in cell signaling processes (Figure 
1.10) (Jaworski et al., 2007). Activation of lipolysis is tightly regulated by insulin and 
catecholamine secretion, which is dependent upon nutritional regulation. In the fed 
state, insulin functions to suppress lipolysis and insulin is the most potent anti-
lipolytic hormone. In contrast, catecholamines are the major regulators stimulating 
lipolysis during fasting. Adipose triacylglyceride lipase (ATGL) and hormone-sensitive 
lipase (HSL) are the major enzymes involved in lipolysis within adipocytes 
(Schweiger et al., 2006).  
 
Lipolysis of stored triacyglycerides in lipid droplets is a sequential process requiring 
several steps. Catecholamine binding to -adrenergic G-protein coupled receptors 
activates cAMP-dependent PKA (Figure 1.10). This will activate the release of CGI-
58 from perilipin to interact with and activate ATGL, the primary triacylglyceride lipase 
for basal lipolysis (Granneman et al., 2007; Gruber et al., 2010; Subramanian et al., 
2004; Zimmermann et al., 2004). ATGL is the primary lipase for hydrolysing the first 
fatty acid from triacylglyceride to yield diacylglyceride (DAG) (Zimmermann et al., 
2004). DAG is then hydrolysed by HSL, the primary DAG lipase, to yield 
monoacylglyceride (MAG). Finally, monoacylglyceride lipase (MAGL) is responsible 
for hydrolysing MAG into the final fatty acid and glycerol molecules. Therefore, during 
the lipolytic process, one molecule of glycerol and three fatty acid molecules are 
produced by the hydrolysis of one molecule of triacylglyceride. 
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Figure 1.10 Regulation of lipolysis in adipocytes. Lipolysis is under tight control, 
being stimulated during fasting by increased catecholamines (via increased cAMP) 
and glucocorticoids but suppressed in the fed state by insulin. Lipolysis is catalyzed 
by 3 lipases. Desnutrin/ATGL predominantly performs the initial step in 
triacylglyceride (TAG) hydrolysis, resulting in the formation of diacylglyceride (DAG) 
and fatty acid (FA). Hormone sensitive lipase (HSL) catalyzes hydrolysis of TAG, 
DAG, and monoacylglyceride (MAG) at a ratio of 1:10:1 in vitro. Monoacylglyceride 
lipase (MGL/MAGL) catalyzes hydrolysis of MAG to form glycerol and FA. AC = 
adenylate cyclase, α AR = alpha-adrenergic receptor, ATP = adenosine triphosphate, 
 AR = beta adrenergic receptor, cAMP = cyclic adenosine 3',5'-monophosphate, 
Gαs = stimulatory GTP-binding protein alpha subunit, Gα1 = inhibitory GTP-binding 
protein alpha subunit, IR = insulin receptor, IRS = insulin receptor substrate, PDE3B 
= phosphodiesterase 3B, PKA = protein kinase A, PI3K/PKB = protein kinase B, PP1 
= protein phosphatase-1. Reproduced from Jaworski et al. (2007). 
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Dysregulation of lipolysis has been shown to be detrimental to cell metabolism. For 
example, impairment of ATGL activity leads to reduced lipolysis, and increased 
triacylglyceride deposition in multiple tissues in both human (Fischer et al., 2007; 
Lefevre et al., 2001) and mouse (Haemmerle et al., 2006) is a factor leading to 
obesity and insulin resistance. In contrast, uncontrolled lipolysis in the context of 
lipodystrophy syndrome leads to the release of toxic free fatty acids into the 
bloodstream (Garg and Agarwal, 2009). As a consequence, an excess of free fatty 
acids will be imported into non-adipocytes, leading to intracellular free fatty acid 
accumulation which could result in lipotoxcity, as described earlier (Section 1.4.2.1).     
 
1.4.3 Altered cellular metabolism in cancer 
 
As discussed in section 1.1.2, cancer is a disease involving numerous altered 
signaling pathways (Greaves and Maley, 2012). Cancer cells are highly proliferating 
cells hence their bioenergetic and biosynthetic demands are higher compared to 
normal healthy cells. Cancer cells were initially recognized by Otto Warburg in the 
1920s to exhibit differential cellular metabolism capabilities compared to non-
cancerous cells. Since termed the “Warburg effect”, Otto Warburg observed that 
cancer cells consumed high amounts of glucose and produced high levels of lactic 
acid under aerobic conditions (Warburg, 1956b). He concluded possible impairment 
of mitochondrial regulation in cancer cells (Warburg, 1956a). However, it was 
reported that most highly proliferative tumor cell lines showed no defects in oxidative 
metabolism (Moreno-Sanchez et al., 2007). Recent reports of genomic and 
transcriptomic data revealed alterations of lipid-associated genes, hence providing 
critical evidence of altered metabolic pathways in cancer cells (Budhu et al., 2013; 
Hirsch et al., 2010; Kumar-Sinha et al., 2003; Wang et al., 2013). It is now being 
increasingly recognized that altered lipid metabolism in cancer reflects changes in 
upstream and downstream signaling pathways regulating cellular metabolism, most 
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importantly lipogenesis and lipolysis. Hence, altered metabolism has been proposed 
as another important hallmark in cancer pathogenesis (Hanahan and Weinberg, 
2011).  
 
1.4.3.1 Altered lipid metabolism in cancer   
 
Generally, normal cells show low rates of de novo fatty acid synthesis, and low levels 
of expression of lipogenic enzymes (Weiss et al., 1986). This is in contrast to cancer 
cells, which often show high rates of de novo fatty acid synthesis or lipogenesis 
(Kuhajda, 2000; Swinnen et al., 2006). Increased lipogenesis in cancer is supported 
by numerous reports of increased expression of several key lipogenic enzymes such 
as ACLY (Bauer et al., 2005), ACC (Milgraum et al., 1997) and FASN (Swinnen et 
al., 2002) suggesting that increased lipogenesis plays an important role in cancer 
pathogenesis. Furthermore, compared to normal cells, cancer cells preferentially use 
free fatty acids synthesized de novo, instead of dietary free fatty acids (Kannan et al., 
1980; Ookhtens et al., 1984; Vazquez-Martin et al., 2008). These synthesized fatty 
acids are important for fuelling membrane biogenesis and lipid-based protein 
modifications that serve numerous cellular functions as described earlier (Section 
1.4.1), with these activities being enhanced in cancer cells.  
 
Cancer cells such as breast cancer cell lines, have been shown to have high 
numbers of lipid droplets and/or increased lipid droplet storage capacity compared to 
that of most normal cells (Kourtidis et al., 2010). This can be explained by increased 
lipogenesis (Kourtidis et al., 2010), but also represents a survival strategy, preventing 
lipotoxicity which could otherwise lead to cell death (Listenberger et al., 2003).  
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1.4.3.1.1 The role of FASN 
 
FASN was initially identified by Kuhajda et al.(1994) as OA-510, a breast cancer 
marker associated with poor patient prognosis. To date, FASN is one of the most 
widely studied lipogenic enzymes. FASN expression is usually low and/or 
suppressed in normal healthy cells. However, numerous reports show FASN being 
overexpressed in many types of cancers such as prostate (Migita et al., 2009; 
Swinnen et al., 2002), ovarian (Gansler et al., 1997), colon (Ogino et al., 2007), lung 
(Piyathilake et al., 2000), endometrial (Tsuji et al., 2004) and melanoma (Innocenzi et 
al., 2003). Studies from prostate (Swinnen et al., 2002) and ovarian (Piyathilake et 
al., 2000) cancers suggest that increased FASN expression is important for tumor 
initiation and progression. The mechanisms producing FASN overexpression include 
enhanced transcription of the FASN gene, gain of FASN gene copies, enhanced 
translation of FASN mRNA and increased stabilization of FASN protein (Menendez 
and Lupu, 2007). FASN expression may also be upregulated by growth factors 
receptors such as EGFR and ERBB2 via signalling pathways such as PI3K/Akt, 
MAPK pathways. 
 
1.4.3.1.2 Oncogene and tumor suppressor involvement in lipogenesis 
 
Increased lipogenesis in cancer has been linked to activated oncogenes or loss of 
tumor suppressor genes (Cairns et al., 2011; Koppenol et al., 2011; Levine and 
Puzio-Kuter, 2010; Vander Heiden et al., 2009). These oncogenes (eg. EGFR, 
ERBB2, Akt, Myc) and tumor suppressor genes (eg. PTEN, p53) regulate upstream 
signaling pathways such as RTKs, PI3K/Akt and MAPK pathways which control 
cellular proliferation and survival (Figure 1.12).  
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The PI3K/Akt signaling pathway was shown to regulate FASN expression at both the 
transcriptional and protein level. Treatment with PI3K inhibitor or exogenous PTEN 
overexpression in PTEN-null LNCaP prostate cancer cells resulted in reduced FASN 
expression and consequently fatty acid production (Van de Sande et al., 2002). This 
effect was, however, rescued by transfection of constitutively active Akt (Van de 
Sande et al., 2002). A similar observation was made in ovarian cancer cells upon 
exogenous Akt overexpression. This led to increased fatty acids and phospholipids 
due to activated SREBP-1c (sterol regulatory element binding protein-1c) expression 
that subsequently enhanced the expression of lipogenic enzymes (Porstmann et al., 
2005). H-Ras transfected MCF-10A cells (non-tumorigenic human mammary cells) 
showed induced MAPK and PI3K activity together with increased SREBP-1c, which 
activated FASN expression resulting in enhanced fatty acid synthesis (Yang et al., 
2002). Akt has also been shown to directly activate another lipogenic enzyme, ACLY, 
by phosphorylation (Berwick et al., 2002; Migita et al., 2008).  
 
Transcriptomic and proteomic analysis revealed that proteins involved in metabolic 
pathways are highly expressed in ERBB2 positive breast tumors, including FASN 
(Kumar-Sinha et al., 2003; Zhang et al., 2005). Using Herceptin treatment, Kumar-
Sinha et al. (2003) concluded that ERBB2 regulates FASN expression activity via 
activating the FASN promoter, through a PI3K-dependent pathway. They showed 
that downregulation of ERBB2 expression following either Herceptin or a PI3K-
inhibitor treatment also reduced FASN expression in SK-BR-3 breast cancer cells, 
whereas overexpression of ERBB2 stimulated FASN promoter activity leading to 
increased fatty acid synthesis and treatment with Herceptin or a PI3K-inhibitor 
markedly decreased fatty acid synthesis (Kumar-Sinha et al., 2003). This study 
highlights the involvement of ERBB2 in regulating fatty acid synthesis in ERBB2-
overexpressing breast cancer cells (Kumar-Sinha et al., 2003). It is also interesting to 
note that the key lipogenic genes FASN, ACC and ACLY are located in proximity to 
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ERBB2 on chromosome 17q (Figure 1.11). NR1D1 (nuclear receptor subfamily 1, 
group D, member 1), and PBP/MED1 (peroxisome proliferator-activated receptor-
binding protein (PBP)/mediator subunit 1 (MED1)) transcription factors which 
regulate lipid metabolism are also located close to ERBB2 (Figure 1.11), and RNA 
interference studies have shown that these proteins are survival factors in ERBB2-
positive breast cancer cells (Kourtidis et al., 2010). ERBB2 has been shown to 
regulate FASN, ACC and ACLY, while MED1 and NR1D1 have been shown to 
regulate these and other lipogenic genes (Kourtidis et al., 2010; Kumar-Sinha et al., 
2003; Menendez and Lupu, 2007; Yoon et al., 2007; Zhang et al., 2005). Copy 
number increases including ERBB2 could therefore directly or indirectly affect the 
activity of other co-located chromosome 17q lipogenic genes. These results provide 
evidence to suggest that ERBB2-positive cancer cells are addicted to de novo fatty 
acid synthesis.  
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Figure 1.11 Lipid associated genes located at chromosome 17q. Gene positions 
are shown using hg 18 chromosome 17 co-ordinates, in MB, corresponding to the 
cytogenetic bands on the lower ideogram. Approximate positions of genes are shown 
using vertical arrows. (ACACA or ACC = Acetyl-CoA carboxylase, ACLY = ATP 
citrate lyase, FASN = fatty acid synthase, MED1 or PBP = peroxisome proliferator-
activated receptor-binding protein (PBP)/mediator subunit 1 (MED1), NR1D1 = 
nuclear receptor subfamily 1, group D, member 1, STARD3 = StAR-related lipid 
transfer domain protein 3). Reproduced from Kamili and Byrne (in press). 
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1.4.3.1.3 Increased -oxidation of fatty acids  
 
As discussed earlier (Section 1.4.1.1), fatty acids also serve as an alternative source 
of energy through the -oxidation pathway. It is presumed that in cancer cells, 
increased -oxidation at times of limited glucose supply is another strategy to avoid 
cell death. -oxidation is proposed to be the dominant bioenergetic pathway in 
prostate cancer (Liu, 2006). Prostate cancer cells were observed to have low glucose 
consumption (Effert et al., 1996), increased fatty acid uptake (Liu et al., 2010) as well 
as increased levels of -oxidation enzymes (Zha et al., 2005). Ovarian cancer cells 
were also shown to have increased -oxidation (Nieman et al., 2011). Leukemia cells 
have also been reported to be dependent on -oxidation for cell proliferation and 
survival, using inhibition of -oxidation by RNA interference (Samudio et al., 2010). In 
addition, Akt-transformed glioblastoma cells showed activation of the -oxidation 
pathway, which rescued cells from cell death upon glucose withdrawal. This suggests 
that -oxidation substituted for glycolysis sufficiently to maintain cell survival of these 
glioblastoma cells (Buzzai et al., 2005).  
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Figure 1.12 Signaling pathways regulating lipid metabolism in cancer cells. 
SREBP (sterol regulatory element-binding protein) regulates many lipogenic 
enzymes (yellow boxes) within the fatty acid (boxed in light blue) and cholesterol 
synthesis (boxed in orange) pathways. Oncogenic activation of the PI3K/Akt pathway 
increases glucose uptake and usage through SREBP activation. Mutant p53 
(p53mut) activates expression of genes involved in the cholesterol synthesis 
pathway. Reduced cellular energy levels will activate AMPK (AMP-activated protein 
kinase) which will prevent lipid synthesis and activate the -oxidation pathway by 
inhibiting ACC (acetyl-CoA carboxylase) activity. AMPK can also directly 
phosphorylate SREBP, inhibiting SREBP activity. Hypoxia activates HIF1 (hypoxia-
inducible factor 1) which reduces glucose flux to acetyl-CoA through the 
mitochondria. Cytoplasmic citrate can be derived from the TCA (tricarboxylic acid 
cycle) in mitochondria or through reductive metabolism of glutamine derived α-
ketoglutarate. (ACAT = acetyl-CoA acetyltransferase, ACLY = ATP citrate lyase, 
ACSL = acyl-CoA synthetase long-chain, ADP = adenosine diphosphate, ATP = 
adenosine triphosphate, CPT1 = carnitine palmitoyltransferase 1, ETC = electron 
transport chain, FADH2 = flavin adenine dinucleotide (hydroquinone form), FASN = 
fatty acid synthase, GLUT = glucose transporter, HMG = 3-hydroxy-3-methylglutaryl, 
HMGCS = HMG coenzyme A synthase, HMGCR = HMG coenzyme A reductase, 
IDH = isocitrate dehydrogenase, MCT = monocarboxylate transporter, mTORC1 = 
mammalian target of rapamycin complex 1, NADH = nicotinamide adenine 
dinucleotide, PDH = pyruvate dehydrogenase, PDK = pyruvate dehydrogenase 
kinase, SCD = stearoyl-CoA desaturases). Reproduced from Santos and Schulze 
(2012). 
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1.4.3.2 Impact of altered lipid metabolism on cancer therapy 
 
Altered lipid metabolism in cancer cells is produced by overexpression of key 
lipogenic genes (FASN, ACC, ACLY) in the lipogenesis pathway. These enzymes are 
therefore potential therapeutic targets in lipogenic cancers (Zhang and Du, 2012). 
RNA interference studies using breast cancer cell lines targeting the lipogenic genes 
ACC or FASN showed a decrease in palmitic acid synthesis, which was associated 
with induced apoptosis (Chajes et al., 2006). Supplementation of palmitate then 
rescued cells from apoptosis induced by ACC and FASN knock-down (Chajes et al., 
2006). Similarly in prostate cancer cells, FASN or ACC knock-down led to reduced 
cell growth and induced apoptosis (Bandyopadhyay et al., 2005; Brusselmans et al., 
2005). ACLY inhibition using RNA interference also resulted in reduced lipogenesis, 
which eventually reduced cell proliferation and survival in human lung 
adenocarcinoma A549 cells displaying aerobic glycolysis (Migita et al., 2008) and in 
prostate cancer PC3 cells (Hatzivassiliou et al., 2005). Both of these studies also 
showed that inhibition of ACLY led to reduced tumorigenesis in mice (Hatzivassiliou 
et al., 2005; Migita et al., 2008). A study by Bauer et al. (2005) showed siRNA knock 
down of ACLY significantly impaired Akt-mediated tumorigenesis in vivo (Bauer et al., 
2005). Collectively, these results indicate the dependence of certain cancer cells on 
lipogenesis for survival and tumor formation.  
 
These and other observations have led to the development of chemical inhibitors 
targeting these lipogenic enzymes. Several FASN inhibitors have been developed 
(eg. cerulenin, C75, orlistat) which provided promising in vitro results however, 
clinical trials have shown side effects such as anorexia (Menendez and Lupu, 2007). 
A chemical inhibitor targeting ACLY, SB-204990 was found to reduce tumor cell 
proliferation and survival in vitro and in vivo (Hatzivassiliou et al., 2005). Lipogenic 
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enzymes are therefore emerging as potential targets to treat lipogenic cancers, 
although adverse side-effects are currently limiting their clinical application. 
 
 
1.5 Chromosome 8q21 gain in cancer  
 
Cytogenetic analyses using fluorescent in-situ hybridization (FISH) and comparative 
genomic hybridization (CGH) analyses have identified that DNA copy number at 
chromosome 8q is frequently increased in different cancer types such as breast and 
prostate (Baudis, 2007; Myllykangas et al., 2006). To date, numerous genes have 
been proposed as chromosome 8q oncogenes, such as MYC, eukaryotic translation 
initiation factor 3-S3 (EIF3S3), WW domain containing E3 ubiquitin protein ligase 1 
(WWP1), E2F5, elongin C or TCEB1 transcription elongation factor B (SIII), 
polypeptide 1(TCEB1/ElonginC), and Tumor protein D52 (TPD52), based upon the 
separate gain of different chromosome 8q regions, including 8q21.  
 
Chromosome 8q21 spans about 19.5 Mb (74,000,001-93,500,000 bp) and encodes 
up to 91 genes (Byrne et al., 2012). Numerous studies have reported 8q21 gain in 
the breast cancer SK-BR-3 cell line (Kallioniemi et al., 1994), breast cancer (Fejzo et 
al., 1998), prostate cancer (Cher et al., 1996), bladder cancer (Kallioniemi et al., 
1995; Richter et al., 1997) and osteosarcoma (Tarkkanen et al., 1995). Furthermore, 
it has also been shown that chromosome 8q21 gain was significantly associated with 
increased risk of death in a large breast cancer cohort (Rennstam et al., 2003). 
Collectively, these reports suggest gene(s) located at 8q21 are of importance in the 
initiation and/or progression of various types of cancers.  A number of amplification 
targets within this region have been proposed, including TPD52 at 81.1–81.2 MB 
(Figure 1.13) (Byrne et al., 2012).  
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Figure 1.13 Summary of high-resolution amplicon mapping studies at 
chromosome 8q21 identifies TPD52 amplification in cancer tissues or cell 
lines. Gained regions are indicated by horizontal lines according to hg18 
chromosome 8 coordinates below (in MB), corresponding to the cytogenetic bands 
indicated on the lower ideogram. Arrows within cytogenetic bands indicate that these 
extend beyond the region shown. The study reporting each gained region is indicated 
to the left or right, with colored lines and text highlighting studies examining particular 
cancer types. A region of overlap between gained regions (shaded in light blue) 
identified as 81 to 82 Mb includes the gene TPD52 (vertical arrow), supporting 
TPD52 as a gene amplification target. Adapted from Byrne et al. (2012)  
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1.6 Tumor protein D52 (TPD52)  
 
1.6.1 History - Gene identification and related genes 
 
The human tumor protein D52 gene (TPD52) was identified by differential screening 
of a human breast carcinoma cDNA library (Byrne et al., 1995). Identification of other 
related genes identified the TPD52-like gene family, which encodes a family of 
adaptor proteins containing a conserved coiled-coil motif (Boutros et al., 2004; Byrne 
et al., 1996). The human TPD52-like family includes 4 genes: TPD52 (D52) (Byrne et 
al., 1995), TPD52L1(D53) (Byrne et al., 1996; Byrne et al., 1998a), TPD52L2 (D54) 
(Nourse et al., 1998) and TPD52L3 (D55) (Cao et al., 2006). Phylogenetic analysis of 
the vertebrate TPD52-like proteins revealed that corresponding genes may have 
evolved from ancestral, TPD52-like sequences such as those found in Drosoplila 
melanogaster and Caenorhabditis elegans through gene duplication events (Figure 
1.14) (Boutros et al., 2004).  
 
Orthologues of TPD52 have been reported in species such as mouse (Tpd52) (Byrne 
et al., 1996), rat (CRHSP-28) (Groblewski et al., 1996), Japanese quail (R10) (Proux 
et al., 1996), rabbit (CSPP28) (Parente et al., 1996) and Drosophila melanogaster 
(CG5174) (Giot et al., 2003). Human TPD52L1 and mouse Tpd52 proteins are 
predicted to be 52% and 86% identical to human TPD52, respectively (Byrne et al., 
1996). While these sequences show significant similarity, TPD52-like sequences 
show little similarity to members of other protein families. This identifies the TPD52-
like protein as having their own unique characteristics (Byrne et al., 1996; Shehata et 
al., 2008b).  
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Figure 1.14 Phylogenetic tree of TPD52-like protein sequences. Phylogenetic 
analysis based on amino-acid sequences of TPD52-like proteins (unrooted tree 
construction, using the H. magnipapillata sequence as the outgroup). Colours 
represent the separation of vertebrate sequence groups. D52 = TPD52, D53 = 
TPD52L1, D54 = TPD52L2, NYD-SP25 = TPD52L3. Reproduced from Boutros et al. 
(2004). 
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TPD52-like sequences encode hydrophilic polypeptides between 180 and 200 amino 
acids in length (Byrne et al., 1996; Byrne et al., 1995), that include a predicted coiled-
coiled motif (40-50 amino acids) and N- and C-terminally located PEST domains 
(Byrne et al., 1996) (Figure 1.15). PEST domain refers to a domain which is rich in 
proline (P), glutamic acid (E), serine (S), and threonine (T). TPD52-like protein 
sequences are highly conserved in their central regions which include the coiled-coil 
motif (Byrne et al., 1996) (Figure 1.15), whereas the C-terminal regions are more 
diverse (Boutros et al., 2004; Byrne et al., 1995). TPD52 has been shown to exist as 
homodimers or multimers in vitro (Chen et al., 1997). A yeast two-hybrid analysis and 
gluthathione S-transferase pull down assays confirmed that TPD52-like proteins can 
bind each other (Byrne et al., 1998b). The coiled-coil motif was required for this 
interaction to occur (Byrne et al., 1998b; Sathasivam et al., 2001) but more C-
terminal regions may be involved in facilitating and/or stabilising these interactions 
(Sathasivam et al., 2001). It was also proposed that interactions with itself or related 
proteins are important for TPD52 to exert and/or regulate its activities (Byrne et al., 
1998b).  
 
The TPD52 gene includes at least 9 exons and encodes a 184 amino acid 
polypeptide, with a predicted molecular mass of 19.8 kDa (Byrne et al., 1995). 
Alternative splicing events have been identified, generating TPD52 isoforms. Firstly, 
alternative use of the first exon generates TPD52 (exon 1a) and PrLZ (exon 1b) 
isoforms (Figure 1.15). TPD52 has been shown to have high expression levels in 
breast cancer cells (Byrne et al., 1996) as well as in tumor derived cell lines from 
multiple cancers (Chen et al., 1996), whereas PrLZ is highly elevated in prostate 
cancer cells (Wang et al., 2004). Generation of other isoforms is due to alternative 
splicing of an exon encoding a 14-3-3 binding motif (Boutrous et al., 2003). These 
isoforms were found to be expressed in neural tissues (Nourse et al., 1998).  
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Figure 1.15 Schematic diagram of TPD52 isoforms. Numbers represent exons, 
with exons 1a, 1b, 5 and 6 being subjected to alternative splicing. Exons 1a and 1b 
are included in TPD52 and PrLZ, respectively. TPD52 isoforms bear a single coiled-
coil domain towards the N-terminus and 2 PEST domains located towards the N- and 
C-terminus, as indicated by a dotted line above the diagram, and solid lines below 
the diagram, respectively. Scale bar: 30 amino acids (aa). Adapted from Della Franca 
et al. (2012). 
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1.6.2 Understanding the physiological functions of TPD52 
 
Numerous experimental approaches have been taken to understand TPD52 
physiological functions, including the analysis of TPD52 expression and localization 
in cells and tissues. TPD52 transcript and protein expression have been found within 
normal tissues of the prostate, pancreas, gastrointestinal tract, kidney and brain 
(Byrne et al., 1995; Chen et al., 1996; Chen et al., 1997; Groblewski et al., 1999; 
Parente et al., 1996; Wilson et al., 2001). Microscopic analysis of TPD52 subcellular 
localization revealed it to be a cytoplasmic protein (Balleine et al., 2000; Groblewski 
et al., 1999; Kaspar et al., 2003; Proux et al., 1996; Tiacci et al., 2005). TPD52 
proteins have been subsequently shown to be involved in several cellular functions, 
such as exocytotic secretion, vesicle trafficking, calcium-mediated signal 
transduction, cell proliferation and apoptosis (Shehata et al., 2008b).  
 
The rabbit TPD52 orthologue, CSPP28 was identified as being phosphorylated in 
response to cholinergic stimulation of gastric parietal cells, therefore CSPP28 was 
proposed to be involved in calcium signaling cascades in rabbit tissues (Parente et 
al., 1996). CRHSP-28 (the rat TPD52 orthologue) was found to be highly expressed 
in cultured mucosal secretory T84 cells (Kaspar et al., 2003). Specifically, they 
showed by confocal microscopy analysis that CRHSP-28 was detected in the 
cytoplasmic compartment and displayed perinuclear accentuation (Kaspar et al., 
2003). Introduction of recombinant CRHSP-28 into rat pancreatic acinar cells 
stimulated the secretion of amylase (Thomas et al., 2001), with CRHSP-28 also 
undergoing a rapid translocation from supranuclear to subapical cytoplasmic 
compartments after stimulation of mucosal T84 and rat pancreatic acinar cells with 
secretagogue (Thomas et al., 2004). A secretagogue is a substance that causes 
another substance to be secreted. Yeast two hybrid screenings have identified 
partners for TPD52 which have been commonly associated with membrane 
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trafficking and lipid rafts, namely MAL2 (Wilson et al., 2001) and the phospholipid-
binding protein annexin VI (Thomas et al., 2002). These results supported a 
regulatory role for TPD52 in apical membrane trafficking. 
 
Several observations suggest TPD52 involvement in cell growth and differentiation. 
An early study identified R10 (the TPD52 orthologue in quail) as being encoded by a 
retrovirally transduced gene in proliferating neuroepithelial cells (Proux et al., 1996). 
R10 transcripts levels were relatively high in the neuroretina of 14 day old chick 
embryos compared to cultured chicken fibroblasts  and remained at elevated levels in 
16, 18, and 20 day old embryos and in newly hatched chicks (Proux et al., 1996). 
They also revealed the R10 gene product as a cytoplasmic protein in cultured avian 
fibroblasts. In a different study it was observed that mouse Tpd52 transcripts were 
highly expressed in olfactory epithelium, salivary gland and gut of 18 day old mouse 
embryos and in one day old mouse retina (Chen et al., 1996). TPD52 was also 
suggested to have an important role during B cell maturation (Tiacci et al., 2005), as 
TPD52 was identified as a B-cell differentiation marker, being highly expressed in  all 
mature B cells, and maximally expressed at the plasma cell stage (Tiacci et al., 
2005). TPD52 may also be involved in maintaining and/or developing an epithelial 
cell phenotype. The first evidence of this was observed when TPD52 overexpression 
in mouse NIH 3T3 fibroblast cells was associated with epithelial-like characteristics 
(Chen et al., 1997). TPD52 was also found to be expressed in higher levels in 
epithelial cells than in mesenchymal cells (Chen et al., 1997).  
 
1.6.3 Significance of TPD52 overexpression in human cancers  
 
Numerous studies have shown that TPD52 is overexpressed  in many forms of 
human cancer, including ovarian (Byrne et al., 2005), breast (Balleine et al., 2000; 
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Byrne et al., 1995), prostate (Rubin et al., 2004; Wang et al., 2004), lung (Chen et al., 
1996; Zhu et al., 2007), melanoma (Roesch et al., 2007), colon (Malek et al., 2002), 
B cell malignancies (Tiacci et al., 2005) and testicular germ cell tumors (Alagaratnam 
et al., 2009). In a proportion of these cancers, increased TPD52 expression was 
associated with an increase in chromosome 8q21 copy number, as found in breast 
(Balleine et al., 2000), prostate (Rubin et al., 2004) and ovarian cancers (Byrne et al., 
2005). Shehata et al. (2008a) carried out tissue microarray analyses of breast tissue 
samples from breast cancer patients, and reported that high TPD52 expression was 
significantly associated with reduced overall patient survival (Shehata et al., 2008a). 
It was suggested that this finding may underpin previous associations of 
chromosome 8q21 gain in breast cancer and poor patient outcome (Han et al., 2006; 
Melchor et al., 2005; Rennstam et al., 2003). TPD52 was also included in gene 
expression signatures associated with adverse prognosis in breast (Adler et al., 
2006; Liu et al., 2007b) and prostate cancer (Bismar et al., 2006). As a further 
example, TPD52 was significantly up-regulated in all 6 cases of colorectal cancer 
investigated, irrespective of tumor localization, pTNM (pathological Tumor-Node-
Metastasis) stage or tumor grade (Petrova et al., 2008). 
 
Collectively, the above reports suggest that TPD52 represents a cancer biomarker 
and therapeutic target. TPD52 overexpression can induce immunoglobulin G (IgG) 
antibodies in human breast cancer which suggests a lack of normal immunologic 
tolerance to TPD52 (Scanlan et al., 2001). TPD52 may be sufficiently immunogenic 
to be explored as an anticancer vaccine target, and Lewis et al. (2009) have taken 
this approach using mouse Tpd52 cDNA as DNA vaccine. Their data suggest that 
Tpd52 vaccination induced a cellular immune response that resulted in protection 
from murine prostate tumors that endogenously overexpress Tpd52 (Lewis et al., 
2009). 
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It has also been reported that TPD52 serves as a marker or regulator of cancer cell 
proliferation. This was initially proposed following the observation that TPD52 levels 
were reduced in TPA-treated HL60 leukemic cells (Byrne et al., 1996). Further 
studies in vitro showed that increasing mouse or human TPD52 expression by 
transfection in 3T3 fibroblast cell lines produced increased cellular proliferation and 
anchorage independent growth (Lewis et al., 2007; Shehata et al., 2008a). 
Overexpression of PrLZ in LnCaP prostate cancer cells also led to enhanced 
proliferation and tumorigenesis (Wang et al., 2004; Zhang et al., 2007a). When 
mouse Tpd52-expressing 3T3 cells were inoculated into naive, syngeneic, 
immunocompetent mice, these cells formed subcutaneous tumors and spontaneous 
lethal lung metastases (Lewis et al., 2007). These studies collectively support TPD52 
overexpression playing a causal role in cancer.  
 
Loss of function RNA interference studies have been a useful tool for studying the 
effects of reduced TPD52 expression in cell lines (Shehata et al., 2008a; Ummanni et 
al., 2008; Zhang et al., 2007a). Shehata et al. (2008a) observed that reduced TPD52 
expression resulted in significantly increased cell death or apoptosis of SK-BR-3 
cells, a breast cancer cell line which is known to be TPD52-amplified, but not in MCF-
7 cells, a breast cancer cell line that does not harbour TPD52 amplification (Shehata 
et al., 2008a). This result is in agreement with previous studies where the reduced 
expression of other oncogenes produced increased apoptosis in oncogene-
overexpressing cell lines (Kao and Pollack, 2006; Lutterbach et al., 2007; Park et al., 
2006). A similar observation was obtained in LnCaP prostate cancer cells, where 
TPD52 knockdown resulted in significant cell death (Ummanni et al., 2008).  These 
results might suggest that TPD52-amplified or –overexpressing cell lines may be 
more sensitive to reduced TPD52 expression and are “addicted” to TPD52 
expression for the cell’s survival. Interestingly, these studies indicate the possibility of 
developing new therapeutic strategies involving reducing TPD52 expression or 
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inhibiting TPD52 function, specifically for TPD52-amplified or -overexpressing 
cancers.  
 
1.6.3.1 TPD52 and ERBB2 in cancer  
 
Previously, numerous reports have persistently linked TPD52 and ERBB2 co-
expression in clinical and cell lines studies. TPD52 transcript levels were found to be 
increased in ERBB2-positive breast cancer cell lines (Wilson et al., 2002), followed 
by reports that Tpd52 transcript or protein levels were increased in mammary tissues 
from Erbb2 transgenic animals (Chen et al., 2010; Landis et al., 2006; Landis et al., 
2005; Whiteaker et al., 2007). Kourtidis et al. (2010) also identified increased TPD52 
levels in ERBB2-positive human breast cancers and cell lines, through a meta-
analysis of 22 human expression studies. In addition, chromosome 8q21 
amplification has been significantly associated with both ERBB2 amplification and 
poor patient outcome in breast cancer (Choschzick et al., 2010). As discussed ealier 
(Section 1.5), TPD52 has been proposed as a gene amplification target at 
chromosome 8q21. Thus ERBB2 and TPD52 are both amplified genes whose 
overexpression is reproducibly associated with poor patient outcomes in breast 
cancer. The significance of TPD52 and ERBB2 co-expression in breast cancer cell 
lines will be further examined in Chapter 3. 
 
1.6.4 TPD52 and lipid metabolism 
 
As mentioned in Section 1.4.3.1, increased lipid droplets has been observed in 
cancer cells due to increased lipogenesis. Several studies have reported links 
between TPD52 and lipid metabolism, specifically in lipid droplet regulation. Reduced 
lipid droplets in C. elegans were observed following knock-down of the TPD52 
orthologue F13E6.1 (Ashrafi et al., 2003). In addition, expression microarray analysis 
in both human and mouse showed increased TPD52 levels in adipose tissue from 
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obese versus non-obese subjects (Clement et al., 2004; Keller et al., 2008; Nadler et 
al., 2000). The relationship between TPD52 expression and cellular lipid droplets will 
be explored in Chapter 4. 
 
1.7 Project Hypotheses and Aims 
 
Combining experimental results with frequent TPD52 overexpression in many cancer 
types, points to TPD52 acting as an oncogene in the development of many forms of 
human cancer (Section 1.6.3). This also indicates that TPD52 may represent a novel 
therapeutic target. However, the molecular and cellular basis of TPD52 function 
remains unclear. The main goal of the project presented in this thesis is to 
understand the function of TPD52 in promoting cancer tumorigenesis. Thus, the 
overall hypotheses and aims of this project are: 
 
Hypotheses:  
 
(1) TPD52 represents a potential therapeutic target in ERBB2-positive cancers 
 
 Aim: To employ RNA interference approaches to characterise the effects of 
reducing TPD52 expression in breast cell lines according to TPD52 and 
ERBB2 gene amplification status. 
 
(2) TPD52 is involved in the regulation of lipid storage and therefore contributes 
to the lipogenic phenotype in cancer cells 
 
 Aim: To examine effects of lipid droplets (numbers and/or size) under basal 
or stimulated conditions using mouse fibroblast 3T3 cells, that either do or do 
not stably express TPD52.  
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Chapter 2 
Materials and Methods 
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2.1 Materials 
 
All chemicals and reagents used were of analytical grade (Table 2.1). All tissue 
culture materials were purchased from Life Technologies unless otherwise stated.  
 
2.1.1 Chemicals and reagents 
 
 Table 2.1 Chemicals and reagents used 
Chemical / Reagent  Source  
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
2-Mercaptoethanol Sigma-Aldrich  
2-Propanol  Sigma-Aldrich  
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) 
Sigma-Aldrich  
4',6-diamidino-2-phenylindole (DAPI)  Sigma-Aldrich 
30% Acrylamide/Bis solution Bio-Rad 
Acetic acid, glacial  BDH  
Acetone Lab-Scan 
Agar  BD  
Agarose Amresco 
Ammonium persulfate (APS) Amresco 
BenchMark prestained protein ladder Life Technologies 
BODIPY 493/503  Molecular Probes 
Boric acid Sigma-Aldrich 
Bovine Serum Albumin (BSA)  New England BioLabs 
Bromophenol blue  BDH  
Calcium chloride dihydrate (CaCl2.2H2O) Sigma-Aldrich 
SuperScript III First Strand Synthesis System for 
RT-PCR kit 
Life Technologies 
Chemiluminescent reagents Perkin Elmer 
Chloroform Merck 
Cholera toxin Sigma-Aldrich 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich  
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Chemical / Reagent  Source  
DMSO (sterile for tissue culture)  Sigma-Aldrich  
Sodium phosphate dibasic anhydrous (Na2HPO4)  BDH  
Epidermal Growth Factor (EGF) Sigma-Aldrich 
Ethanol, absolute (molecular grade)  Merck  
Ethylenediamine tetra-acetic acid (EDTA)  Amresco 
Ethidium bromide (EtBr) GibcoBRL 
Fatty acid-free BSA  Sigma-Aldrich 
Fetal bovine serum (FBS) Gibco 
FluorSave reagent Calbiochem 
Fuji X-ray film Fuji Film Corporation 
Geneticin (G418) Gibco 
Glycerol  Amresco 
Glycine Amresco 
Horse serum Gibco 
Hydrochloric acid (HCl)  Lab-Scan  
Hydrocortisone Sigma-Aldrich 
Immobilor polyvinylidene difluoride (PVDF) 
membrane 
Milipore, Australia 
Insulin solution, human Sigma-Aldrich 
Isoamyl alcohol 
 
Kanamycin Sulfate Sigma-Aldrich 
KAPA SYBR® Fast Universal qPCR kit Kapa Biosystems 
Lapatinib Selleck Chemicals 
L-Glutamine  Gibco 
Methanol Chem supply 
Oleic acid  Sigma Aldrich 
Paraformaldyhyde (PFA) Sigma-Aldrich 
Peptone  BD  
Phenol:chloroform:isoamyl alcohol (25:24:1)  Life Technologies 
Phenylmethanelsulfonyl fluoride (PMSF) Sigma-Aldrich 
Ponceau S Sigma-Aldrich 
Potassium chloride (KCl)  BDH  
Potassium dihydrogen orthophosphate (KH2PO4)  BDH  
Protease inhibitor cocktail tablets Roche 
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Chemical / Reagent  Source  
RNaseA Sigma-Aldrich 
Saponin from Quillaja bark Sigma-Aldrich 
Skim milk powder Diploma 
siRNA buffer (5X) Dharmacon 
Sodium acetate (NaOAc)  BDH  
Sodium chloride (NaCl)  Amresco 
Sodium dodecyl sulphate (SDS)  Amresco 
Sodium hydroxide (NaOH)  Amresco 
TransIT-LT1 transfection reagent Mirus Bio 
TransIT-TKO transfection reagent Mirus Bio 
Tris base Amresco 
Trizol LS reagent Life Technologies 
Trypan blue Sigma-Aldrich 
Trypsin Gibco 
Tryptone BD  
Tween 20 Sigma-Aldrich 
Yeast extract BD 
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2.1.2 Buffers and Solutions 
All solutions were prepared using autoclaved Milli Q water (aH2O). Unless otherwise 
indicated, solutions were either autoclaved or filter sterilized through 0.22 m filters 
when appropriate (Table 2.2). All glassware used for cell or bacterial culture was 
autoclaved prior to use. All solutions were stored at room temperature (RT) unless 
otherwise stated (Table 2.2). 
 
Table 2.2 Buffers and solutions composition and preparations 
SOLUTION COMPOSITION PREPARATION AND 
STORAGE 
10% APS 10% (w/v) APS Prepared fresh in aH2O  
Antibody diluent for 
immunofluorescent 
staining (Section 2.6.2) 
1X PBS 
1mg/ml BSA 
0.01% (w/v) saponin 
Make up in aH2O  
to 100 ml 
Store at 4°C 
 
Blocking buffer for 
immunofluorescent 
staining (Section 2.6.2) 
1.5% (w/v) glycine 
3% (w/v) BSA 
1X PBS 
0.01% (w/v) saponin 
 
Make up in aH2O to  
100 ml 
Store at 4°C 
 
1mg/ml BODIPY 
493/503 stock solution 
 
10 mg BODIPY 493/503  
10 ml 100% Ethanol 
 
Divide into 500 μl 
aliquots, and store at  
-20°C 
3% BSA 
 
3% (w/v) BSA Make up fresh in 1X 
TTBS (see below) 
 
CaCl2 : glycerol 85 mM CaCl2 
15% (v/v) glycerol 
Filter-sterilise  
EDTA pH 8.0  0.5 M EDTA Adjust pH with NaOH 
Sterilise by autoclaving  
 
Glycerol (10%) 10% (v/v) glycerol  Sterilise by autoclaving  
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SOLUTION COMPOSITION PREPARATION AND 
STORAGE 
Kanamycin 50 mg/ml Kanamycin Filter-sterilise  
Store at – 20˚C 
10X Loading dye -DNA 50% (v/v) Glycerol 
1 mM EDTA pH 8.0 
1.0% (w/v) Bromophenol blue 
1.0% (w/v) Xylene cyanol 
Sterilize glycerol by 
autoclaving 
Luria Bertani (LB) 
media 
1% (w/v) Tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
Adjust pH to 7.5 with  
10 M NaOH 
Sterilize by autoclaving 
Luria Bertani (LB) 
plates  
LB media as above  
15 g/L agar 
Sterilise by autoclaving  
Add antibiotics to 
appropriate concentration  
Pour plates. Store at 4°C 
MTT reagent 0.2% (w/v) MTT Make up in 1X PBS 
Filter-sterilise  
Store in dark at 4˚C 
10X PBS 137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.47 mM KH2PO4 
Dilute in aH20 
Adjust pH to 7.4 
Sterilize by autoclaving 
Paraformaldehyde 
(PFA) fixative 
16% (w/v) PFA Make up in 1X PBS 
Adjust pH to 7.4 
Store in dark at 4°C 
Ponceau S stain 0.1% (v/v) Ponceau S 
5% (v/v) Glacial acetic acid 
Autoclaving not required 
10X Running Buffer 25 mM Tris 
250 mM Glycine 
0.1% (v/v) SDS 
 
Dilute in aH20 
Autoclaving not required 
4X Sample buffer - 
Protein 
0.5 M Tris pH 6.8 
20% (v/v) Glycerol 
2% (w/v) SDS  
20% (v/v) -2-mercaptoethanol 
0.01% (w/v) Bromophenol blue 
Autoclaving not required 
Store at -20°C 
  
Nuruliza Roslan 61 
SOLUTION COMPOSITION PREPARATION AND 
STORAGE 
0.5% Saponin 0.5% (w/v) Saponin Make up in 1X PBS 
Store at 4°C 
10% SDS 10% (w/v) SDS Make up in autoclaved 
aH2O 
Heat to 65°C to aid 
dissolution 
SDS-lysis buffer  125 mM Tris pH 8.8 
3% (w/v) SDS 
5% (v/v) -2-mercapthoethanol 
Protease inhibitor (Roche)  
(1 tablet/10mL buffer) 
 
Autoclaving not required 
SE lysis buffer 75 mM NaCl 
25 mM EDTA pH 8.0 
Dilute in aH2O 
5% Skim milk  
 
5% (w/v) Skim milk powder Make up fresh in 1X 
TTBS (see below) 
SOC Broth 5 g/L yeast extract  
0.5 g/L NaCl 
2.5 mM KCl 
10 mM MgCl
2
 
2% (w/v) dextrose 
Sterilise by autoclaving  
Add filter-sterilised 
dextrose  
Store aliquots at – 20°C  
Pre-warm to 37°C prior to 
use 
Sodium chloride 5 M NaCl Sterilise by autoclaving 
Sodium hydroxide 0.5 M NaOH Sterilise by autoclaving 
10X TBE  0.9 M Tris  
0.9 M Boric acid 
20 mM EDTA pH 8.0 
Dilute in aH20 
Sterilize by autoclaving 
10X TBS 100 mM Tris-HCl 
150 mM NaCl 
Dilute in aH20 
Adjust pH to 7.5  
10X TE 100 mM Tris pH 7.5 
10 mM EDTA pH 8.0 
Sterilize by autoclaving 
1M Tris pH 8.8 or 7.5 
or 6.8  
1 M Tris Dilute in aH20 
Adjust pH with HCl 
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SOLUTION COMPOSITION PREPARATION AND 
STORAGE 
1X TTBS 1X TBS 
0.1% (v/v) Tween 20 
Dilute in aH20 
Make sure Tween 20 is 
dissolved completely 
Western blot Transfer 
buffer 
25 mM Tris 
192 mM Glycine 
20% (v/v) Methanol     
0.005% (w/v) SDS 
Prepared fresh and pre-
chilled at 4°C 
 
2.1.3 Antibodies 
 
2.1.3.1 Primary Antibodies 
All primary antibodies (Table 2.3) were kept at -80ºC or -20ºC for long term storage 
or at 4ºC for short term storage (<1month), unless otherwise stated. 
 
Table 2.3 Primary antibodies used 
Antibody (source or 
reference) 
Application and 
dilution 
Species Reactivity 
TPD52 (747) 
(Balleine et al., 2000) 
WB: 1:100 
IF: 1:100 
Rabbit polyclonal 
 
Human  
TPD52 
(Tiacci et al., 2005) 
IF: 1:10 Mouse monoclonal Human, Mouse 
TPD52 (748) 
(Shehata et al., 2008a) 
WB: 1:100 Rabbit polyclonal 
 
Human, Mouse  
α-tubulin 
(Sigma) 
WB: 1:1000 Mouse monoclonal 
 
Human, Mouse  
GAPDH 
(Ambion) 
WB: 1:5000 Mouse monoclonal 
 
Human, Mouse  
ERBB2 
(Cell signaling) 
WB: 1:1000 
IF: 1:200 
Rabbit monoclonal 
 
Human, Mouse 
Phos-ERBB2 
(Cell signaling) 
WB: 1:1000 Rabbit monoclonal 
 
Human 
  
Nuruliza Roslan 63 
Antibody (source or 
reference) 
Application and 
dilution 
Species Reactivity 
Phos-Akt (Ser473) 
(Cell signaling) 
WB: 1:1000 
 
Rabbit monoclonal 
 
Human, Mouse 
Phos-MAPK 44/42 
(Cell signaling) 
WB: 1:2000 Rabbit monoclonal 
 
Human, Mouse 
Cleaved-PARP 1 
(Cell signaling) 
WB: 1:1000 
 
Rabbit polyclonal 
 
Human 
FASN 
(Santa Cruz) 
WB: 1:200 
IF: 1:50 
Mouse monoclonal 
 
Human, Mouse 
ADRP 
(Progen Biotechnik) 
WB: 1:2000 
IF: 1:200 
Guinea-pig 
polyclonal 
Mouse 
Perilipin 
(Progen Biotechnik) 
WB: 1:2000 
IF: 1:200 
Guinea-pig 
polyclonal 
Human, Mouse 
TIP47 
(Progen Biotechnik) 
WB: 1:2000 
IF: 1:200 
Guinea-pig 
polyclonal 
Human 
PDI 
(Cell signaling) 
IF: 1:50 Rabbit polyclonal Human, Mouse 
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2.1.3.2 Secondary antibodies  
All secondary antibodies (Table 2.4) were received lyophilized and were 
reconstituted according to the manufacturer’s instructions. Secondary antibodies 
were kept at -80ºC for long term storage and at 4ºC for short term storage (<1month). 
 
Table 2.4 Secondary antibodies used 
Secondary antibody (Source) Application and 
dilution 
Donkey anti-mouse-Alexa488 IgG 
(Molecular Probes) 
IF: 1:1000 
Donkey anti-rabbit-Alexa488 IgG 
(Molecular Probes) 
IF: 1:1000 
Donkey anti-mouse-Cy3 IgG 
(Jackson Immunoresearch Laboratories) 
IF 1:1000 
Donkey anti-rabbit-Cy3 IgG 
(Jackson Immunoresearch Laboratories) 
IF 1:1000 
Donkey anti-rabbit-Cy5 IgG 
(Jackson Immunoresearch Laboratories) 
IF 1:1000 
Donkey anti-mouse-HRP 
(GE Healthcare) 
WB: 1:5000 
Donkey anti-rabbit-HRP 
(GE Healthcare) 
WB 1: 10 000 
Anti-guinea pig-HRP (Novex®) WB 1:2000 
Anti-guinea pig-Alexa633 
(Molecular Probes) 
IF 1:1000 
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2.2 Mammalian cell culture 
 
2.2.1 Breast cell lines 
Breast cancer cell lines AU-565, BT-483, MDA-MB-175, HS-578T, MDA-MB-157, 
MDA-MB-134, DU4475, MDA-MB-468 and ZR-75-30 were kindly provided by Prof. 
Roger Daly from the Garvan Institute (Sydney, Australia). SK-BR-3, BT-474, MCF-7, 
T-47D, MDA-MB-231 and MCF-10A cell lines were obtained from the American Type 
Culture Collection (Rockville, MD, USA). All cell lines were subjected to short tandem 
repeat profiling by CellBank Australia (Westmead, Australia), which confirmed their 
identities. Cell lines were cultured at 37oC in a humidified incubator with 5% CO2 in 
RPMI media (Life Technologies) supplemented with 10% fetal bovine serum (FBS, 
Life Technologies) and 3% L-glutamine (Life Technologies), except for MCF-7 cells, 
where the above media were supplemented with 10 g/ml insulin (Sigma-Aldrich, St 
Louis, MO, USA), and MCF-10A cells, which were cultured as described (Hope et al., 
2002).  Stably transfected TPD52-expressing MDA-MB-231 cell lines, as well as 
vector control MDA-MB-231 cell lines were derived by Rose Boutros (Boutros, 2005) 
and cultured in RPMI media as above, with 1 mg/ml G418 (Gibco) as described 
(Boutros, 2005). Cells were plated in 10 cm tissue culture dishes and allowed to grow 
until cells were approximately 70% confluent, after which time cells were either 
passaged, subjected to treatment, or harvested for analysis.  
 
2.2.2 3T3 mouse fibroblast cell lines 
The mouse Balb/c 3T3 fibroblast cell line was a gift from Robert K. Bright 
(Department of Microbiology and Immunology, Texas Tech University, Health 
Sciences Center, Lubbock, Texas, USA) and was maintained at 37°C in RPMI media 
(Life Technologies) supplemented with 10% FBS (Life Technologies), and 3% L-
glutamine (Life Technologies). Stably transfected TPD52-expressing 3T3 fibroblasts, 
as well as vector-transfected 3T3 cells (Vector-3) were derived by Mona Shehata 
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(Shehata et al., 2008a) and cultured in RPMI media as above, with 1 mg/ml G418 
(Gibco) as described previously (Shehata et al., 2008a). Cells were plated in 10 cm 
tissue culture dishes and allowed to grow until cells were approximately 70% 
confluent, after which cells were either passaged, subjected to treatment, or 
harvested for analysis.  
 
For all experiments requiring exact cell numbers, cells were trypsinized and 
centrifuged at 1500 rpm for 5 min in a Beckman GS-6R centrifuge at RT. The 
supernatant was carefully removed and the remaining cell pellet was resuspended in 
10 ml media. Twenty l of cell supernatant were added to 20 l of trypan blue 
(Sigma-Aldrich) which stains dead cells blue. Cell numbers were then calculated 
using a hemacytometer.   
 
2.3 Genomic DNA extraction  
Genomic DNA (extracted from cultured cells) was purified using the phenol 
chloroform extraction method. Cells were washed twice with 1X PBS, centrifuged at 
1200 rpm for 5 min, the supernatant was discarded, and 4.5 ml SE lysis buffer was 
added to disperse cells. Proteinase K (300 l) was added followed by 500 l 10% 
SDS, and samples were incubated in a 50°C water bath for 1 h. Samples were then 
rotated overnight at RT. The following day, samples were briefly centrifuged, and 5 
ml phenol:chloroform:isoamyl alcohol (25:24:1) (Life Tecnologies) was added. 
Samples were rotated for 2-4 h at RT, and then centrifuged at 3000 rpm for 20 min. 
Each upper layer was transferred into a new tube containing 5 ml of 
phenol:chloroform:isoamyl alcohol (25:24:1), and then rotated overnight at RT. The 
next day, samples were centrifuged at 3000 rpm for 20 min, and each upper layer 
was transferred into a new tube containing 5 ml chloroform:isoamyl alcohol (24:1), 
rotated for 30 min at RT followed by centrifugation at 3000 rpm for 10 min at RT. This 
  
Nuruliza Roslan 67 
process was repeated twice. The upper layer was transferred into a new 50 ml tube 
(cooled on ice) and 10 ml 100% ethanol (pre-chilled at -20°C) was slowly added. The 
tube was inverted several times until a white thread appeared, which was transferred 
into a new 1.5 ml eppendorf tube containing 500 l 70% ethanol. The tube was 
inverted several times, and centrifuged at 3000 rpm for 5 min. The supernatant was 
discarded and the DNA was left to dry for ~30 min at RT. TE buffer was added (50 – 
500 l) to dissolve the DNA. Samples were stored overnight at 4°C, followed by DNA 
quantitation (Section 2.14). DNA was then stored at -20°C.    
 
2.4 Total RNA extraction and cDNA synthesis 
Total RNA was extracted using the Trizol LS reagent (Life Technologies) according 
to the manufacturer’s protocol, and quantitated to determine RNA concentration and 
purity (Section 2.14). One μg of RNA was subjected to cDNA synthesis using the 
SuperScript III First Strand Synthesis System for RT-PCR kit (Life Technologies), 
according to the manufacturer’s instructions. 
 
2.5 Real-time PCR (genomic DNA) 
The resulting DNA was amplified using Taq DNA polymerase (KAPA Biosystems) 
and a set of TPD52 PCR primer sequences: sense, 5’-CAG TTT AGA GCC CAG 
GGA AA-3’ and antisense, 5’-CGA TCA TCC AAC GTA GCA TG-3’. These target a 
225 bp TPD52 fragment (ENST00000518937, transcript TPD52-001) including the 
whole of exon 5 (27 bp). Prior to performing real-time PCR, primers were validated 
by standard PCR using genomic DNA. Fifty ng/μl DNA per sample was subjected to 
quantitative real-time PCR performed using the Corbett Rotor-Gene 6000 (Qiagen) 
using the KAPA SYBR® Fast Universal qPCR kit (Kapa Biosystems). Thermal cycling 
conditions comprised of an initial denaturation step of 95°C for 10 min, and 40 cycles 
of 95°C for 15 sec, 57°C for 30 sec and 72°C for 30 sec. Relative DNA copy numbers 
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were calculated using Roto-Gene 6 (Version 6.1) software (Qiagen) by normalizing 
raw data obtained for each cell line against the MCF-10A cell line as a control. A 
single peak at the appropriate melting curve was used to determine that there was 
only one PCR product amplified.  
 
2.6 Real-time reverse-transcriptase (RT-) PCR (cDNA) 
The resulting cDNA was amplified using Taq DNA polymerase (KAPA Biosystems) 
and a set of TPD52 PCR primer sequences: sense, 5’- GGA AGA GGA GCA GGA 
AGA GC -3’ and antisense, 5’- GAT GAC TGA GCC AAC AGA CG -3’; which 
amplified a 264 bp region of the TPD52 coding sequence (GenBank U18914) from nt 
187-451. Prior to performing real-time RT-PCR, primers were validated by standard 
RT-PCR using cDNA. cDNA samples were subjected to quantitative real-time RT-
PCR performed using the Corbett Rotor-Gene 6000 (Qiagen) using the KAPA SYBR® 
Fast Universal qPCR kit (Kapa Biosystems). Thermal cycling conditions comprised 
an initial denaturation step of 95°C for 10 min, and 40 cycles of 95°C for 15 sec, 60°C 
for 30 sec and 72°C for 30 sec. Relative mRNA transcript levels were calculated 
using the Roto-Gene 6 (Version 6.1) software (Qiagen) by normalizing the raw data 
obtained for each cell line against that obtained for the MCF-10A cell line as a 
control. A single peak at the appropriate melting curve was used to determine that 
there was only RT-PCR product amplified.  
 
2.7 SDS PAGE and Western blot analyses 
 
2.7.1 SDS-PAGE 
Cells were washed twice in cold 1X PBS and lysed in SDS-lysis buffer for total 
protein extracts. Samples were sonicated using a Branson Sonifier 150 
(ProSciTech). Protein concentrations were determined using the BCA protein assay 
kit as per the manufacturer’s instructions (Pierce). 
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Protein extracts (12-18g/well) were resolved using SDS-PAGE 7.5% or 12.5% 
polyacrylamide gels (gel components are outlined in Table 2.5 or using pre-cast 4-
12% gradient polyacrylamide gels (Life Technologies). Protein samples were mixed 
in a 3:1 ratio with 4X Sample protein buffer and boiled for 5 min. Samples were 
loaded onto gels with 12 l BenchMark prestained protein ladder (protein size range 
10-200 kDa, Life Technologies) loaded into SDS-PAGE 7.5% or 12.5% 
polyacrylamide gels, or with 12 l  Novex® Sharp prestained protein standard (protein 
size range 3.5-260 kDa, Life Technologies) for 4-12% gradient gels. Gels were run at 
90 V for 30 min, or until the leading dye band had traversed the stacking gel, and 
then at 120 V for 1.5-2 h, or until the leading dye band had run off the gel. 
 
Table 2.5 Resolving and stacking SDS-PAGE gel compositions 
Gel component 
Volume for 
10% 
resolving gel 
Volume for 
12.5% 
resolving gel 
Volume for 
15% 
resolving gel 
Volume for 
stacking 
gel 
1M Tris pH 8.8 3.75 mL 3.75 mL 3.75 mL - 
1M Tris pH 6.8 - - - 500 μL 
MilliQ water 2.7 mL 1.9 mL 1.1 mL 2.9 mL 
10% SDS 100 μL 100 μL 100 μL 40 μL 
30% bis 
acrylamide 
stock 
3.3 mL 4.15 mL 5.0 mL 530 μL 
10% APS 4 μL 4 μL 4 μL 4 μL 
TEMED 75 μL 75 μL 75 μL 30 μL 
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2.7.2 Western blot transfer 
The SDS-PAGE gel was then electrotransferred to a PVDF membrane as follows. 
Sponges and Whatman filter papers were pre-soaked in 1X transfer buffer (prepared 
fresh and cold) (Section 2.1.2) and the PVDF  membrane was rehydrated in 100% 
methanol, and then rinsed in 1X transfer buffer prior to transfer assembly. Filter 
papers were placed on top of the pre-soaked sponges on an electrode cassette (red 
side) with the PVDF membrane placed on top of the filter paper. A 15 ml falcon tube 
was rolled over the top to remove air bubbles. The gel was carefully removed from 
the running apparatus and the stacking gel was detached and discarded. The gel 
was placed on top of the PVDF membrane, being careful to exclude air bubbles. 
More filter paper was laid on top of the gel, as well as the final sponge. The gel-
membrane sandwich was placed into the Western transfer tank (Bio-Rad) in cold 1X 
transfer buffer at 80 V for 2 h on ice, or overnight at 30 V in a cold room (4°C). Once 
transfer was completed, membranes were rinsed once in 100% methanol, and air 
dried for 15 min. Membranes were rehydrated in 100% methanol, washed in water to 
remove all traces of methanol, and then briefly placed in Ponceau S stain to reveal 
protein bands. Excess stain was washed off in water, and the membranes were then 
scanned using an EPSON scanner (EPSON, Australia) for future reference. 
 
2.7.3 Immunostaining of Western blots 
Membranes were either blocked overnight at 4°C or at RT for 60 min with shaking in 
either 5% skim milk powder in 1X TTBS or 3% BSA in 1xTTBS. Blocked membranes 
were washed 3 times (10 min each with shaking) with 1X TTBS and incubated with 
the relevant primary antibodies (Section 2.1.3.1) for 1-2 h at RT or overnight at 4°C in 
either 1X TTBS, 5% skim milk powder or 3% BSA, with shaking. Membranes were 
washed 3 times in 1X TTBS (10 min each), and then incubated with the relevant 
horseradish peroxidase-conjugated secondary antibody (Section 2.1.3.2) for 1 h at 
RT in either 5% skim milk powder or 3% BSA, with shaking. Membranes were then 
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washed for 3 times in 1X TTBS (10 min each), and incubated for 5 min with Western 
Lightning Chemiluminescent reagent (Perkin Elmer). Membranes were sandwiched 
between 2 plastic sheets and placed in a film cassette (Kodak). Protein bands were 
revealed by exposing membranes to X-ray film for 30 secs to overnight, depending 
on signal strength. Films were developed using an automatic X-ray processor 
(Konica SRX-101A). Densitometry analysis using ImageJ 1.45s software was used to 
quantitate fold changes in protein levels, relative to loading controls. 
 
2.9 Transient small interfering RNA transfections 
The TPD52 small interfering RNA (siRNA) duplexes (Shehata et al., 2008a) siD52-1 
(5’-GCGGAAACTTGGAATCAAT-3’) and siD52-2 (5’-GGAGAAGTCTTGAATTCGG-
3’) were employed, that target the TPD52 coding sequence (GenBank U18914) at nt 
295-313 and nt 566-584, respectively. ON-TARGETplus siRNA pool ERBB2 target 
sequences were as follows: 5’-TGG AAG AGA TCA CAG GTT A-3’, 5’-GAG ACC 
CGC TGA ACA ATA C-3’, 5’-GGA GGA ATG CCG AGT ACT G-3’ and 5’-GCT CAT 
CGC TCA CAA CCA A-3’, targeting the ERBB2 coding sequence (NM_004448.2) at 
four different regions from nt 1446-1464, 597-614, 1861-1879 and 490-509, 
respectively. Both the TPD52 and ERBB2 siRNAs were obtained from Dharmacon, 
whereas non-targeting siRNA (siControl) was obtained from Qiagen. Cells were 
seeded at 2x104 cells/well into 24-well plates. After 24 h, cells were transfected with 
50 nM siRNA duplexes using TransIT-TKO transfection reagent (Mirus Bio) in 
complete media following the manufacturer’s instructions. After 24 h, transfection 
media were removed and replaced with complete media. Cells were harvested for 
analysis 48 h later.  
 
2.10 Cell death detection assay 
Cells were transfected with siRNAs and 72 h later, the level of DNA fragmentation 
was quantified using the Cell Death ELISAPLUS kit according to the manufacturer’s 
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instructions (Roche). Briefly, cells were lysed and centrifuged, and supernatants were 
transferred to 96-well pre-coated plates to assay cytoplasmic histone-associated 
DNA fragments. After incubations and washes, stop substrate was added and color 
development was measured at 405 nm using a Multiskan Ascent plate reader 
(Thermo Scientific). Samples were analysed in duplicate in 3 independent 
experiments. Doxorubicin (Sigma-Aldrich) was used as a positive control for 
apoptosis in SK-BR-3 cells (500 nM, 72 h) or BT-474 cells (1 μM, 72 h). The 
enrichment of mono- and oligonucleosomes released into the cytoplasm of cell 
lysates was detected by biotinylated anti-histone- and peroxidase-coupled anti-DNA-
antibody and is calculated using the formula: absorbance of sample cells/absorbance 
of control cells. Enrichment factors were used as a measure of apoptosis, calculated 
relative to the control value for cells treated by transfection only (which was set to 
1.0). 
 
2.11 Plasmids used in generating stably TPD52-depleted cell lines 
Four Hush 29mer short hairpin RNA (shRNA) constructs targeting four different 
regions of TPD52 coding sequence (GenBank U18914): shRNA-D52-1: 5’-AGG AGA 
AGA TGT TGC TGC CAC GAT CAG TG-3’, targeting nt 142-170; shRNA-D52-2: 5’-
AAT TCG GCT GCA AAT GCT AGT GCC ACC AC-3’, targeting nt 578-506; shRNA-
D52-3: 5’-ATC CAG ACT CTG TCT CAA GTG TTA GCA GC-3’, targeting nt 239-
267; shRNA-D52-4: 5’-GCA TCT AGC AGA GAT CAA GCG GAA ACT TG-3’, 
targeting nt 277-305, and a non-targeting control shRNA 5’-GCA CTA CCA GAG 
CTA ACT CAG ATA GTA CT-3’) were cloned into the same sites of a pGFP-V-RS 
expression vector which were all obtained from OriGene Technologies. The pGFP-V-
RS plasmid encodes a GFP tag driven by a CMV promoter and is kanamycin 
resistant.  
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2.12 E.coli transformation using electrophoration 
The bacterial strain Escherichia coli (E. coli) XL1-Blue (recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F′ proABlaclqZΔM15 Tn10 (Tetr)]) (Stratagene) was used 
to obtain competent cells prepared by Dr. Yuyan Chen. Approximately 50 l 
competent cells were transformed with plasmid DNA in ice-cold 0.2 cm cuvettes by 
electrophoration (Bio-Rad Gene Pulser II) at 2.5 kV, 25 F and 200 Ω for 4-5 
milliseconds. One ml pre-warmed SOC media was then added immediately, and cells 
were transferred to 14 ml falcon tubes and incubated with shaking at 37°C, 250 rpm 
for 1-1.5 h. Each cell suspension was then placed into a 1.5 ml eppendorf tube and 
centrifuged at 3000 rpm for 3 minutes at RT to pellet bacterial cells, and the majority 
of the supernatant was discarded. Cells were resuspended in the remaining 
supernatant and plated onto LB agar plates supplemented with 50 g/ml kanamycin 
and incubated at 37°C overnight to allow colony formation.  
 
2.13 Screening of bacterial colonies and large scale plasmid DNA preparation 
Single bacterial colonies were picked and plasmid DNA was isolated using a QIAprep 
Miniprep Kit (Qiagen), according to manufacturer’s instructions. Mini-preparations of 
plasmids were quantified (Section 2.14) and sent for DNA sequencing (Section 2.15) 
to confirm the insert. Once sequences were confirmed, plasmid DNA was prepared in 
large quantities using the QIAfilter Plasmid Midi Kit (Qiagen), according to the 
manufacturer’s instructions. DNA concentration and purity were again quantified 
(Section 2.14) followed by DNA sequencing for sequence verification (Section 2.15). 
 
2.14 Spectrophotometric quantitation of DNA and RNA 
DNA and RNA concentration and purity were determined using the Nanodrop 
spectrophotometer (Thermo Scientific) by measuring absorbance at 260 nm (A260). 
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The absorbance values were then calculated for DNA or RNA concentration 
according to the following formula:  
 
Concentration of DNA or RNA (ng/μL) = A260 x dilution factor x 50 (DNA) 
       = A260 x dilution factor x 40 (RNA) 
  
The purity of DNA or RNA was also determined by measuring the A260/A280 
absorbance ratio. A ratio of 1.8-1.9 indicates a pure DNA or RNA preparation. 
 
2.15 DNA sequencing 
The plasmid DNA pellets were resuspended in 1 x TE buffer and quantitated by 260 
nm absorbance readings (Section 2.14). Samples containing 200–500 ng plasmid 
DNA plus 5–10 pmol of the primers used. The primer sequences were sense: 5’-GAC 
TAT CAT ATG CTT ACC GTA ACT-3’ and antisense: 5’-CTA TGG TTG CTG ACT 
AAT TGA GAT-3’, which amplified the pGFP-V-RS shRNA-29 expression vector 
either (with or without the TPD52 shRNA sequence fragments) at nt 261-487. 
Plasmids were sequenced by either Sydney University Prince Alfred Molecular 
Analysis (SUPAMAC, Australia) or Australian Genome Research Facility (AGRF) at 
Westmead, Australia. The sequence traces were subjected to BLASTN analysis to 
confirm the identity of the inserts and inspected visually to ensure the correct reading 
frame. 
 
2.16 Generation of stably TPD52 depleted SK-BR-3 cell lines 
For generating stably-depleted cell lines, shRNA plasmids (Section 2.11) were 
transfected into SK-BR-3 cells by seeding cells at ~ 60% confluence in 10 cm dishes 
and transfecting 24 h later using 3 μg DNA with TransIT-LT1 transfection reagent 
(Mirus Bio) in serum-free media. After 3 days, cells were seeded into nine 10 cm 
dishes, and 2 μg/ml puromycin (Sigma-Aldrich) was added 24 h later. Puromycin 
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selection continued for 2 weeks, after which selected resistant clones were screened 
using Western blot analyses for TPD52 protein levels. Four cell lines stably depleted 
of TPD52 and 2 control cell lines were selected and maintained in 1μg/ml puromycin 
media for further analyses.     
 
2.17 Cell proliferation assay (MTT assay) 
Briefly, untreated, non-target control or stably TPD52 depleted SK-BR-3 cells were 
plated in triplicate in 96-well plates (3x103 cells/well). Cells were cultured for 24 h and 
then 50 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
reagent (Sigma-Aldrich) was added to each well either immediately (time 0 h) or at 
the designated number of days post-seeding. MTT reactions were incubated at 37°C 
in the presence of 5% CO2 for 4 h. To stop each reaction, media were replaced with 
100 μl DMSO (Sigma-Aldrich) per well and mixed thoroughly. Absorbances at 540 
nm were read using a Multiskan Ascent plate reader (Thermo Scientific). Means of 
triplicate wells from 3 independent experiments were used to generate data points 
and SE values.  
 
2.18 Lapatinib treatment 
Lapatinib was dissolved in DMSO to produce a 54 μM stock solution. Cells were 
treated with vehicle control (DMSO, 0.01%) or Lapatinib (100 nM) in triplicate per 
treatment group. MTT cell proliferation assays were performed over 5 days as 
described (Section 2.17). Proteins were harvested for Western blot analysis at days 1 
and 5 of Lapatinib treatment. Means of triplicate wells obtained from MTT cell 
proliferation assays from 3 independent experiments were used to generate data 
points and SE values. Cell proliferation was calculated as percentage differences in 
absorbance values of treated (Lapatinib) versus untreated (DMSO) cells. 
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2.19 In situ staining of cultured cells 
 
2.19.1 Indirect immunofluorescent staining analyses 
Cells were plated onto glass coverslips, and cultured overnight until reaching 70-80% 
confluency the next day. Cells were washed twice with 1X PBS, fixed in 2% 
paraformaldehyde/PBS for 15 min at RT, washed 3 times with 1X PBS, 
permeabilized with cold acetone:methanol (1:1) for 15 min at -20°C, washed 3 times 
with 1X PBS and left for at least 30 min at RT, and incubated with the relevant 
primary antibodies (Section 2.1.3.1) in 3% BSA in 1X PBS overnight at 4°C. Cells 
were washed 3 times with 1X PBS and incubated with the relevant secondary 
antibodies (Section 2.1.3.2) in 3% BSA in 1X PBS, for 1 h in the dark at RT. After 
washing (3 times in 1X PBS), cells were mounted in FluorSave mounting medium 
(Calbiochem) onto glass slides, and kept in a horizontal position for at least 48 h for 
the coverslips to stick to the slides before viewing. Cells were visualized using either 
a TCS SP2 or TCS SP5 confocal laser scanning microscope (Leica), using a 63X 
objective lens.  
 
2.19.2 Neutral lipid staining of lipid droplets 
Cells were prepared and washed as described (Section 2.19.1) and fixed in 3% 
paraformaldehyde/PBS for 30 min at RT, then washed 3 times with 1X PBS. BODIPY 
493/503 working solution were prepared fresh by adding 10 l of 1 mg/ml BODIPY 
493/503 stock solution to 10 ml of 150 mM NaCl. Cells were stained with BODIPY 
493/503 working solution for 30 min in the dark at RT. Cells were then washed 3 
times with 1X PBS, and DNA was counterstained with 10 nM DAPI (Sigma-Aldrich) 
for 5 min. After washing (3 times in 1X PBS), cells were mounted and visualized as 
described (Section 2.19.1). 
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2.19.3 Combined cellular staining for proteins and neutral lipid  
For simultaneous visualization of intracellular proteins and lipid droplets, cells were 
prepared, washed and fixed as described (Section 2.19.1). Cells were then incubated 
with blocking buffer (Section 2.1.2) for 45 min at RT, washed 3 times with 1X PBS 
and incubated with the relevant antibodies (Section 2.1.3.1) diluted in antibody 
diluent (Section 2.1.2) overnight at 4°C. Cells were left to warm at RT for 30 min 
before proceeding. Cells were washed 3 times (10 min each) on a rocking platform, 
and incubated with the relevant secondary antibodies (Section 2.1.3.2) and 1:1000 of 
BODIPY 493/503 stock solution diluted in antibody diluent, for 1 h in the dark at RT. 
After washing (3 times in 1X PBS), cells were mounted and visualized as described 
(Section 2.19.1). 
  
2.19.4 Image capture and analyses 
Images were taken using a Leica TCS SP2 or TCS SP5 confocal laser scanning 
microscope (Leica Technologies), using a Plan 63X oil objective. The 405, 488, 543 
and 633 nm lasers were used to excite DAPI, Alexa488, BODIPY 493/503, Cy3, Cy5 
and Alexa633, respectively. Leica confocal software and Image ProPlus 5.1 software 
(Media Cybernetics) were used for image analyses.  
 
2.19.5 Lipid droplet quantitation 
All image data intended for quantitative comparison were acquired at the same 
subsaturating exposure time. Images of at least 10 panels per cell line in each of 3 
independent experiments were used to quantify lipid droplets using Image ProPlus 
5.1 software. The data collected were numbers, maximum diameters of lipid droplets, 
with areas calculated using diameters. The 3T3 cell line, D52-2-7 was used as the 
BODIPY 493/503 fluorescence intensity control to set the intensity range. Further 
filtering was done to exclude objects with diameters smaller than 0.3 μm, to reduce 
noise from potential non-specific staining, based on expected lipid droplet sizes in 
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non-adipocytes ranging from 0.2 – 1 μm (Suzuki et al., 2011; Walther and Farese, 
2012). The same parameters were then used to quantify lipid droplets in all 3T3 cell 
lines.  
 
2.20 Oleic acid treatment 
 
2.20.1 Oleic acid/BSA complex solution preparation 
A 100 mM oleic acid stock solution was prepared in 0.1 M NaOH by heating in a 
70oC water bath. In an adjacent 55oC water bath, a 10% (wt/vol) FFA-free BSA 
solution was prepared in 1xPBS. A 5 mM FFA/10% BSA stock solution was prepared 
by adding 50 μL 100 mM oleic acid solution dropwise to 950 μL 10% BSA solution at 
55oC, which was then vortex-mixed for 10 sec, followed by a further 10 min 
incubation at 55oC. The 5 mM oleic acid/10% BSA stock solution was cooled to RT 
filtered through 0.45 μM membrane filter, and stored at 4°C. The 5 mM oleic 
acid/10% BSA stock solution was then diluted to 400 m oleic acid in growth media 
and used as the working solution.  
 
2.20.2 Oleic acid treatment of 3T3 cell lines 
3T3 cells were cultured as described (Section 2.2.2) in 6-well plates until ~60-70% 
confluency. Growth media were removed and cells were washed twice with 1XPBS. 
Cells were either untreated (harvested at 0 h) or treated with 400 m oleic acid in 
growth media (prepared in Section 2.20.1). After 6 h or 24 h of oleic acid treatment, 
cells were harvested for further analyses. 
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2.21 Statistical analyses 
 
The SPSS for Windows package (version 19; SPSS) was used in most analyses. 
The Spearman’s rank test was used for correlation tests between samples. The 
Mann-Whitney test was used to compare relative transcript and protein levels and 
other variables. Results of all cell death detection, proliferation and lipid quantitation 
assays were expressed as means ± SE of three independent experiments. 
Comparisons between groups were made using two-tailed, unequal variance 
Student’s t tests calculated using Excel (Microsoft). 
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Chapter 3 
TPD52 represents a survival factor in 
ERBB2-amplified breast cancer cells 
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3.1 Introduction 
 
As discussed in Chapter 1, cancer incidence is predicted to continue to rise. 
Therefore, there is a growing need to understand cancer pathogenesis in depth, due 
to the multiple genetic alterations whose significance still needs to be elucidated. 
Studying gene amplification targets and the phenomenon of oncogene addiction has 
led to the successful development of molecular therapies, such as Herceptin 
targeting the oncoprotein ERBB2. However, not all breast cancer patients with 
ERBB2-positive disease respond well to therapy and some develop resistance to 
Herceptin (Cobleigh et al., 1999; Vogel et al., 2002). Therefore, there is an urgent 
need to understand the basis of drug resistance to targeted agents. Understanding 
the functions of proteins co-expressed with ERBB2 may identify co-operating factors 
which promote or enhance tumor cell phenotypes, and which may contribute to 
primary or secondary resistance to ERBB2-targetted therapies. 
 
Like ERBB2 (Section 1.3.3), TPD52 is amplified or gained in breast cancer (Balleine 
et al., 2000), and associations between gene copy number and expression support 
TPD52 representing a gene amplification target in breast and other cancers (Byrne et 
al., 2012; Guedj et al., 2012). This was recently underscored by a large-scale 
genomic study identifying focal amplification of TPD52 and 3 neighbouring 
chromosome 8q21.13 genes in breast cancer (Cancer Genome Atlas Network, 
2012). Furthermore, increased TPD52 immunohistochemical staining was associated 
with reduced overall survival in breast cancer patients, where this was an 
independent prognostic factor (Shehata et al., 2008a). TPD52 has similarly been 
included in gene expression (Adler et al., 2006; Liu et al., 2007b; Ross-Innes et al., 
2012) or copy number (Zhang et al., 2009) signatures associated with poor prognosis 
in breast cancer patients. However, the functional significance of TPD52 and ERBB2 
co-expression in breast cancer is not well understood. Therefore, based on 
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numerous reports supporting possible TPD52 and ERBB2 co-expression (Chen et 
al., 2010; Choschzick et al., 2010; Kourtidis et al., 2010; Landis et al., 2006; Landis et 
al., 2005; Whiteaker et al., 2007; Wilson et al., 2002), we proposed TPD52 may co-
operate with ERBB2 in promoting cancer pathogenesis.  
 
The Akt signaling pathway is known to be important in regulating cell proliferation and 
survival (Nicholson and Anderson, 2002). It is also well established that ERBB2 lies 
upstream of Akt within the PI3K/Akt pathway (Blume-Jensen and Hunter, 2001). In 
agreement with previous studies reporting ERBB2 and TPD52 co-expression as 
discussed in Chapter 1 (Section 1.6.3.1), TPD52 has also been shown to regulate 
signaling through the Akt pathway. Exogenous TPD52 expression has been reported 
to lead to increased cell proliferation as well as increased migration and invasion in 
3T3 mouse fibroblasts (Della Franca, 2012; Shehata et al., 2008a)  and LnCaP 
prostate cancer cell lines (Li et al., 2009; Ummanni et al., 2008; Zhang et al., 2007a). 
Furthermore, exogenous expression of TPD52 or its isoform PrLZ led to increased 
pAkt(Ser473) levels in LnCaP prostate cancer cells (Ummanni et al., 2008; Zhang et 
al., 2011; Zhang et al., 2007a) and 3T3 mouse fibroblast cells (Della Franca, 2012). 
In addition, reduced PrLZ levels in C4-2 prostate cancer cell lines was associated 
with reduced cell proliferation and pAkt(Ser473) levels (Zhang et al., 2011). Figure 
3.1 summarizes proposed possible links between ERBB2, TPD52 and Akt that have 
emerged from the literature to date.  
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Figure 3.1 Schematic diagram showing proposed links between ERBB2, TPD52 
and Akt. This is based on previous reports of TPD52 and ERBB2 co-expression in 
breast cancer, and of increased pAkt levels occurring in response to increased 
TPD52 expression in prostate cancer. The relevant studies contributing to this 
diagram were summarized in Section 1.6.3.1 in the case of breast cancer studies, 
and Section 3.1 in the case of prostate cancer studies. 
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3.1.1 Specific aims for Chapter 3 
 
The specific aims for Chapter 3 were as follows: 
 
1. To examine TPD52 gene amplification, transcript and protein levels status in 
a panel of breast cell lines. 
 
2. To employ small interfering RNA (siRNA) approaches to characterise the 
effects of transiently reducing TPD52 expression in breast cell lines with 
different TPD52 and ERBB2 gene amplification status. 
 
3. To investigate the effects of transiently reducing TPD52 and ERBB2 
expression, both singly and in combination, in ERBB2-amplified breast cancer 
cell lines.  
 
4. To study the long-term effects of reduced TPD52 expression in the TPD52- 
and ERBB2-amplified breast cancer cell line SK-BR-3. 
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3.2 Results 
 
3.2.1 TPD52 and ERBB2 copy number and expression in breast cancer cell 
lines 
 
Previously, TPD52 has been reported to be significantly overexpressed in breast 
cancer tissue relative to normal breast (Balleine et al., 2000; Porter et al., 2003; 
Shehata et al., 2008a; Yu et al., 2004). However, TPD52 copy number, transcript and 
protein levels have not been directly examined in breast cell lines. We selected a 
panel of 14 breast cancer cell lines with varying TPD52 levels to compare TPD52 
and ERBB2 expression, and select the appropriate cell lines for further analysis. 
Table 3.1 shows the known/general molecular characteristics of these 14 breast 
cancer cell lines. Predicted TPD52 amplification status for the 14 breast cancer cell 
lines (Mackay et al., 2009; Neve et al., 2006; Pollack et al., 2002) was assessed via 
the ROCK database (http://rock.icr.ac.uk/) (Table 3.2), and MCF-10A cells were used 
for comparative purposes as a non-tumorigenic breast cell line (Soule et al., 1990). 
Cell lines were subjected to quantitative real-time (RT)-PCR to determine TPD52 
DNA copy number and transcript levels relative to those in MCF-10A cells. TPD52 
and ERBB2 protein levels were analysed by Western blot analyses. 
 
Real-time (RT-) PCR and Western blot analyses revealed differences in relative 
TPD52 copy number, transcript and protein levels between the 15 breast cell lines, 
which included 14 breast cancer cell lines and MCF-10A cells (Figure 3.2). Overall, 
when compared with MCF-10A cells, most (12/14) breast cancer cell lines had higher 
relative TPD52 copy numbers, and 13/14 breast cancer cell lines had higher relative 
TPD52 transcript levels (Figure 3.2A and 3.2B). A significant positive correlation was 
measured between relative TPD52 transcript and protein levels (Spearman’s test, 
rs=0.743; p=0.002; n=15). Similarly, 11 breast cancer cell lines with increased TPD52  
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Table 3.1 Molecular characteristics of breast cell lines used. 
Cell line ER PR ERBB2 
amp 
p53 
SK-BR-3 + - + +M 
AU-565 + - + +M 
BT-483 + + - -del 
MDA-MB-175 + - - +WT 
HS-578T - - - +M 
BT-474 + + + + 
MCF-7 + + - +WT 
MDA-MB-157 - - - -del 
MDA-MB-134 + - - +M 
DU4475 -  - +WT 
T-47D + + - ++M 
MDA-MB-231 - - - ++M 
MDA-MB-468 - - - +M 
ZR-75-30 + - + +WT 
MCF-10A - - - WT 
 
ER, PR positivity, ERBB2 amplification, and p53 protein levels and mutational status 
(del, deletion; M, mutant protein; WT, wild-type protein) are indicated. (ER = estrogen 
receptor, PR = progesterone receptor, ERBB2 amp = ERBB2 amplification, p53 = 
tumor protein p53, + = positive, - = negative). Data obtained from Kenny et al. (2007), 
Lacroix et al. (2006) and Neve et al. (2006). 
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Table 3.2 Predicted TPD52 amplification status from published array CGH data. 
Cell line Predicted TPD52 amplification status  
Pollack et al. (2002) Neve et al. (2006) Mackay et al. (2009) 
SK-BR-3 Amp (1.0036)  Amp (1.2374) Amp (1.2841) 
AU -565  Amp (1.0979)  
BT-483  Amp (0.8767)  
MDA-MB-175  Amp (0.5921) Amp (0.4822) 
HS-78T  Amp (0.5326) Amp (0.4161) 
MDA-MB-134  Gain (0.3455) Gain (0.3657) 
MDA-MB-157 Gain (0.1538) Gain (0.1949) Gain (0.2837) 
T-47D Gain (0.1214) Gain (0.299) Gain (0.1074) 
BT-474 Gain (0.1162) Gain (0.1376) Gain (0.2255) 
MCF-7 Dip (0.0443) Gain (0.2677) Gain (0.178) 
DU4475  Gain (0.1269) Gain (0.2053) 
MDA-MB-231  Loss (-0.1183) Gain (0.3699) 
MDA-MB-468  Dip (0.0196) Dip (0.0459) 
MCF-10A   Dip (-0.0608)  Dip (-0.0276)  
ZR-75-30 Dip (0.0307) Loss (-0.2158) Loss (-0.235) 
Numbers in brackets represent TPD52 array CGH ratios according to the ROCK 
database (http://rock.icr.ac.uk/).  For Pollack et al. (2002) and Neve et al. (2006) 
thresholds of 0.4 = amplified (Amp); 0.1 = copy number gain (Gain); -0.1 = copy 
number loss (Loss). In Mackay et al. (2009), the threshold for gain was 0.08 and loss 
was -0.08. Array CGH ratios between these ratios (< 0.1 and > -0.1, or < 0.08 and > -
0.08 were considered diploid. 
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transcript levels also had significantly higher TPD52 protein levels than the remaining 
4 cell lines (Mann-Whitney U test, p=0.037, n=15). 
 
TPD52 copy number, transcript and protein levels were highest in SK-BR-3 and AU-
565 cells (Figure 3.2), which was in broad agreement with the results of Northern blot 
analyses of a smaller cell line cohort that included SK-BR-3 (Balleine et al., 2000). 
This result also supported published microarray data indicating SK-BR-3 and AU-565 
to be TPD52-amplified (Kao et al., 2009; Mackay et al., 2009; Neve et al., 2006; 
Pollack et al., 2002) (Table 3.2), which was also reported for SK-BR-3 cells using 
single cell genome sequencing (Navin et al., 2011). The SK-BR-3 and AU-565 cell 
lines were derived from a single patient, and both are highly ERBB2-positive (Figure 
3.2C), and ERBB2-amplified (Neve et al., 2006). Interestingly, 4 ERBB2-amplified 
cell lines in our study (SK-BR-3, AU-565, BT-474, ZR-75-30) showed significantly 
higher relative TPD52 transcript and protein levels than the remaining non-ERBB2-
amplified cell lines (n=11) (Mann-Whitney U test, p=0.006, n=15, TPD52 transcript 
levels; p=0.037, n=15, TPD52 protein levels) (Figure 3.2B-3.2D), and significant or 
borderline positive correlations were measured between ERBB2 protein and TPD52 
transcript or protein levels, respectively (Spearman test, rs=0.681; p=0.005; n=15, 
TPD52 transcript levels; rs=0.513; p=0.051; n=15, TPD52 protein levels). Therefore, 
results from real-time (RT-) PCR and Western blot analyses of 15 breast cell lines 
confirmed SK-BR-3 and AU-565 as TPD52-amplified and overexpressing cell lines.  
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Figure 3.2 TPD52 copy number and expression status in breast cell lines. 
Breast cell lines were subjected to quantitative real-time (RT)-PCR to determine 
relative (A) TPD52 DNA copy number and (B) TPD52 transcript levels, both 
normalized against levels in MCF-10A cells. Results shown are the means ± SE from 
3 independent experiments performed in triplicate. (C) Representative Western Blot 
analysis demonstrating TPD52 and ERBB2 levels. Left, proteins analysed. Right, 
molecular weights of detected species. Results shown are representative of those 
obtained in at least 3 independent experiments. (D) Densitometric analysis of TPD52 
and ERBB2 levels in breast cell lines from 3 independent experiments. Mean 
intensities (relative to GAPDH) of TPD52 (grey bars) or ERBB2 (black bars) are 
plotted on the Y axis (+/- SE), with breast cell lines shown on the X axis.  
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3.2.2 Optimization of transient TPD52 knock-down conditions       
 
Our group previously has shown that transient reduction of TPD52 levels in MCF-7 
and SK-BR-3 cells was associated with significantly increased apoptosis in SK-BR-3 
cells only (Shehata et al., 2008a). As previously, the present study used two TPD52 
siRNAs (siD52-1 and siD52-2, Figure 3.3A) which were compared with the effects of 
the non-targeting siRNA (siControl) used by Shehata et al. (2008a), transfection 
reagent (TKO)-treated cells and parental (SK-BR-3) cells. Doxorubicin treatment (100 
nM for 48 h, 72 h, 96 h) of SK-BR-3 cells was used as a positive control for the 
induction of apoptosis. The previous transient TPD52 knock down method (Shehata 
et al., 2008a) was modified slightly, in that TPD52 siRNA concentrations were 
reduced from 100 nM to 50 nM, as similarly reduced TPD52 levels were obtained by 
transfecting either 50 or 100 nM TPD52 siRNAs (data not shown).  
 
We also optimised the duration of siRNA treatment in terms of maximally reducing 
TPD52 expression (Figure 3.3B) and inducing apoptosis (Figure 3.3C). TPD52 levels 
were reduced at all time points upon TPD52 knock-down, being least reduced at 48 h 
and most reduced at 96 h (Figure 3.3B). Densitometry analyses indicated that upon 
transient TPD52 knock-down with both TPD52 siRNAs, 48 h treatment reduced 
TPD52 levels to ~50%, 72 h treatment reduced TPD52 levels to ~30% and 96 h 
treatment reduced TPD52 levels to ~20% of control levels (data not shown).  
 
The Cell Death Detection ElisaPlus kit (Roche) detects apoptosis by quantitatively 
determining the formation of cytoplasmic histone-associated DNA fragments in the 
form of mononucleosomes and oligonucleosomes after apoptosis (Bonfoco et al., 
1995; Nagata, 2000). We aimed to choose the earliest time point where increased 
cell death was detected following TPD52 knock-down. Overall, reduced  
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Figure 3.3 Optimization of siRNA TPD52 knock-down. (A) Schematic diagram of 
TPD52 coding region showing the positions of siRNA targets (siD52-1, nt 295-313 
and siD52-2, nt 566-584). Numbers represent exons, with exons 1a, 1b, 5 and 6 
being subject to alternative splicing. Exons 1a and 1b are included in TPD52 and 
PrLZ transcripts, respectively.  (B) Selection of siRNA knock-down time points using 
SK-BR-3 cells which were subjected to transient TPD52 knock-down using 50 nM of 
two different siRNAs (siD52-1 and siD52-2). TPD52 protein expression levels were 
assessed by Western blot analyses, with GAPDH being used as a loading control. 
Left, proteins analysed. Right, molecular weights of detected species. (C) The effects 
of TPD52 knock-down 48 h, 72 h and 96 h post-transfection were assessed using a 
Cell Death Detection ElisaPlus kit (Roche). Untreated cells, TKO transfection reagent 
only and non-targeting siRNA transfected cells (siControl) were used as negative 
controls. Doxorubicin treatment of SK-BR-3 cells (100 nM for 48 h, 72 h, 96 h; Dox) 
was used as a positive control for inducing apoptosis. Assay results were expressed 
as enrichment factors which were normalized against TKO for all treatments. The 
data presented are the mean (average) values from one experiment, performed in 
duplicate.  
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TPD52 levels reflected the apoptosis enrichment factor values obtained (Figure 
3.3C), as TPD52 knock-down after 48 h treatment produced the least cell death, 
whereas the 96 h timepoint was associated with the most cell death (Figure 3.3C). 
No differences in cell death were noted between cells transfected with either TPD52 
siRNA compared to TKO or parental SK-BR-3 cells at 48 h. Increased cell death was 
noted in cells transfected with either TPD52 siRNA when compared to TKO and 
parental SK-BR-3 cells at 72 h and 96 h (Figure 3.3C). Only minor differences in 
apoptotic cell death were noted at 72 h and 96 h following TPD52 knock-down, as 
per the minor differences noted in TPD52 levels at these timepoints (Figure 3.3B, 
3.3C, data not shown). Non-targeting control siRNA showed increased levels of cell 
death at 72 h and 96 h (Figure 3.3C), suggesting that this non-targeting control 
siRNA was not a valid control. Hence we obtained a different non-targeting control 
siRNA from Qiagen, which was shown to have similar effects as no treatment or 
TKO-treatment only in 4 breast cell lines tested (Figure 3.4). Therefore, we decided 
to choose the 72 h time point for all experiments, since this was the shortest time that 
efficiently reduced TPD52 levels and generated detectable apoptotic cell death. 
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Figure 3.4 Transient TPD52 knock-down effects in breast cell lines. Four breast 
cell lines (A) SK-BR-3, (B) MCF-7, (C) MDA-MB-231 and (D) MCF-10A were 
subjected to transient siRNA knock-down using two different siRNAs, siD52-1 and 
siD52-2. Untreated cells, TKO transfection reagent only and non-targeting siRNA 
transfected cells (siControl) were used as negative controls. Doxorubicin treatment of 
SK-BR-3 cells (500 nM, Dox, 72 h) was used as a positive control for inducing 
apoptosis. The effects of TPD52 knock-down after 72 h were assessed using a Cell 
Death Detection ElisaPlus kit (Roche). Assay results were expressed as enrichment 
factors normalized against TKO for all treatments, and means ± SE are presented for 
3 independent experiments done in duplicate. (*, p<0.005, Student’s t test). TPD52 
protein levels were assessed by Western blot analyses, with results shown being 
representative of those obtained in 3 independent experiments. GAPDH or α-tubulin 
was used as a loading control. Proteins analysed are indicated at the left or right of 
the panels, with the molecular weights of detected species shown in brackets. 
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3.2.3 Transient TPD52 knock-down in different TPD52-expressing cell lines 
 
Next, we expanded the previous study of Shehata et al. (2008a) by comparing the 
effects of reduced TPD52 expression in 4 cell lines differing in TPD52 copy number. 
We chose to compare SK-BR-3 cells which are universally predicted to be TPD52-
amplified and MCF-7 cells reported to show TPD52 gain in 2/3 array CGH studies 
(Table 3.2, Figure 3.2) with MDA-MB-231 and MCF-10A cells, which showed no 
apparent increased in relative TPD52 copy number (Figure 3.2). Similarly, we used 
the two TPD52 siRNAs (siD52-1 and siD52-2, Figure 3.3A) employed by Shehata et 
al. (2008a) and a different non-targeting siRNA (siControl) purchased from Qiagen, 
and transfection reagent (TKO)-treated cells as negative controls. Doxorubicin (500 
nM, 72 h) treatment of SK-BR-3 cells was used as a positive control for the induction 
of apoptosis. Variable effects of Doxorubicin on TPD52 levels were obtained, 
indicating that Doxorubicin may indirectly affect TPD52 levels (Figures 3.3, 3.4 and 
3.5). 
 
After 72 h of TPD52 siRNA treatment, TPD52 levels were reduced in all 4 cell lines 
but were unaffected by non-targeting siRNA or TKO treatment (Figure 3.4). 
Apoptosis assays revealed that reduced TPD52 expression by TPD52 siRNA target 
si-D52-1 in SK-BR-3 cells was associated with significantly increased apoptosis at 72 
h post-transfection, relative to siControl-treated cells (Figure 3.4A). Treatment of SK-
BR-3 cells with siRNA siD52-2 reproducibly led to less efficient reductions in TPD52 
levels and lower apoptosis, compared with siRNA si-D52-1 (Figure 3.4A), although 
these siRNAs produced similar levels of TPD52 knock-down in all other cell lines 
(Figure 3.4B, 3.4C, 3.4D). Despite the substantially reduced TPD52 levels produced 
in all 4 breast cell lines, reduced TPD52 expression with siRNA siD52-1 was 
associated with significantly increased apoptosis in SK-BR-3 cells only (Figure 3.4).  
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3.2.4 Transient TPD52 and/or ERBB2 depletion in ERBB2-amplified breast 
cancer cell lines 
 
Since SK-BR-3 is amplified for both TPD52 and ERBB2  (Navin et al., 2011) and the 
majority of cell lines indicated to be sensitive to the effects of TPD52 knock-down 
were either ERBB2-amplified or positive for ERBB2 expression (Kourtidis et al., 
2010; Shehata et al., 2008a) (Figure 3.4), we investigated whether the effects of 
reduced TPD52 expression might be associated with ERBB2 amplification status. We 
therefore compared the effects of TPD52 and ERBB2 knock-down, alone or in 
combination, in the ERBB2-amplified and overexpressing cell lines BT-474 and SK-
BR-3 (Hynes et al., 1989; Kallioniemi et al., 1992). We selected BT-474 cells to 
compare with SK-BR-3 cells, as BT-474 cells express lower TPD52 levels (Figure 
3.2), and have no apparent increase in TPD52 copy number (Figure 3.2A). While this 
result contrasts with previous reports of TPD52 copy number gain in BT-474 cells 
(Table 3.2), neither our results nor those previously reported identify TPD52 
amplification in BT-474 cells, and in this sense, they clearly contrast with SK-BR-3 
cells. We employed the single TPD52 target siD52-1 in these studies, based on 
results (Figure 3.4, data not shown) showing that siD52-1 reduced TPD52 levels to a 
greater extent than siD52-2 in SK-BR-3 cells.  
 
Both SK-BR-3 and BT-474 cells showed increased apoptosis following ERBB2 
knock-down relative to siControl-transfected cells, as supported by quantitative 
apoptosis assays and the detection of cleaved PARP-1 (Figure 3.5). Both methods 
indicated that higher levels of apoptosis were produced by ERBB2 knock-down in 
BT-474 compared with SK-BR-3 cells (Figure 3.5), consistent with previous results 
where ERBB2 knock-down was associated with ~73% reduced cell proliferation and  
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Figure 3.5 Transient TPD52 and ERBB2 knock-down in ERBB2-amplified cell 
lines. SK-BR-3 (A) or BT-474 cells (B) were treated with TPD52 (siD52-1) and/or 
ERBB2 siRNA (siERBB2) or non-targeting siRNA (siControl) for 72 h, and harvested 
for apoptosis assays and Western blot analyses. Doxorubicin treatment of BT-474 (1 
μM, 72 h) (Dox) was used as a positive apoptosis control. The effects of siRNA 
treatment were assessed using a Cell Death Detection ElisaPlus kit (Roche). Results 
were expressed as enrichment factors normalized against TKO results, and means ± 
SE are presented for 3 independent experiments done in duplicate. Significant 
differences between the mean enrichment factors measured following TPD52 and/or 
ERBB2 knock-down versus other treatments are indicated (* p<0.05, ** p<0.001, 
n.s.= not significant, Student’s t test). TPD52, pERBB2, ERBB2, cleaved PARP-1, 
pAKT and pMAPK levels were determined using Western blot analyses. Results 
shown are representative of those obtained in 3 independent experiments. Left, 
proteins analysed. Right, molecular weights of detected species.  
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viability in BT-474 cells, compared with ~ 26% in SK-BR-3 cells after 4 days 
(Kourtidis et al., 2010). Both SK-BR-3 and BT-474 cells showed similar significant 
increases in apoptosis following TPD52 knock-down (Figure 3.5), despite their 
differing TPD52 expression levels (Figure 3.2C). Interestingly, SK-BR-3 cells showed 
similar sensitivity to both TPD52 and ERBB2 knock-down, and knock-down of both 
genes produced significantly higher levels of apoptosis, compared with the knock-
down of either gene alone (Figure 3.5A). However, as BT-474 cells were more 
sensitive to ERBB2 knock-down than SK-BR-3 (Figure 3.5), the increased apoptosis 
produced by knock-down of both genes was only significant when compared with the 
effects of TPD52 knock-down (Figure 3.5B). 
 
Both total ERBB2 and the pERBB2-Tyr1221/1222 phosphorylated form of ERBB2 
(pERBB2) were used to examine the effects of ERBB2 and/or TPD52 knock-down. In 
both cell lines, TPD52 or ERBB2/pERBB2 levels were reduced after 72 h of 
treatment with the corresponding siRNA, either alone or in combination, but were 
unaffected by non-targeting siRNA or TKO treatment (Figure 3.5A and 3.5B). 
Transient TPD52 knock-down did not reproducibly alter ERBB2 or pERBB2 levels in 
both cell lines, and similarly ERBB2 knock-down did not alter TPD52 levels (Figure 
3.5).  
 
Overexpression of TPD52 or its isoform, PrLZ, in LnCaP prostate cancer cells has 
been reported to result in increased pAKT (pSer473) (Ummanni et al., 2008; Zhang 
et al., 2011; Zhang et al., 2007a). While ERBB2 knock-down was associated with 
reduced pAKT (pSer473) levels in both BT-474 and SK-BR-3 cells as anticipated 
(Yang et al., 2004), pAKT (pSer473) levels were unchanged by TPD52 knock-down 
(Figure 3.5). There were similarly no changes to pMAPK44/42 levels upon transient 
TPD52 knock-down (Figure 3.5). 
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On a side note, Doxorubicin was used as a positive control for assessing cell death 
status (ELISA method) and apoptotic status (cleaved-PARP-1 detection), but we did 
not intend to assess Doxorubicin’s effects on TPD52 levels. As seen in the results 
obtained (Section 3.2.3 and 3.2.4), variable effects of Doxorubicin on TPD52 levels 
were obtained, indicating that Doxorubicin may indirectly affect TPD52 levels. 
 
3.2.5 Subcellular distributions of TPD52 and ERBB2 in SK-BR-3 cells 
 
To further investigate the significance of TPD52 and ERBB2 co-expression in SK-
BR-3 cells, we compared the distributions of both proteins using indirect 
immunofluorescence analyses, to investigate possible co-localization of TPD52 and 
ERBB2. TPD52 has been detected within the perinuclear cytoplasm of breast cancer 
cells (Balleine et al., 2000), whereas ERBB2 is detected mainly at the cell membrane 
(Hommelgaard et al., 2004). Detection of both proteins in SK-BR-3 cells reproduced 
these expected subcellular distributions, with TPD52 and ERBB2 co-localization 
being focally limited towards the cell membrane (Figure 3.6). The lack of substantial 
co-localization of TPD52 and ERBB2 supported the different downstream 
consequences of reductions in TPD52 and ERBB2 noted in ERBB2-amplified cell 
lines (Figure 3.5). 
 
 
 
 
 
 
 
 
 
TPD52 ERBB2 Merge 
Top 
Middle 
10 µm 
10 µm 
Figure 3.6 Limited co-localization of TPD52 and ERBB2 in SK-BR-3 cells. 
Immunofluorescence images of SK-BR-3 cells co-stained with TPD52 monoclonal 
antibody (red) and ERBB2 polyclonal antisera (green) and combined images on the 
right (Merge). Representative images are shown from the top and middle sections of 
the same cell groups. White arrows show co-localization between TPD52 and 
ERBB2. Images shown are representative of those obtained in 3 independent 
experiments. Images were taken using a TCS SP2 confocal laser scanning upright 
microscope (Leica Technologies) using a 63X objective. Scale bar = 10 µm. 
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3.2.6 Optimizing conditions for generating stably TPD52-depleted SK-BR-3 cell 
lines         
 
As transiently reduced TPD52 expression led to significant apoptosis in SK-BR-3 
cells, with comparable effects noted for TPD52 and ERBB2 knock-down (Figures 3.4 
and 3.5), we investigated the long-term effects of reduced TPD52 levels in this cell 
line. We obtained 4 plasmids each containing TPD52 shRNAs targeting different 
regions of TPD52 (Figure 3.7A). A 29-mer scrambled shRNA cassette in a pGFP-V-
RS plasmid vector (Origene Technologies) was employed as a non-targeting control 
(Figure 3.7B). Transient transfections were performed to determine whether TPD52 
shRNAs could efficiently reduce TPD52 levels, as assessed by Western blot analysis 
(Figure 3.7B). Using protein lysates from cells harvested 72 h post-transfection, we 
noted that both shRNA-D52-2 and shRNA-D52-3 were able to efficiently reduce 
TPD52 levels, compared to parental (parent) and non-targeting control cells (non-
target) (Figure 3.7B). A total of 5 optimization attempts were made to identify the 
ideal amount of plasmid DNA as well as transfection reagent used (Invitrogen or 
Mirus Bio) that would optimally reduce TPD52 levels (Figure 3.7B, data not shown). 
From these experiments, 3 μg shRNA-D52-2 and shRNA-D52-3-containing plasmids 
and transfection reagent from Mirus Bio were used to generate stably TPD52-
depleted SK-BR-3 cell lines.     
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Figure 3.7 Optimization of shRNA TPD52 knock-down conditions. (A) Schematic 
diagram of the TPD52 coding region showing the positions of 4 shRNA targets 
(shRNA-D52-1: nt 142-170, shRNA-D52-2: nt 578-506, shRNA-D52-3: nt 239-267, 
shRNA-D52-4: nt 277-305) and 2 siRNA targets (siD52-1 and siD52-2, highlighted in 
red, as per Figures 3.3, 3.4). Regions of overlap between shRNA and siRNA targets 
are highlighted in light blue. Numbers represent exons, with exons 1a, 1b, 5 and 6 
being subject to alternative splicing. Exons 1a and 1b are included in TPD52 and 
PrLZ transcripts, respectively. (B) The 4 shRNA targets were optimized for efficient 
TPD52 knock-down in SK-BR-3 cells. 3 μg plasmid DNA containing either TPD52 
shRNA or non-targeting shRNA were transfected into SK-BR-3 cells. TPD52 protein 
levels were analysed 72 h after transfection using Western blot analyses. Results 
shown used 3 μg plasmid DNA with Mirus Bio transfection reagent and are 
representative from 5 optimization attempts with different amounts of plasmid DNA 
and transfection reagents (either from Invitrogen or Mirus Bio). GAPDH was used as 
a loading control. Left, proteins analysed. Right, molecular weight of detected 
species. 
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3.2.7 Generation of stably TPD52-depleted SK-BR-3 cell lines 
 
Next, we proceeded by transfecting SK-BR-3 cells with 3μg shRNA-D52-2 or shRNA-
D52-3 containing plasmids to generate stably TPD52-depleted SK-BR-3 cell lines. A 
schematic diagram of the strategy used for generating these stably TPD52-depleted 
SK-BR-3 cell lines is shown in Figure 3.8. Transfected plasmids containing TPD52 
shRNA targets (shRNA-D52-2 and shRNA-D52-3, Figure 3.7A) also included GFP 
tags, which allowed visual assessment of transfection efficiency (Figure 3.10A). Cells 
were harvested during early propagation in 24 well plates (termed “early passage” 
cells), to identify cell lines with reduced TPD52 levels for further propagation (Figure 
3.9). These cell lines and relevant controls were then re-harvested at passage 10 
(Figures 3.10A, 3.10B, 3.11B).  
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shRNA transfection of SK-BR-3 cells in 10 cm dishes 
 
 
Separate transfected cells in 8 X 10 cm dishes 
(add selection media containing puromycin) 
 
 
Pick single colonies, seed into 96-well plates 
 
 
Propagate into 24-well plates 
 
 
Assess TPD52 protein levels using Western blot 
 
 
Further propagation into 6-well plates, 
followed by 10 cm dishes 
 
 
Figure 3.8 Generation of stably TPD52-depleted SK-BR-3 cell lines using 
puromycin selection. SK-BR-3 cells were transfected with 3 μg plasmid DNA 
containing shRNA targets (shRNA-D52-2, shRNA-D52-3 or non-target control 
shRNA). Total protein lysates harvested from single cell colonies propagated into 24-
well plates (termed “early passage” cells), were assessed for reduced TPD52 levels 
using Western blot analyses. Cell colonies identified with reduced TPD52 levels were 
further propagated. Total protein lysates were harvested after 10 passages (termed 
“passage 10” cells) and assessed for stably reduced TPD52 levels using Western 
blot analyses. 
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Total protein lysates were harvested from cells during early propagation and used in 
Western blot analyses to assess TPD52 expression. We screened a total of 9 cell 
colonies transfected with the non-targeting control shRNA plasmid. All 9 colonies 
showed similar TPD52 levels when compared to parental SK-BR-3 cells (Figure 
3.9A). A total of 26 cell colonies were screened for reduced TPD52 expression (14 
cell colonies for shRNA-D52-2, 12 cell colonies for shRNA-D52-3) (Figure 3.9B and 
3.9C). Western blot analyses identified 6 colonies (3 for shRNA-D52-2, 3 for shRNA-
D52-3) with the most reduced TPD52 levels compared to parental SK-BR-3 cells, 
and these were further propagated until passage 10 under puromycin selection 
(Figure 3.9B and 3.9C).  
 
Immunofluorescence (Figure 3.10A, data not shown) and Western blot analyses 
(Figures 3.10B, 3.11A, 3.11B) confirmed stably reduced TPD52 expression in 
shRNAD52-2 and shRNAD52-3-transfected cell lines after 10 passages, compared 
with non-targeting control and parental cell lines. shRNA-D52-3 transfected cells 
reproducibly showed greater reductions in TPD52 expression than shRNA-D52-2 
transfected cells (Figures 3.10, 3.11A, 3.11B, data not shown). Similarly, whereas 3 
shRNA-D52-3 cell lines maintained stably reduced TPD52 levels at both early 
passage and passage 10 (Figure 3.11A and 3.11B), only 1/3 shRNA-D52-2 cell lines 
retained reduced TPD52 expression (Figure 3.11A, 3.11B, data not shown). The 
remaining 2 shRNA-D52-2 cell lines regained parental SK-BR-3 levels of TPD52 
expression by passage 6, and were not analysed further (data not shown).  
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Figure 3.9 Screening of stably TPD52-depleted SK-BR-3 cell colonies. SK-BR-3 
cells were transfected with plasmid DNA containing (A) non-target control shRNA, (B) 
shRNA-D52-2, (C) shRNA-D52-3. Protein lysates from SK-BR-3 parental cells 
(parent) were used as a positive control for comparing TPD52 levels. Total protein 
lysates were harvested from single colonies propagated in 24-well plates under 
puromycin selection, and assessed for TPD52 levels using Western blot analyses. 
Numbers identify the cell colonies screened. Two non-target colonies and 6 TPD52 
shRNA target colonies that showed most reduced TPD52 levels were selected for 
further propagation and analysis (numbers shown in red or green). Two shRNA-D52-
2 colonies subsequently regained parental TPD52 levels after passage 6 (numbers in 
green, data not shown). The remaining 4 shRNA-D52 colonies (shown in red) were 
renamed as shRNA-D52-2-5 = shRNA-D52-2-A, shRNA-D52-3-1 = shRNA-D52-3-B, 
shRNA-D52-3-4 = shRNA-D52-3-C, shRNA-D52-3-5 = shRNA-D52-3-D. Left, 
proteins analysed. Right, molecular weights of detected species. 
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Figure 3.10 Generation of stably TPD52-depleted SK-BR-3 cell lines. (A) 
Immunofluorescence images of SK-BR-3 cells stably transfected with shRNA-D52-2 
(shRNA-D52-2-A) or shRNA-D52-3 (shRNA-D52-3-D) or non-target shRNA and 
harvested at passage 10. Cells were stained with human TPD52 monoclonal 
antibody (top row, red). shRNA constructs were also GFP-tagged (bottom row, 
green). Images were taken using a TCS SP2 confocal laser scanning upright 
microscope (Leica Technologies) using a 63X objective. Scale bar = 10 μm. (B) 
TPD52 levels in SK-BR-3 cell lines stably transfected with shRNA-D52-2 (shRNA-
D52-2-A) and shRNA-D52-3 (shRNA-D52-3-D) and non-target shRNA, as assessed 
by Western blot analyses at passage 10. Left, proteins analysed. Right, molecular 
weights of detected species.  
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3.2.8 Protein expression analyses of stably TPD52-depleted SK-BR-3 cell lines 
 
The consequences of stably depleted TPD52 levels were compared in early passage 
and passage 10 cells, relative to controls. Increased cleaved PARP-1 levels were 
detected in early passage TPD52-depleted cells (Figure 3.11A), in accordance with 
the results of transient TPD52 knock-down in SK-BR-3 cells (Figure 3.5A). Cleaved 
PARP-1 levels were lower in TPD52-depleted cell lines harvested at passage 10 
(Figure 3.11B). Depletion of TPD52 by 40-90% in early passage cells was associated 
with increased pERBB2 but not total ERBB2 levels in all 4 cell lines, relative to 
controls (Figure 3.11A and 3.11C). When cell lines were grown to passage 10, 
TPD52 levels remained reduced by 50-90% in TPD52-depleted cell lines, and 
pERBB2 expression remained increased by ~ 2-fold (Figure 3.11B and 3.11C). 
Passage 10 cell lines with lower TPD52 levels showed higher pERBB2 levels (Figure 
3.11B, cell lines B and D), whereas cell lines which had partially recovered TPD52 
expression showed lower pERBB2 levels (Figure 3.11B, cell lines A and C). 
Significant negative correlations were measured between mean TPD52 and pERBB2 
levels (obtained through densitometric analysis of 3 replicate Western blots) in early 
passage and passage 10 cells (Spearman rank correlation, rs=-0.886, p=0.019, n=6, 
early passage; rs=-0.943, p=0.005, n=6, passage 10), and in the combined 
populations (Spearman rank correlation, rs=-0.846, p=0.001, n=12) (Figure 3.11C). 
While no changes in pAKT (Ser473) or pMAPK44/42 levels were noted in early 
passage cell lines (Figure 3.11A), increased pERBB2 levels were accompanied by 
~2-4-fold increases in pAKT (Ser473) levels in 3/4 TPD52-depleted cell lines 
analysed (Figure 3.11B), with pMAPK44/42 levels remaining unchanged harvested at 
passage 10. Taken together, these results suggest that SK-BR-3 cells compensate 
for the deleterious effects of TPD52 depletion by increasing ERBB2 signaling. 
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Figure 3.11 Analysis of stably TPD52-depleted SK-BR-3 cell lines. Western blot 
analyses of total protein extracts from parental SK-BR-3 cells and SK-BR-3 cell lines 
stably transfected with non-targeting control, shRNA-D52-2 (cell line A) or shRNA-
D52-3 shRNAs (cell lines B-D) and harvested at early passage (A) or at passage 10 
(B). Results shown are representative of those obtained in 3 independent 
experiments. Left, proteins analysed. Right, molecular weights of detected species. 
(C) Scatter plot comparing mean TPD52 (X axis) and pERBB2 levels (Y axis) 
measured in parental, non-target control and stably TPD52-depleted SK-BR-3 cell 
lines. Open circles represent values obtained for early passage cells, whereas black 
circles represent values obtained for cell lines at passage 10. Densitometric values 
were obtained through the analysis of 3 replicate Western blots, normalized to the 
loading control GAPDH, and then to levels measured in parental cells, set at 1.0.  
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3.2.9 Cell proliferation effects in stably TPD52 depleted SK-BR-3 cell lines 
 
Previously, TPD52 overexpression in 3T3 fibroblast and prostate cancer cell lines led 
to increased cell proliferation (Shehata et al., 2008a; Ummanni et al., 2008), whereas 
stably reduced TPD52 in prostate cancer cell lines was associated with reduced cell 
proliferation (Ummanni et al., 2008; Zhang et al., 2007a). Cell proliferation was 
therefore assessed using MTT assays in stably TPD52 depleted cell lines harvested 
after passage 10, relative to the parental SK-BR-3 and non-targeted control cell line. 
This revealed that all 4 stably TPD52 depleted cell lines proliferated at similar rates 
as parental or non-targeting control cells over 3 days (Figure 3.12).  
 
3.2.10 Lapatinib sensitivity in stably TPD52 depleted SK-BR-3 cell lines 
 
Since stably reduced TPD52 expression led to increased pERBB2 levels (Figure 
3.11), we determined whether stably reduced TPD52 expression was associated with 
altered sensitivity to Lapatinib (Diermeier-Daucher et al., 2011). Lapatinib 
(GW572016) is a small molecule inhibitor of EGFR and ERBB2 tyrosine kinases that 
causes apoptosis in ERBB2-overexpressing cells (Xia et al., 2002). Lapatinib 
concentration (100 nM) was based on the previously reported lapatinib IC50 values 
(ie, the concentration of lapatinib necessary to reduce cell viability by 50%), which 
ranged between 50 – 100 nM for SK-BR-3 cells (O'Brien et al., 2010; O'Neill et al., 
2012; Zhang et al., 2008). MTT assays indicated all cell lines showed comparable 
viability when cultured in the presence of 100 nM Lapatinib over 5 days (Figure 
3.13A). Western blot analysis of proteins harvested on day 1 revealed that Lapatinib 
treatment reduced pERBB2 levels as expected (Rusnak et al., 2001) (Figure 3.13B).  
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Figure 3.12 Proliferation of stably TPD52-depleted SK-BR-3 cell lines. Cell 
proliferation was quantified using MTT assays, in SK-BR-3 cells stably depleted of 
TPD52 (using shRNA-D52-2 or shRNA-D52-3 shRNAs), and in parental or non-
targeting (non-target) control cells. Values plotted are means ± SE for 3 independent 
experiments done in triplicate.  
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Figure 3.13 Lapatinib sensitivity of TPD52 depleted SK-BR-3 cell lines. (A) SK-
BR-3 cells stably depleted of TPD52, parental and non-target control cells were 
treated with 100 nM Lapatinib and subjected to MTT assays over 5 days. Means ± 
SE are shown for 3 independent experiments done in triplicate. The percentage of 
cell proliferation was calculated as the percentage difference between the A540 values 
for treated (Lapatinib) and vehicle control (DMSO, 0.01%) cells at each time-point. 
(B) Western blot analyses of cells with or without lapatinib treatment (100 nM 
Lapatinib, + or 0.01% DMSO, -). Cell lines stably transfected with non-target control 
or shRNA-D52-2 (shRNAD52-2-A) or shRNA-D52-3 (shRNA-D52-3-B, -C, D) were 
analysed after 1 day of 100 nM Lapatinib or 0.01% vehicle control treatment. Levels 
of pERBB2 were determined by Western blot analysis and GAPDH was used as a 
loading control. Right, proteins analysed. Left, molecular weights of detected species. 
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3.2.11 Transient ERBB2 knock-down effects in stably TPD52-depleted SK-BR-3 
cells  
 
Lapatinib is a dual ERBB2/EGFR inhibitor (Rusnak et al., 2001), however it has been 
shown to predominantly target ERBB2 (Zhang et al., 2008). As lapatinib treatment 
did not show any altered lapatinib sensitivity in stably TPD52-depleted SK-BR-3 cells, 
we decided to extend this result by directly comparing the effects of transiently 
reducing ERBB2 in TPD52-depleted and non-targeting control cells using ERBB2 
siRNA knock-down. Transient TPD52 (using siD52-1 and siD52-2) and ERBB2 
knock-down was performed in the non-targeting control cell line in parallel. The 
TPD52, pERBB2, cleaved-PARP-1, pAkt (Ser473) and pMAPK44/42 levels obtained 
(Figure 3.14A) were similar to those resulting from transient TPD52 and/or ERBB2 
knock-down in parental SK-BR-3 cells (Figure 3.5A).  
 
In contrast, transient ERBB2 knock-down in 4 stably TPD52-depleted SK-BR-3 cell 
lines was not associated with increased cleaved PARP-1 detection (Figure 3.14B) 
compared to increased cleaved PARP-1 in non-targeting control cells (Figure 3.14A). 
Furthermore, ERBB2 knock-down did not reduce pERBB2 levels to those of non-
targeting control cells in 3/4 stably TPD52-depleted SK-BR-3 cell lines (Figure 
3.14B). This could in part reflect the high pERBB2 levels in stably TPD52-depleted 
SK-BR-3 cells (Figures 3.11 and 3.14). In addition, transient ERBB2 knock-down 
showed markedly reduced pAkt (Ser473) levels in non-targeting control cells (Figure 
3.14A), similar to previous results (Figure 3.5A), whereas pAkt (Ser473) levels were 
only marginally reduced upon ERBB2 knock-down in stably depleted TPD52 cell 
lines (Figure 3.14B). This agrees with the relatively high pERBB2 levels in these cell 
lines following ERBB2 knock-down and the fact that baseline pAkt levels were also 
increased in stably TPD52-depleted cell lines (Figures 3.11 and 3.14).  
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Figure 3.14. Transient ERBB2 knock-down effects in stably depleted TPD52 SK-
BR-3 cell lines. (A) Non-targeting control cell line or (B) stably depleted TPD52 SK-
BR-3 cell lines (cultured at > 10 passages) were treated with TPD52 siRNA (siD52-1 
or siD52-2) and/or ERBB2 siRNA (siERBB2) or non-targeting siRNA (siControl) for 
72 h, and harvested for Western blot analyses. Doxorubicin treatment of SK-BR-3 
(500 nM, 72 h) (Dox) was used as a positive apoptosis control. TPD52, pERBB2, 
ERBB2, cleaved PARP-1, pAKT and pMAPK levels were determined using Western 
blot analyses. Results shown are representative of those obtained from 2 
independent experiments. Left, proteins analysed. Right, molecular weights of 
detected species. 
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Transient ERBB2 knock-down showed reduced pMAPK44/42 levels in both non-
targeting control and stably TPD52-depleted cells (Figure 3.14), as in parental SK-
BR-3 cells (Figure 3.5A), although reductions in stably TPD52-depleted cell lines 
(Figure 3.14B) were less than those noted in the non-targeting control (Figure 3.14A).  
While total ERBB2, Akt and MAPK levels were not examined, based on previous 
results (Fig. 3.5, 3.11 and data not shown), we expect that these would have 
remained unchanged. Taken together, these results revealed that transient ERBB2 
knock-down was relatively ineffective on a background of existing TPD52 knock-
down and did not lead to increased apoptosis. These results therefore contrasted 
with those of lapatinib treatment of these cell lines, as will be discussed in the 
following section (Section 3.3.3). 
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3.3 Discussion  
 
The work in this chapter explored the significance of TPD52 and ERBB2 co-
expression in breast cancer cell lines since these two gene amplification targets have 
been reported to be co-expressed in numerous breast cancer studies (Chen et al., 
2010; Kourtidis et al., 2010; Landis et al., 2006; Landis et al., 2005; Whiteaker et al., 
2007; Wilson et al., 2002). Data presented in this chapter demonstrate TPD52 as a 
survival factor in ERBB2-amplified breast cancer cells and suggesting a possible co-
operation between TPD52 and ERBB2 in cancer pathogenesis.  
 
3.3.1 TPD52 and ERBB2 co-expression in breast cancer cell lines 
 
The present study used a cell line cohort that was relatively small for statistical 
analyses. However, significant or borderline correlations between TPD52 transcript 
or protein levels and ERBB2 levels were still measured in the panel of 15 breast cell 
lines examined. We also demonstrated significantly higher TPD52 levels in 4 ERBB2-
amplified breast cancer cell lines than in the larger group of 11 non-amplified ERBB2 
breast cell lines. Nevertheless, these assocations were likely driven by the inclusion 
of the TPD52-amplified SK-BR-3 and AU-565 cell lines within this cohort, thus these 
data were further supported by significant positive associations between relative 
TPD52 and ERBB2 transcript levels using RT-PCR analysis of breast cancer patient 
samples (Roslan et al., 2013, Appendix 2). These analyses were performed by an 
independent group in France, and were therefore not described in this thesis. 
 
 
 
 
 
  
Nuruliza Roslan 126 
3.3.2 TPD52 transient knock-down effects 
 
Previous studies using breast cancer cell lines have shown differing sensitivities to 
TPD52 knock-down, but the reasons for this have not been directly examined 
(Kourtidis et al., 2010; Shehata et al., 2008a). Results from our laboratory indicated 
that SK-BR-3 but not MCF-7 cells showed significant apoptotic cell death in response 
to transient TPD52 knock-down (Shehata et al., 2008a). Having demonstrated 
differential TPD52 expression and gene copy number across a panel of 15 breast cell 
lines, we expanded our previous study (Shehata et al., 2008a) to determine the 
effects of transiently reducing TPD52 expression in additional cell lines. Despite 
achieving substantial TPD52 depletion in 4 breast cancer cell lines and MCF-10A 
cells, only the ERBB2-amplified SK-BR-3 and BT-474 cell lines showed significant 
apoptosis in response to reduced TPD52 expression (Figures 3.4 and 3.5).  
 
TPD52 knock-down produced very similar increases in apoptosis in SK-BR-3 and 
BT-474 cells, despite their marked differences in TPD52 expression and TPD52 
amplification status (Figure 3.2). These observations concur with those obtained by 
Kourtidis et al. (2010) who studied the effects of TPD52 gene knock-down using high 
through-put analyses of cell viability, and reported higher reductions in cell viability in 
the ERBB2-amplified cell lines BT-474, MDA-MB-453, MDA-MB-361, and SK-BR-3, 
compared with MCF-7 and HMEC cells. BT-474 cells were more sensitive than SK-
BR-3 cells to reduced ERBB2 expression, suggesting that BT-474 cells are highly 
dependent on ERBB2 for survival (Wang et al., 2011). Similarly, it has been reported 
that BT-474 cells contain a higher ERBB2 copy number than SK-BR-3 cells 
(Kallioniemi et al., 1992; Yeh et al., 2008). In contrast, SK-BR-3 cells showed similar 
levels of apoptotic cell death in response to TPD52 or ERBB2 knock-down, 
suggesting that these two oncogenes may be of similar importance in maintaining 
SK-BR-3 cell viability. A study by Navin et al. (2011) showed that TPD52 and ERBB2 
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are amplified to very similar extents in SK-BR-3 cells. It was interesting to note that 
when both genes were knocked down in SK-BR-3 cells, this resulted in significantly 
higher apoptosis compared to single knock-down of either gene, which could possibly 
suggest an additive effect. However, since knocking down ERBB2 did not affect 
TPD52 levels, or vice versa, in both SK-BR-3 and BT-474 cells, this suggests that 
ERBB2 does not directly regulate TPD52 levels, and vice versa (Figure 3.5). In 
summary, the effects of TPD52 knock-down may be determined by the ERBB2 
status, as opposed to TPD52 amplification or expression status as previously 
proposed (Shehata et al., 2008a).  
 
Transient TPD52 knock-down leading to increased cell death has been repeatedly 
reported in androgen-dependent LnCaP cells (Ummanni et al., 2008), and in the 
androgen-independent derivative cell line C4-2 (Zhang et al., 2011; Zhang et al., 
2007a). Interestingly, both LnCaP and C4-2 cells detectably express ERBB2 (Cortes 
et al., 2012; Misra et al., 2006; Pignon et al., 2009), and thus the consequences of 
TPD52 knock-down in LnCaP and derivative cell lines are consistent with TPD52 
promoting the survival of ERBB2-positive cancer cells. However, Kourtidis et al. 
(2010) also reported that the ERBB2-negative breast cancer cell line MDA-MB-468 
showed similar reductions in viability to TPD52 knock-down as did ERBB2-amplified 
and overexpressing cell lines. It is known that the MDA-MB-468 cell line is an EGFR-
amplified cell line (Gasch et al., 2013), thus it would appear that ERBB2 amplification 
or overexpression, and possibly other amplified oncogenes confer sensitivity to loss 
of TPD52 expression in cancer cells.  
 
Other consequences of TPD52 knock-down were different from those which would 
have been predicted by previous studies. Ectopic TPD52 overexpression resulted in 
increased pAKT levels (Ummanni et al., 2008; Zhang et al., 2011), and reduced 
TPD52 expression in C4-2 prostate cancer cells led to reduced pAKT levels (Zhang 
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et al., 2011). However, in the present study, transient TPD52 knock-down did not 
alter pAKT levels in either SK-BR-3 or BT-474 cells. The siRNA targets employed in 
both the present study (Figure 3.5) and that of Zhang et al. (2011) bind sequences 
that are common to PrLZ and TPD52 transcripts, and therefore the different results 
obtained are unlikely to reflect differential targeting of PrLZ versus TPD52. These 
could however highlight functional differences between PrLZ and TPD52 in prostate 
versus breast cancer cells, or other differences between the particular cell lines 
examined. The fact that ERBB2 but not TPD52 knock-down resulted in reduced 
pAKT levels, while knock-down of both genes produced increased apoptosis, indicate 
that TPD52 regulates cell survival independently of ERBB2 and AKT signaling in 
ERBB2-amplified breast cancer cells.  
 
3.3.3 TPD52 long-term knock-down effects 
 
Whereas transient gene knock-down analyses examine the acute consequences of 
reduced gene activity, longer term gene knock-down analyses allow the assessment 
of whether and how cells can adapt to reduced gene function. We therefore 
examined the longer term effects of TPD52 knock-down in SK-BR-3 cells, as these 
cells have similar TPD52 and ERBB2 copy numbers (Navin et al., 2011), and were 
similarly sensitive to transient TPD52 and ERBB2 knock-down (Figure 3.5A). Even 
though both TPD52 siRNA targets reduced TPD52 levels in all breast cell lines 
tested, only TPD52 siRNA target (siD52-1) resulted in significant cell death in SK-BR-
3 cells, although target siD52-2 showed a similar trend towards increased cell death 
(Figure 3.4A). We also noted that siD52-2 was less efficient in reducing TPD52 in 
SK-BR-3 cells, which also might explain the reduced cell death produced by this 
siRNA. SK-BR-3 cells show a high degree of TPD52 amplification, which could 
disrupt the siD52-2 binding site on some gene copies. The derivation of multiple SK-
BR-3 cell lines with multiple shRNAs also allowed the possibility of extending the 
  
Nuruliza Roslan 129 
results obtained with siD52-1 using additional shRNA targets. The differences in 
residual TPD52 levels (Figures 3.10 and 3.11) were likely due to the different TPD52 
shRNA vectors used. However, even though there were clear differences between 
the shRNA vectors’ performance, both TPD52 shRNAs effectively and stably reduced 
TPD52 levels. 
 
While TPD52 depletion led to increased cell death in the short term, these cells 
simultaneously increased ERBB2 signaling, which was stably maintained over 10 cell 
culture passages and beyond. By 10 passages, most TPD52-depleted cells also 
showed increased pAKT levels, as well as increased pERBB2 levels. Increased 
pAKT levels temporally followed increased pERBB2, in that this was detected by 
passage 10, but not in early passage cells. An inverse relationship between TPD52 
and pERBB2 levels emerged in stably TPD52-depleted versus control SK-BR-3 cell 
lines. As cells harvested at passage 10 showed very similar proliferation as parental 
cells, increased pERBB2 followed by increased pAKT levels are likely to represent 
compensatory mechanisms to overcome the consequences of reduced TPD52 
levels. It seems unlikely that PrLZ upregulation occurred in response to TPD52 
depletion, as the shRNA targets employed bind sequences common to PrLZ and 
TPD52 transcripts, and the TPD52 antisera employed detect an epitope shared by 
TPD52 and PrLZ (Shehata et al., 2008b).  
 
The effects of TPD52 depletion in SK-BR-3 cells contrast with the effects of stably 
reducing PrLZ/ TPD52 expression in C4-2 cells, which was associated with reduced 
cell proliferation and colony-forming capacity (Zhang et al., 2011). Given the many 
differences between SK-BR-3 and C4-2 cells, it is not unexpected that stable TPD52 
depletion produced different responses in these cell lines over time. It is possible that 
reducing TPD52 levels in SK-BR-3 cells requires adaptive changes for cells to 
remain viable, and/or that ERBB2 amplification may allow SK-BR-3 cells to more 
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readily adapt to reduced TPD52 levels. It may be significant that next generation 
sequencing of SK-BR-3 genomic DNA has revealed that 3 regions of chromosome 
8q, one of which includes TPD52, are co-amplified with chromosome 17q (Hillmer et 
al., 2011) which agrees with the similar copy numbers reported for TPD52 and 
ERBB2 in SK-BR-3 in another next generation sequencing study (Navin et al., 2011). 
Hence, co-amplification of TPD52 and ERBB2 in SK-BR-3 cells may partially explain 
the similar effects of transient knock down of TPD52 and ERBB2 in this cell line, and 
therefore the long-term effects of reduced TPD52 provides additional evidence of SK-
BR-3 cells relying upon both proteins for survival.  
 
A limitation in the current study was the use of one cell line (SK-BR-3 cells) to 
generate stably-depleted TPD52 cell lines. The generation of stably-depleted SK-BR-
3 cell lines required multiple screenings and propagation as described (Figure 3.8) 
which took ~ 7 months to successfully obtain. The fact that knocking down TPD52 in 
three non-ERBB2 amplified cell lines did not result in increased cell death would 
predict that stable knock-down of TPD52 in a non ERBB2-amplified cell line would 
probably generate no obvious phenotype. Given the time constraints on the 
completion of this thesis, we did not place a high priority on conducting these 
additional experiments. 
 
Ideally, we would like to extend our results by examining cancer cell lines that are 
TPD52-amplifed but not ERBB2-amplified. To this end, we obtained the HCC2157 
suspension cell line, that was predicted to be TPD52-amplified (Neve et al., 2006) but 
initial transient TPD52 knock-downs failed to reduce TPD52 levels, likely due to cell 
clustering that might have led to reduced transfection efficiency (data not shown). 
Western blot analyses revealed that HCC2157 cells showed high levels of TPD52, 
similar to those in SK-BR-3, but these cells were also positive for ERBB2 expression 
(data not shown). Therefore, future studies will seek to examine the effects of TPD52 
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knock-down in cell lines with high level TPD52 expression that lack similarly high 
ERBB2 levels.  
 
Our collaborators in France analysed TPD52 and ERBB2 transcript levels in a 
diagnostic breast cancer cohort and found a significant positive correlation (Roslan et 
al., 2013, Appendix 2). High-level TPD52 expression was associated with 
significantly poorer metastasis-free survival, both in the overall cohort, the large 
HR+/ERBB2- sub-group, and the smaller HR+/ERBB2+ subgroup in which TPD52 
expression was highest (Roslan et al., 2013, Appendix 2). Furthermore, Shehata et 
al., (2008a) previously reported that increased TPD52 immunohistochemical staining 
was associated with reduced overall survival. These combined results suggest that 
TPD52 and ERBB2 co-expression in breast cancer is both functionally and clinically 
significant.  
 
The poorer metastasis-free survival of patients with tumors with high-level TPD52 
expression (Roslan et al., 2013, Appendix 2), combined with the demonstration that 
ERBB2-amplified cell lines rely upon TPD52 for survival (Figures 3.5 and 3.11), 
indicates that TPD52 overexpression could conceivably promote tumor resistance 
towards ERBB2-targetted therapies, particularly as TPD52 was indicated to regulate 
cell survival independently of ERBB2. Since transient reduction of both TPD52 and 
ERBB2 led to significantly higher apoptosis than knock-down of either gene alone, 
and stably TPD52 reduced SK-BR-3 cells showed increased pERBB2 levels, we 
hypothesised that the latter cell lines would be sensitized to ERBB2 inhibitors.  
 
Lapatinib works intracellularly by reversibly binding to the intracellular domain of the 
tyrosine kinase receptor domain of both EGFR and ERBB2, which then inhibits 
receptor phosphorylation and activation of the downstream signaling pathways 
(Vazquez-Martin et al., 2011). Initially, 50 nM lapatinib was used to examine lapatinib 
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sensitivity in the stably TPD52-depleted SK-BR-3 cells (as this concentration was 
also in the IC50 range (O'Brien et al., 2010; O'Neill et al., 2012; Zhang et al., 2008)). 
The experiment was repeated twice and showed no obvious differential lapatinib 
sensitivity (data not shown). Therefore, we increased the lapatinib concentration to 
100 nM in order to see any differential sensitivity. However, stable reduction of 
TPD52 expression did not lead to significant sensitization to 100 nM Lapatinib 
treatment and pERBB2 levels were reduced in comparable levels as in control cells 
(Figure 3.13), similar to 50 nM Lapatinib treatment (data not shown). Hence, it might 
be useful to use a wider range of Lapatinib concentrations (0.01 μM – 10 μM) to 
extend these current results. 
 
In contrast, transient ERBB2 knock-down in stably TPD52-depleted SK-BR-3 cells 
revealed pERRB2 levels were not reduced as in non-targeting control cells (Figure 
3.14). This could mean that ERBB2 depletion using siRNA was ineffective in these 
stably TPD52-depleted SK-BR-3 cells, but this might not be the case since ERBB2 
depletion in control cells showed pERBB2 levels were markedly reduced (Figure 
3.14A). Lapatinib treatment and ERBB2 siRNA treatment of stably TPD52-depleted 
SK-BR-3 cells are two different experiments using different strategies to reduce 
pERBB2 levels. Lapatinib acts at the protein level, while ERBB2 siRNA targets 
ERBB2 mRNA. Initially, pEGFR, pPTEN and pERBB3 levels were assessed using 
Western blot analyses in the stably TPD52-depleted SK-BR-3 cells, but all protein 
levels assessed were unchanged compared to non-targeting control and parental 
cells (data not shown). Taken together, it is possible that transient ERBB2 knock-
down results reflect other adaptive changes occurring in stably TPD52-depleted SK-
BR-3 cells, such as acquired genetic changes and/or the up-regulation of 
independent pathways, which are yet to be determined. 
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3.4 Summary and conclusion 
 
We have shown that TPD52 and ERBB2 are significantly co-expressed in breast cell 
lines, and that both genes independently contribute to the survival of ERBB2-
amplified breast cancer cells. Short-term TPD52 knock-down produced significant 
cell death in ERBB2 amplified cell lines, via a mechanism independent of AKT 
signaling. However, long-term TPD52 depletion in TPD52- and ERBB2-amplified SK-
BR-3 cell lines was associated with significant inverse correlations between TPD52 
and pERBB2 levels, indicating that ERBB2-amplified cells may compensate for 
reduced TPD52 levels by increasing ERBB2 signaling. These results combined with 
the lack of substantial co-localisation between TPD52 and ERBB2 in SK-BR-3 cells 
indicate that TPD52 promotes the survival of ERBB2-positive cancer cells through 
indirect co-operation with ERBB2. Further studies were carried out in Chapter 4 to 
determine the basis of this co-operation.  
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Chapter 4 
A possible role for TPD52  
in regulating lipid storage 
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4.1 Introduction  
 
In the previous results chapter, we examined the significance of TPD52 and ERBB2 
co-expression in breast cancer cells, by studying the effects of transiently or stably 
reducing TPD52 levels (Chapter 3). So far, we have shown that TPD52 is important 
for maintaining ERBB2-amplified cancer cell survival, although TPD52 may act 
independently of ERBB2 signaling via PI3K/Akt or MAPK pathways. In this chapter 
we therefore examined other mechanisms by which TPD52 might co-operate with 
ERBB2. 
 
Results from Chapter 3 have shown significant associations between TPD52 and 
ERBB2 expression in breast cancer cell lines and this is of interest to us, as ERBB2 
expression has been associated with increased expression of multiple key lipogenic 
genes, such as fatty acid synthase (FASN), Acetyl-CoA carboxylase (ACC), mediator 
complex subunit 1 (PBP/MED1) and nuclear receptor subfamily 1, group D, member 
1 (NR1D1) (Kourtidis et al., 2010; Kumar-Sinha et al., 2003; Yoon et al., 2007; Zhang 
et al., 2005). These genes are located on chromosome 17 together with ERBB2 
(Figure 1.11) (Menendez and Lupu, 2007). ERBB2-amplified cancer cells such as 
SK-BR-3 and BT-474 have been shown to have high levels of intracellular lipid 
(Kourtidis et al., 2010). Studies have also shown that targeting ERBB2 using ERBB2 
inhibitors (e.g. Herceptin) affects these lipid-regulating proteins, leading to reduced 
FASN and ACC levels (Kumar-Sinha et al., 2003; Yoon et al., 2007; Zhang et al., 
2005). This suggests that lipid-associated proteins such as FASN are candidates for 
therapeutic targets in ERBB2-amplified cancers (Vazquez-Martin et al., 2007a; 
Vazquez-Martin et al., 2007b). Kourtidis et al. (2010) reported that knocking down 
lipid-associated genes reduced the viability of ERBB2-positive breast cancer cells 
(Kourtidis et al., 2010). This study used an RNAi screen which identified several 
genes which significantly affected cell viability according to ERBB2 amplification 
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status. These genes included the lipid-associated genes MED1 and NR1D1, and also 
TPD52 (Kourtidis et al., 2010). This study therefore suggested that TPD52 may co-
operate with ERBB2 by regulating lipid storage.  
 
4.1.1 Lipid droplets – a major lipid storage organelle 
 
Until the 1990s, lipid droplets were described as inert organelles (Murphy, 2001). 
However, more recent investigations have discovered that lipid droplets provide more 
than just storage of excess fatty acids and cholesterol esters, as will be described in 
the following Section 4.1.3 (Walther and Farese, 2009). Lipid droplet biogenesis and 
lipolysis are known to be tightly regulated by multiple proteins and enzymes (Section 
1.4.2). Regulation of stored lipids is important for maintaining cell viability, since 
excess free fatty acids are known to be toxic to normal cells (Listenberger et al., 
2003). Hence, highly proliferative cancer cells have evolved to overcome this 
limitation by altering lipid metabolism, in part by increasing their lipid storage 
capacity.  This process helps support the increased biosynthetic and bioenergetic 
demands of the cancer cell. 
 
4.1.1.1 Lipid droplet structure and size 
 
Even though lipid droplets in white adipocytes have been extensively studied, it is 
now known that lipid droplets exist ubiquitously in eukaryotic (Kurat et al., 2009) and 
prokaryotic cells (Alvarez and Steinbuchel, 2002; Ashrafi, 2007; Hsieh and Huang, 
2005; Law and Wells, 1989; Packter and Olukoshi, 1995). Lipid droplets, also known 
as lipid bodies, fat bodies, oil bodies, spherosomes or adiposomes, are cellular 
storage sites for neutral lipids, as described in a recent review (Walther and Farese, 
2012). Lipid droplet structure is highly conserved between lipid droplets in different 
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cell types and species (Yang et al., 2012b). The lipid droplet hydrophobic core 
consists mainly of triacylglycerides and cholesterol esters, and is enclosed by a 
phospholipid monolayer consisting mostly of phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) (Bartz et al., 2007; Tauchi-Sato et al., 2002) (Figure 
4.1). The phospholipid monolayer surrounding lipid droplets has been confirmed 
using cryoelectron microscopy (Tauchi-Sato et al., 2002). The lipid droplet surface is 
coated with various proteins (Tauchi-Sato et al., 2002) that regulate aspects of lipid 
droplet biology such as droplet synthesis, mobilization, interaction with other 
organelles and movement (Wan et al., 2007).  
 
Lipid droplet numbers and sizes may differ between cell types or individual cells 
within a population. Non-adipocytes usually have many small lipid droplets, with 
diameters ranging from 100 nm to 1 µm, whereas adipocyte lipid droplets can have 
diameters up to 100 µm, mostly in the form of one lipid droplet per adipocyte (Suzuki 
et al., 2011). Due to their small sizes, lipid droplets in non-adipocytes often appear to 
be randomly distributed throughout the cell in cultured systems (Suzuki et al., 2011).  
 
Lipid droplets also have the ability to expand either in size and/or numbers (Yang et 
al., 2012a), although this process could be cell type-dependent. For example, lipid 
droplets in adipocytes can expand up to 100 µm, whereas Drosophila S2 cell lipid 
droplets did not increase in size but increased in numbers, resembling clusters of 
grapes, in response to oleate treatment (Guo et al., 2008; Krahmer et al., 2011). Lipid 
droplets can also increase in size under pathological conditions, such as lipid 
droplets in liver cells during hepatic steatosis (Matsusue et al., 2008). Most cell types 
other than adipocytes increase lipid droplet numbers but not size, such as lipid 
droplets in yeast cells upon entering stationary growth phase (Fei et al., 2011). 
Increasing lipid droplet numbers has been suggested to provide more surface area 
for lipases for more efficient lipolysis (Marcinkiewicz et al., 2006). Phospholipids such 
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as phosphotidylcholine (Krahmer et al., 2011) and lipid-associated proteins such as 
FSP27 (fat specific protein 27) (Gong et al., 2011) and perilipin (Brasaemle and 
Wolins, 2012) which localize on the lipid droplet surface, have been shown to be 
involved in regulating the size of lipid droplets (Yang et al., 2012a).  
 
 
 
 
Figure 4.1 Schematic overview of lipid droplet structure. Lipid droplets are 
composed of a core of nonpolar/neutral lipids (mainly triacylglycerides and 
cholesterol/sterol esters), which are enclosed by a monolayer of polar lipids (e.g. 
phospholipids and sterols) and associated proteins which include DGAT2 
(diacylglycerol acyltransferase 2), Rab18, perilipin, and CCT (CTP:phosphocholine 
cytidylyltransferase; the rate-limiting enzyme in phosphatidylcholine synthesis). 
Reproduced from Krahmer et al. (2009). 
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4.1.1.2 Lipid droplet formation 
 
Lipid droplets form rapidly in response to increased free fatty acid levels in cells, as 
reported in studies using cultured cells and in vivo (Pol et al., 2004). Several 
hypotheses or models regarding lipid droplet formation have been proposed (Walther 
and Farese, 2012), which commonly propose that lipid droplets form within the 
endoplasmic reticulum (ER). Lipid droplets have been proposed to originate from the 
ER in what has been called the “budding-off” model (Figure 4.2). This model 
proposes that the lipid droplet core originates as a lens of neutral lipid between the 
leaflets of the ER (Murphy and Vance, 1999). This eventually expands, and buds off 
into the cytoplasm, with the surrounding phospholipid monolayer derived from the 
outer ER monolayer (Murphy and Vance, 1999). Several lines of evidence support 
this model. Ultrastructural studies using electron microscopy revealed lipid droplets to 
be in close proximity with the ER, or to remain attached to the ER, using 3T3-L1 
adipocyte cells (Blanchette-Mackie et al., 1995), HepG2 cells (Tauchi-Sato et al., 
2002), 3T3 cells (Ozeki et al., 2005) and U937 monocytic cells (Wan et al., 2007). In 
addition, proteomic studies revealed the presence of ER proteins isolated from lipid 
droplets from 3T3-L1 adipocytes (Brasaemle et al., 2004), CHO cells (Liu et al., 
2004), and monocytic cells (Wan et al., 2007). Alternatively, an “egg-cup” model has 
been proposed, where lipid droplets grow or expand in apposition to the ER, as 
opposed to within it, which was observed in human monocytes using electron 
microscopy (Robenek et al., 2006).  
 
In mammalian cells, diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 catalyse 
the final step in TAG synthesis (Yen et al., 2008), whilst acyl-coenzyme A cholesterol 
O-acyltransferase 1 (ACAT1) and ACAT2 play major roles in catalyzing the synthesis 
of cholesterol esters (Chang et al., 2009). These enzymes reside primarily in the ER 
(Kuerschner et al., 2008), although DGAT2 can also be found at the LD surface 
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(Stone et al., 2009). Collectively, the ER localization of these enzymes crucial for the 
final steps of lipid droplet formation supports the biogenesis of lipid droplets within 
the ER. 
 
 
 
 
Figure 4.2 Lipid droplet formation from the ER into the cytoplasm according to 
the “budding-off” model. In this model, neutral lipids (triacylglycerols and 
cholesterol esters) are proposed to be synthesized between the leaflets of the ER 
membrane. The nascent LD then buds off from the ER membrane, forming an 
independent organelle enclosed by a monolayer of phospholipids and LD-associated 
proteins such as the members of the PAT-domain family of proteins (perilipin, 
adipophilin and TIP47). ER = endoplasmic membrane, LD = lipid droplet. 
Reproduced from Martin and Parton (2006). 
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4.1.2 Proteins regulating lipid droplet function   
 
4.1.2.1 PAT family proteins: Main players in lipid droplet regulation 
 
The coordination of lipid storage and utilization is mainly regulated by the PAT family 
of proteins. The PAT protein family was originally named after the members of 
perilipin (PLIN1), adipophilin or adipose-differentiated-related-protein (ADRP or 
PLIN2) and TIP47 (for Tail-Interacting Protein of 47 kDa or PLIN3) (Brasaemle, 
2007). Other proteins also important for lipid droplet regulation and included in the 
PAT protein family are S3-12 (PLIN4) and OXPAT (for oxidative protein of the PAT 
family, or PLIN5) (Brasaemle and Wolins, 2012). Most PAT proteins contain a 
conserved lipid-droplet binding motif known as the PAT domain (Miura et al., 2002) 
(Figure 4.3). The types of PAT proteins that associate with lipid droplets vary 
according to cell type, and the maturity or stage of lipid droplet formation. A study 
using 3T3-L1 adipocytes stimulated with oleic acid observed different localizations for 
PAT proteins (Wolins et al., 2005). TIP47 and S3-12 localized to the smallest lipid 
droplets, whereas ADRP localized to intermediate-sized lipid droplets, and perilipin 
was detected at the largest lipid droplets (Wolins et al., 2005).  
 
Perilipin mainly regulates lipid storage in adipocytes (Greenberg et al., 1991), while 
ADRP mainly regulates lipid storage in non-adipocytes  (Brasaemle et al., 1997). In 
contrast, TIP47 is involved in trafficking lipids between the cytoplasm and lipid 
droplets (Brasaemle, 2007; Wolins et al., 2005). Perilipin is highly expressed in 
adipocytes, while adipophilin and TIP47 are mainly expressed in non-adipocytes 
(Brasaemle, 2007). Perilipin acts as the main gatekeeper regulating lipolysis in 
adipocytes, and reduces lipolysis by binding and sequestering CGI-58 (Granneman 
et al., 2007; Miyoshi et al., 2006; Subramanian et al., 2004). Perilipin and ADRP are 
unstable when not bound to lipid droplets, whereas DAG synthesis activates 
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recruitment of TIP47 from the cytoplasm to lipid droplets (Skinner et al., 2009). 
Several studies have shown that ADRP binds fatty acids and cholesterol (Atshaves 
et al., 2001; Serrero et al., 2000), promoting triacylglyceride accumulation (Imamura 
et al., 2002) and stimulating fatty acid uptake (Gao and Serrero, 1999). Therefore, 
PAT proteins control the flux of lipids to and from lipid droplets, resulting in either 
increased lipid storage or increased lipolysis. 
 
 
 
 
Figure 4.3 Schematic diagram of the structural features of perilipin and related 
proteins. The positions of structural features that are shared by mouse perilipin-
related proteins are shown; greater intensity of color represents higher similarity of 
sequences between family members, whereas lighter color represents reduced 
sequence similarity. The N-termini of perilipin, adipophilin, TIP47, and OXPAT, but 
not S3-12, contain 100 amino acid (aa) sequences termed the PAT or PAT1 domain 
that are highly conserved between 4 members of the family (green). Reproduced 
from Brasaemle (2007). 
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4.1.2.2 Other proteins found to be involved in lipid droplet regulation 
 
A number of proteomic studies have analyzed isolated lipid droplets to identify lipid 
droplet-resident or -associated proteins (Bartz et al., 2007; Beller et al., 2006; Binns 
et al., 2006). Apart from reproducibly finding known lipid droplet proteins such as 
ATGL, CGI-58 and the PAT proteins, these studies also reported other proteins that 
provide valuable clues to further understand lipid droplet function and regulation, 
such as ER resident proteins, mitochondrial proteins, cytoskeletal proteins and even 
histones. Rab family proteins, particularly Rab5, Rab7, Rab11 and Rab18, have been 
frequently identified (Brasaemle et al., 2004; Fujimoto et al., 2004; Liu et al., 2004), 
as have caveolins which have been shown to traffic lipids from the Golgi apparatus to 
the plasma membrane (Cohen et al., 2004; Le Lay et al., 2006; Pol et al., 2004). 
Many of these proteins still warrant further investigation, to confirm their involvement 
in lipid droplet regulation.  
  
Rab proteins have been previously shown to be important in regulating exocytic and 
endocytic pathways (Corbeel and Freson, 2008; Grosshans et al., 2006). The 
detection of Rab5 on purified lipid droplets implies the interaction of early endosomes 
with lipid droplets (Liu et al., 2007a). Of most interest is Rab 18, as this appears to 
associate with lipid droplets late in adipogenesis, replacing ADRP (Ozeki et al., 
2005). Another study reported that stimulating lypolysis led to increased Rab18 
association with lipid droplets (Martin et al., 2005). The varied functions of Rab 
proteins that associate with lipid droplets highlight the different functions of lipid 
droplets within the cell, which will be further discussed in the following section.  
  
 
 
 
  
Nuruliza Roslan 144 
4.1.3 Lipid droplet function 
 
Lipid droplets’ most important physiological function is as an energy reservoir, storing 
TAGs and upon lipolysis, providing fatty acids as building blocks for membranes or 
substrates for energy metabolism. Generally, adipocytes supply energy needs for the 
whole organism, whereas lipid storage in non-adipocytes is usually for the cell’s own 
consumption. Lipid droplets also provide a protective role, acting as scavengers for 
free fatty acids in order to avoid lipotoxicity and lipoapoptosis (Schaffer, 2003). 
Increased cellular free fatty acids have been shown to be toxic, and impairment of 
TAG synthesis and storage has also been shown to be detrimental to the cell 
(Listenberger et al., 2003; Schaffer, 2003).  
 
Lipid droplets have also been proposed as organizing centres. They act as sites for 
synthesizing and metabolizing a wide range of signaling lipids such as eicosanoids, 
2-arachidonoylglycerol and N-acylethanolamines (Kaczocha et al., 2010; Zechner et 
al., 2009). In addition, several enzymes for eicosanoid synthesis have been found in 
leukocyte lipid droplets (Bozza et al., 2009). Lipid droplets may also serve as protein 
storage sites, as for example histones were found in the lipid droplets of Drosophila 
oocytes (Cermelli et al., 2006). These histones were localized to lipid droplets until 
needed for rapid nuclear division associated with embryo segmentation. Hence, 
whereas histones were once considered as a contaminating protein in isolated lipid 
droplets, they are now known to be a major lipid droplet protein in Drosophila 
embryos (Cermelli et al., 2006). Lipid droplets may also provide temporary storage of 
other proteins for future use, or sequesteration prior to proteosomal degradation 
(Ohsaki et al., 2006). 
 
Lipid droplets have also been shown to assist in the replication of intracellular 
pathogens such as the Hepatitis C and Dengue (Samsa et al., 2009) viruses, and 
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Chlamydia trachomatis (Kumar et al., 2006). It was reported that the core D2 protein 
of Hepatitis C virus associates with lipid droplets (Hope and McLauchlan, 2000; 
Miyanari et al., 2007) and this process is known to be important in virus assembly 
(Shavinskaya et al., 2007). Another example was observed when HeLa cells were 
infected with Chlamydia trachomatis. This parasite tags lipid droplets with a bacterial 
protein, Lda3 (lipid droplet-associated protein 3), leading to lipid droplet binding and 
sequesteration in the bacteria-containing vacuole, hence utilizing the lipids for 
metabolism (Cocchiaro et al., 2008; Kumar et al., 2006). The authors concluded that 
lipid droplets play a role in the intracellular replication of Chlamydia trachomatis. 
Targeting lipid droplets may therefore provide new therapeutic strategies for treating 
these infections. 
 
4.1.4 3T3 fibroblast cells as a model for investigating TPD52-like function  
 
As described in Section 4.1.2.1, the main regulators of lipid droplet formation are 
members of the PAT protein family which includes perilipin, adipophilin (ADRP) and 
TIP47 (Brasaemle, 2007). PAT protein expression has been examined using 
samples from various types of cancer (Straub et al., 2010), showing that PAT 
proteins are frequently and differentially expressed. TIP47 has also been proposed 
as a biomarker for cervical cancer using blood from cervical carcinoma patients 
(Szigeti et al., 2009). Increased expression of PAT proteins in cancer further supports 
deregulated lipid storage within cancer cells. Several interaction analyses have 
reported that TPD52 binds PAT proteins. TPD52 was identified as a binding partner 
in a yeast two-hybrid screen using a perilipin bait (Yamaguchi et al., 2006). In 
another study, TPD52 co-immunoprecipitated with TIP47 and other proteins, 
including Rab5 (Zhang et al., 2007b). These studies suggest the possibility of TPD52 
associating with PAT proteins in regulating lipid storage. 
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Collectively, based on several studies (Section 1.6.4) reporting links between TPD52 
and lipid droplets and interactions with PAT proteins as mentioned above, we 
hypothesized that TPD52 is involved in regulating lipid storage and therefore 
contributes to the lipogenic phenotype in cancer cells. To date there has been no 
direct demonstration of TPD52 overexpression affecting lipid storage in any cell type. 
Therefore, we sought to study the effects of TPD52 expression on lipid droplets and 
PAT proteins using 3T3 mouse fibroblast cell lines that had been stably transfected 
with TPD52 or TPD52L1 (Shehata et al., 2008a) (Figure 4.4). The 3T3 cell line has 
been a reliable model in studying TPD52 function (Lewis et al., 2007; Shehata et al., 
2008a) as well as being a classic cell line model for studying lipid storage (Bostrom 
et al., 2005; Imamura et al., 2002; Murphy et al., 2010). Previously, Shehata et al. 
(2008a) identified different non-redundant functions for TPD52 and TPD52L1, as 3T3 
cells showed increased cell proliferation and anchorage-independent growth upon 
exogenous TPD52 expression only. This highlights the oncogenic potential of TPD52 
and we decided to extend this finding further by investigating TPD52 effects on lipid 
storage, as another factor which may contribute to TPD52’s oncogenicity.    
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4.1.5 Specific aims for Chapter 4 
 
Experiments described in this chapter aimed to determine whether: 
 
1. Stable TPD52 expression led to an increase in the size and/or numbers of 
lipid droplets in 3T3 cells. 
 
2. Changes in PAT protein localization and/or expression occurred in stably 
TPD52-expressing 3T3 cells, relative to controls. 
 
3. TPD52L1, which does not share the oncogenic functions of TPD52, alters 
lipid droplet sizes and/or numbers, and/or alters PAT protein localisation or 
expression in 3T3 cells. 
 
4. TPD52-expressing 3T3 cells have an enhanced ability to take up exogenous 
lipid, relative to controls. 
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4.2 Results 
 
The parental, vector-transfected and stably TPD52- and TPD52L1-expressing 3T3 
mouse fibroblast cell lines have been previously described (Shehata et al., 2008a) 
(Figure 4.4A). Western blot analysis confirmed that D52-2-1 and D52-2-7 cells 
maintained TPD52 expression (Figure 4.4B), D52L1-4 and D52L1-6 cells maintained 
TPD52L1 expression (Figure 4.4C), whereas the parental and vector (vector-3) 
control cells did not detectably express TPD52 or TPD52L1. These results confirm 
that stably transfected cells retained exogenous expression of TPD52 or TPD52L1, 
as anticipated (Shehata et al., 2008a). 
 
4.2.1 Increased lipid droplets in TPD52- but not TPD52L1-expressing 3T3 cell 
lines  
 
Firstly, we investigated the effects of TPD52 or TPD52L1 expression in 3T3 cells on 
lipid droplets. BODIPY 493/503, a lipid soluble dye, was used to stain lipid droplets 
and was visualized using confocal microscopy. Increased lipid droplet staining was 
shown in the TPD52-expressing 3T3 cell lines D52-2-1 and D52-2-7 (Figure 4.5B) 
compared to parental and vector-3 control cell lines, where smaller and fewer lipid 
droplets were detected (Figure 4.5A). Interestingly, the TPD52L1-expressing 3T3 cell 
lines D52L1-4 and D52L1-6 (Figure 4.5C) showed similar lipid droplet staining as 
parental and vector-3 control cell lines (Figure 4.5A).  
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Figure 4.4 3T3 mouse fibroblast cell line model. (A) Graphic representation of the 
TPD52- and TPD52L1-expressing 3T3 fibroblast cell lines used in this study. Vector 
only (vector-3) and parent 3T3 (not shown) fibroblast cell lines were used as control 
cells. Western blot analysis of (B) TPD52 and (C) TPD52L1 levels in TPD52- or 
TPD52L1-expressing 3T3 cell lines, compared to parent and vector-3 control 3T3 
cells. Results shown are representative of those obtained from 3 independent 
experiments. Left, proteins analysed. Right, molecular weights of detected species. 
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Figure 4.5 Increased lipid droplets in TPD52- but not TPD52L1-expressing 3T3 cells. 
(A) Control cells (parent, vector-3), (B) TPD52-expressing (D52-2-1, D52-2-7) and (C) 
TPD52L1-expressing (D52L1-4, D52L1-6) 3T3 cells were stained with BODIPY 493/503 
(green) for lipid droplets and DAPI (blue) for nuclear staining and visualised using 
confocal microscopy with a X63 objective. Images are representative of 3 independent 
experiments. Scale bar = 15µm.  
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Lipid droplets in these and other BODIPY images (Figure 4.5) were quantified using 
the Image Pro Plus 5.1 software. The image analysis results confirmed that there 
was a significant increase in mean lipid droplet numbers per cell in the two TPD52-
expressing 3T3 cell lines, but not in the two TPD52L1-expressing 3T3 cell lines, 
compared to vector-3 control cells (Figure 4.6A). There was a ~ 10-fold increase in 
lipid droplet numbers per cell in D52-2-7 cells and a ~ 4-fold increase in D52-2-1 
cells, when compared to vector-3 control cells (Figure 4.6A). There were also smaller 
but significant increases in the mean lipid droplet diameter (μm) and area (μm2) in 
D52-2-7 cells compared to vector-3 control cells (Figures 4.6B and 4.6C). In addition, 
Western blot analyses clearly showed that D52-2-7 cells expressed higher TPD52 
levels than D52-2-1 cells (Figure 4.4B). Taken together, our results provide direct 
evidence for the first time that TPD52 expression leads to significant increases in 
lipid droplet numbers and sizes in 3T3 fibroblasts.          
 
4.2.2 Increased lipid droplets in TPD52-expressing MDA-MB-231 cells  
 
Since TPD52-expressing 3T3 cells revealed significant increased lipid droplet 
numbers, we examined a second stably TPD52-expressing cell line, derived from the 
breast cancer cell line MDA-MB-231. These cell lines were derived as previously 
described (Boutros, 2005) and were chosen for TPD52 overexpression since MDA-
MB-231 cells showed no apparent increase in TPD52 copy number (Figure 3.2A, 
Table 3.2), and hence express lower TPD52 levels than many breast cancer cell 
lines (Figure 3.2). BODIPY staining revealed increased lipid droplets in the stably 
TPD52-expressing MDA-MB-231 cells compared to parent and vector control cells 
(Figure 4.7). This provided evidence of possible involvement of TPD52 in lipid droplet 
regulation in a second cell line.  
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Figure 4.6 BODIPY quantitation analyses of TPD52- and TPD52L1-expressing 
3T3 cell lines. (A) Mean lipid droplet number per cell, (B) mean lipid droplet diameter 
(µm) and (C) mean lipid droplet area (µm2) were quantified from 10 random fields of 
view per cell line using images such as those shown in Figure 4.5, using Image-Pro 
Plus 5.1 software. Data are presented as means ± SE (y-axis) from 3 independent 
experiments. Comparisons which were significantly different from vector-3 control 
cells are shown with their corresponding p values (Student’s t test). 
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Figure 4.7 Increased lipid droplets in TPD52-expressing MDA-MB-231 cells. (A, B) 
Control cells (parent, vector) and (C) TPD52-expressing (H1D2) MDA-MB-231 cells were 
stained with BODIPY 493/503 (green) for lipid droplets and visualised using confocal 
microscopy using X63 magnification. Images were derived from one experiment. Scale 
bar = 10µm.  
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4.2.3 Altered distribution of adipophilin (Adrp) in TPD52- but not TPD52L1-
expressing 3T3 cell lines 
 
Next, we examined the effects of stable TPD52 or TPD52L1 expression on PAT 
protein expression and distribution in 3T3 cells. Since ADRP is the major PAT protein 
that regulates lipid droplets in non-adipocytes (Brasaemle et al., 1997), we analysed 
Adrp expression and sub-cellular localization in TPD52- and TPD52L1-expressing 
3T3 cell lines, compared to parental and vector-3 control cell lines. Results from 
immunofluorescent staining of Adrp in two TPD52-expressing 3T3 cell lines, D52-2-7 
and D52-2-8, revealed that whereas TPD52 was mainly detected in the perinuclear 
region, Adrp staining appeared as clustered ring structures (Figure 4.8A and 4.8B, 
long arrows). These Adrp-stained ring structures resembled lipid droplets (Imamura 
et al., 2002). In contrast, the parental and vector-3 control cell lines showed more 
diffuse cytoplasmic Adrp staining (Figure 4.8C and 4.8D). Enlarged images of a D52-
2-7 cell (Figure 4.8A), showed detectable but limited co-localization between Adrp 
and TPD52 within ring structures (short arrows).  
 
Interestingly, the TPD52L1-expressing 3T3 cell lines D52L1-4 and D52L1-6 showed 
similar Adrp staining patterns to the parental and vector-3 control cell lines (Figure 
4.9). The altered distribution of Adrp in TPD52-expressing cells supports increased 
lipid droplet numbers and sizes in these cell lines (Figures 4.5 and 4.6). 
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Figure 4.8 Altered distribution of adipophilin (Adrp) in TPD52-expressing 3T3 
cells. Immunofluorescent staining visualized using confocal microscopy with a X63 
objective, demonstrated that Adrp staining (green) was clustered (long arrows) in two 
TPD52-expressing 3T3 cells (A, B), compared to a more diffuse cytoplasmic 
distribution of Adrp staining in the parent and vector control cells (C, D, long arrows). 
Higher magnification (white boxed region, images below A) revealed Adrp structures 
resembling lipid droplets (long arrows), and co-localization of Adrp and TPD52 
(merge, yellow) (short arrows). Cells were stained with guinea-pig polyclonal Adrp 
(green) and rabbit polyclonal TPD52 (red) antisera, whereas nuclei were stained with 
DAPI (blue) in combined images on the right (merge). Images shown are 
representative of those obtained in 3 independent experiments. Scale bar = 20 m. 
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Figure 4.9 Adipophilin (Adrp) distribution in TPD5L1-expressing 3T3 cells is 
similar to that of parent and vector control cells. Immunofluorescent staining 
visualized using confocal microscopy with a X63 objective demonstrated that two 
TPD52L1-expressing 3T3 cells showed similar diffuse cytoplasmic Adrp (green) 
staining patterns (A, B, long arrows) as 3T3 parent and vector controls (C, D, long 
arrows). Cells were stained with guinea-pig polyclonal Adrp antisera (green, left 
panels), whereas nuclei were stained with DAPI (blue) combined images on the right 
(merge). Images shown are representative of those obtained in 3 independent 
experiments. Scale bar = 20 m. 
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4.2.4 Localization of TPD52 relative to adipophilin (Adrp) and lipid droplets in 
TPD52-expressing 3T3 cells 
 
The altered distribution of Adrp around structures resembling lipid droplets (Figure 
4.8A and 4.8B) in TPD52-expressing 3T3 cells needed to be confirmed. ADRP co-
localization with lipid droplets, specifically at the surface of lipid droplets has been 
shown previously in many different cell types (Brasaemle et al., 1997). We also 
wanted to compare the localization of TPD52 to that of lipid droplets. Therefore, triple 
staining of TPD52 (red or pseudo-coloured green), ADRP (green) and lipid droplets 
(pseudo-coloured magenta) was performed in TPD52-expressing 3T3 cells 
compared to parental and vector control cells. This was attempted on several 
occasions, but triple-staining of cells was successful in only one experiment. 
Microscopy analyses in the D52-2-7 cell line revealed that Adrp-clustered ring 
structures in the cytoplasm surrounded lipid droplets (Figure 4.10C, long arrows), as 
also reported in an Adrp-expressing 3T3 cell line (Imamura et al., 2002). Limited 
TPD52 labelling co-localized with Adrp and also surrounded some lipid droplets 
(Figure 4.10A and 4.10B, short arrows). The perinuclear staining of TPD52 did not 
co-localize with Adrp or lipid droplets (Figure 4.10A and 4.10B, open arrows). 
Therefore, we confirmed that Adrp co-localized to lipid droplets in TPD52-expressing 
3T3 cells, which agrees with these cells having increased lipid droplets when 
compared to vector control cells (Figure 4.10D). 
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Figure 4.10 TPD52 localization relative to that of adipophilin (Adrp) and lipid 
droplets in TPD52-expressing 3T3 cells. Immunofluorescent images of the TPD52-
expressing 3T3 cells D52-2-7  (A, B, C) and vector-3 cells (D) triple stained with 
rabbit polyclonal TPD52 (red or pseudo-coloured for green), guinea pig polyclonal 
Adrp (green) antisera and BODIPY 493/503 (pseudo-coloured for magenta) for lipid 
droplets. Cells were also treated with DAPI to stain the nuclei (blue). Combined 
images are shown on the right (merge). Images were visualized using confocal 
microscopy with a X63 objective. Below each image (A, B) are enlarged images of 
boxed regions showing limited co-localization between TPD52, Adrp and lipid 
droplets (small arrowheads), or no co-localization between TPD52 and Adrp or lipid 
droplets seen at the perinuclear region (A, B; open arrowheads). The expected co-
localization of Adrp and lipid droplets was detected in D52-2-7 cells (C, arrows). Adrp 
was detected as clusters in D52-2-7 cells (A, C) compared to a more diffuse 
cytoplasmic distribution in vector-3 cells (D). Images shown were from a single 
experiment. Scale bar = 20 m.  
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4.2.5 PAT protein and Fasn levels in TPD52-expressing 3T3 cells, relative to 
controls 
 
Since there was a significant increase in lipid droplet numbers in the TPD52-
expressing 3T3 cells (Figure 4.6A), we investigated PAT protein levels in these cells. 
Protein lysates of differentiated 3T3-L1 cells (provided by Ms. Sarah Frost) were 
used as a positive control for perilipin and Adrp expression (Brasaemle et al., 1997). 
Western blot analyses revealed that perilipin was not detected in the TPD52-
expressing 3T3 cells, parental or vector control cells, with the possible exception of 
D52-2-7 cells (Figure 4.11A). In contrast, perilipin was abundantly detected in 
differentiated 3T3-L1 cells (Figure 4.11A). Western blot analyses revealed that there 
were no obvious differences in Adrp levels in either TPD52- or TPD52L1-expressing 
3T3 cells, when compared with parent and vector control cells (Figure 4.11A, data 
not shown). This suggests that Adrp levels are similar in all 3T3 cells examined, and 
that increased lipid storage in TPD52-expressing cells led to Adrp being re-located to 
lipid droplets. 
 
We also analysed fatty acid synthase (Fasn) levels in the 3T3 cell lines. Fasn is the 
major rate-limiting enzyme involved in synthesis of de novo free fatty acids 
(Menendez and Lupu, 2007). Increased lipid droplet numbers could indicate an 
increase in available free fatty acids, requiring increased lipid storage to overcome 
lipotoxicity. However, Western blot analyses revealed that Fasn levels were similar in 
TPD52-expressing 3T3 cells and the vector control cells (Figure 4.11B), indicating 
that the increased lipid storage in TPD52-expressing cells was not accompanied by 
altered Fasn expression. 
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Figure 4.11 Western blot analyses of PAT protein and Fasn levels in 3T3 cell 
lines. Total protein extracts from parent, vector only and TPD52-expressing 3T3 cell 
lines were subjected to Western blot analyses for (A) perilipin, adipophilin (Adrp), 
TPD52 and (B) fatty acid synthase (Fasn) levels. Gapdh was used as loading control. 
Differentiated 3T3-L1 adipocytes were used as a positive control for perilipin and 
Adrp expression. Left, proteins analysed. Right, molecular weights of detected 
species. Results shown are representative of those from 3 independent experiments. 
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4.2.6 PAT protein and FASN levels in stably TPD52-expressed MDA-MB-231 
cells, relative to controls 
 
We wanted to further confirm our results obtained in Figure 4.11 by investigating PAT 
protein and FASN levels in TPD52-expressing MDA-MB-231 cells. Protein lysates of 
differentiated 3T3-L1 cells (provided by Ms. Sarah Frost) were used as a positive 
control for perilipin (Brasaemle et al., 1997). Western blot results again revealed 
perilipin was not detected, except in 3T3-L1 cells (Figure 4.12A). ADRP was not 
detected in TPD52-expressing MDA-MB-231 cells (Figure 4.12A), although it was 
subsequently confirmed using transient ADRP expression in SK-BR-3 breast cancer 
cells that Adrp antisera only detect mouse Adrp (S. Frost, unpublished results) and 
the bands detected in protein lysates of MDA-MB-231 cells were likely non-specific 
(Figure 4.12A). In contrast, transient expression of perilipin in SK-BR-3 cells 
confirmed that perilipin antisera detect human perilipin as well (S. Frost, unpublished 
results). Therefore, we were unable to examine ADRP expression in TPD52-
expressing MDA-MB-231 cells. TIP47 and FASN levels were similar in all MDA-MB-
231 cell lines examined (Figure 4.12B). The high FASN levels in SK-BR-3 cells 
(Figure 4.12B) are consistent with previous results (Kumar-Sinha et al., 2003; Yoon 
et al., 2007; Zhang et al., 2005). Thus, these results together with those shown in 
Figure 4.11, indicate that increased lipid storage in TPD52-expressing cells is not 
accompanied by altered perilipin, TIP47 or FASN expression.  
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Figure 4.12 Western blot analyses of PAT protein and Fasn levels in stably 
TPD52-expressing MDA-MB-231 cell lines. Total protein extracts from SK-BR-3, 
vector only and stably TPD52-expressing MDA-MB-231 cell lines (H1D2 and H2D2) 
were subjected to Western blot analyses for (A) perilipin, adipophilin (Adrp/ADRP), 
TPD52 and (B) TIP47 and fatty acid synthase (FASN) levels. Gapdh/GAPDH was 
used as loading control. Differentiated 3T3-L1 adipocytes were used as a positive 
control for perilipin and Adrp expression. Left, proteins analysed. Right, molecular 
weights of detected species. Results shown are from a single experiment. 
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4.2.7 FASN expression and localization in breast cell lines 
 
It has been shown that ERBB2-amplified breast cancer cells have high intracellular 
lipid content (Kourtidis et al., 2010). Furthermore, in ERBB2-amplified breast cancer 
cell lines, FASN was found to be associated with ERBB2 expression (Kumar-Sinha et 
al., 2003). Reduced FASN expression was shown using ERBB2 inhibitors such as 
Herceptin in the SK-BR-3 breast cancer cell line (Kumar-Sinha et al., 2003). Based 
on our results showing increased intracellular lipid droplets in TPD52-expressing 3T3 
cells (Figure 4.5) and together with significant positive associations between TPD52 
and ERBB2 expression in breast cancer cell lines (Chapter 3), we decided to 
compare TPD52 and FASN expression in a panel of 15 breast cell lines. Western blot 
results revealed frequent co-expression of TPD52 and FASN (Figure 4.13A), 
although statistical analysis revealed no significant correlation between FASN and 
TPD52 levels (Spearman test, rs=0.418; p=0.121; n=15). Therefore, TPD52 
involvement in lipid droplet regulation does not seem to be associated with FASN 
expression in this breast cell line cohort, in agreement with results shown in Figures 
4.11 and 4.12.  
 
Next, we compared the localizations of FASN and TPD52 in the ERBB2- and TPD52-
amplified cell line SK-BR-3 using indirect immunofluorescent staining. FASN was 
mainly detected in the cytoplasm and at the plasma membrane (Figure 4.13B) as 
reported previously (Jin et al., 2010), whereas TPD52 showed cytoplasmic, plasma 
membrane and perinuclear staining (Figure 4.13B). Co-localization of FASN and 
TPD52 was detected at the plasma membrane, and to a limited extent within the 
cytoplasm, but FASN did not co-localize with TPD52 within the perinuclear cytoplasm 
(Figure 4.13B). Together, these results provide preliminary evidence that TPD52 and 
FASN may be co-localized in breast cancer cell lines, however a larger cell line 
cohort is needed to confirm this observation.  
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Figure 4.13 FASN expression in breast cell lines. (A) FASN levels were compared 
with those of ERBB2 and TPD52 in a panel of human breast cell lines. Total protein 
lysates were subjected to Western blot analyses. GAPDH was used as a loading 
control. Images shown are representative from 3 independent experiments. Western 
blot images of TPD52, ERBB2 and GAPDH were also shown in Figure 3.2C. Left, 
proteins analysed. Right, molecular weights of detected species. (B) 
Immunofluorescent staining of FASN (green) and TPD52 (red) in SK-BR-3 cells 
showing cytoplasmic and plasma membrane distributions with focal areas of co-
localization (arrows). Cells were co-stained with mouse monoclonal FASN antibody 
(green) and rabbit polyclonal TPD52 antisera (red), with combined images shown on 
the right (merge). Images were visualized using confocal microscopy using a X63 
objective. The results from a single experiment are shown. Scale bar = 20 m. 
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4.2.8 TIP47 expression and localization in breast cell lines 
 
TIP47 has been reported to be involved in the trafficking of lipids (Wolins et al., 
2001). To date, no study has compared TIP47 and TPD52 expression in any cell line. 
Initially, we wished to examine Tip47 expression and sub-cellular distribution in 3T3 
cells, but the TIP47 antisera proved to only detect human TIP47 (data not shown). 
Therefore, Western blot analyses of TIP47 compared to TPD52 levels in 8 breast cell 
lines was performed by Ms Sarah Frost. TIP47 was detected in all cell lines, with no 
obvious association between TIP47 and TPD52 levels (Figure 4.14A). Interestingly, 
indirect immunofluorescent staining showed co-localization of TPD52 and TIP47 in 
distinct ring structures in SK-BR-3 cells (Figure 4.14B, arrows), which resembled lipid 
droplets previously detected in HeLa cells (Smirnova et al., 2006; Wolins et al., 
2001). Either rabbit polyclonal TPD52 antisera or mouse monoclonal TPD52 antibody 
were used in 2 independent experiments. One experiment used rabbit polyclonal 
TPD52 and one experiment used mouse monoclonal TPD52, with guinea pig 
polyclonal TIP47 antisera, and both TPD52 antisera produced the same co-
localization result (Figure 4.14B, data not shown). 
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Figure 4.14 TIP47 expression in breast cell lines. (A) Total protein lysates were 
subjected to Western blot analyses. GAPDH was used as a loading control. Images 
shown are representative from 3 independent experiments. Left, proteins analysed. 
Right, molecular weights of detected species. (B) Immunofluorescent staining of 
TIP47 (green) and TPD52 (red) in the TPD52-amplified cell line SK-BR-3 showing 
distinct co-localization of TIP47 with TPD52 in ring structures (arrows, merge). Cells 
were co-stained with guinea-pig polyclonal TIP47 (green) and rabbit polyclonal 
TPD52 (red) antisera, with combined images shown on the right (merge). Images 
were visualized using confocal microscopy using a X63 objective. Images shown are 
representative from a total of 2 independent experiments, in which rabbit polyclonal 
TPD52 antisera and mouse monoclonal TPD52 antibody were each used once. 
Scale bar = 20 m. 
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4.2.9 Oleic acid uptake by TPD52-expressing versus control 3T3 cells 
 
Since we demonstrated that TPD52-expressing 3T3 cells showed increased numbers 
of lipid droplets per cell compared with parent and vector control cells (Figure 4.6A), 
we queried whether these cells would also show an increased capacity to take up 
and store lipid, compared with parent and vector control cells. We decided to treat 
3T3 cell lines with oleic acid, an unsaturated fatty acid which is not toxic to cultured 
cells over short incubation periods (< 24 h). The chosen concentration of 400 M 
oleic acid has been used in numerous reports using different cell types such as 
mouse 3T3-L1 cells (Beller et al., 2008; Brasaemle et al., 2000), CHO cells (Tansey 
et al., 2003), HEK 293, MCF-7, HeLa, and BHK cells (Listenberger et al., 2007). We 
therefore treated 3T3 cell lines with 400 M oleic acid for 24 h, and compared these 
with cells cultured in media only and harvested at 0 h to obtain a baseline control. 
Cells were stained with BODIPY 493/503 to visualize lipid droplets using confocal 
microscopy.  
 
Confocal microscopy analyses revealed that 24 h oleic acid treatment produced 
increased lipid droplets in all cell lines, relative to those detectable prior to oleic acid 
treatment (Figure 4.15).  However, more lipid droplets were detected in all TPD52-
expressing 3T3 cells, relative to parent and vector control cells (Figure 4.15). This 
was confirmed by quantitation of BODIPY staining. There was a significant ~2-fold 
increase in the mean lipid droplet number per cell in the 3 TPD52-expressing 3T3 
cells, compared with the parent and vector control cells (Figure 4.16A). Interestingly, 
all 3 TPD52-expressing 3T3 cells showed very similar mean lipid droplet numbers 
per cell after oleic acid treatment, despite different basal numbers of lipid droplets per 
cell (Figure 4.16A). The mean lipid droplet numbers per cell in parent and vector 
control cells were very similar before and after oleic acid treatment. 
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Figure 4.15 Lipid droplets following oleic acid treatment of 3T3 cell lines. (A-C) 
TPD52-expressing, (D) vector or (E) parent 3T3 cell lines were incubated with 400 
M oleic acid for 24 h (right panel), and compared with the same cell lines harvested 
at 0 h, grown in media only (left panel). Cells were stained for lipid droplets using 
BODIPY 493/503 (green) and visualized by confocal microscopy using a X63 
objective. (A) An enlarged image of a D52-2-7 cell (white boxed region, right hand 
panel) following incubation with 400 M oleic acid for 24 h is shown at the far right. 
Images shown are representative of those obtained in 3 independent experiments. 
Scale bar = 20 m. 
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Figure 4.16 BODIPY staining quantitation before and after oleic acid treatment 
of 3T3 cell lines. Confocal images of 10 random fields of view were taken of all cell 
lines before (0 h) or after 400 M oleic acid (24 h), that were stained with BODIPY 
495/503 as per Figure 4.14. Images were analysed using Image Pro Plus 5.1 for 
mean lipid droplet numbers per cell (A), mean lipid droplet diameter (C) and mean 
lipid droplet area (E). Relative fold changes in mean lipid droplet numbers per cell 
(B), mean lipid droplet diameter (D) or mean lipid droplet area (F) were calculated 
from the results shown in A, C and E respectively. Data are presented as means ± 
SE, from 3 independent experiments. Significantly different comparisons between 
groups (TPD52-expressing 3T3 cells were grouped together, compared to parent and 
vector-3 control cells) are shown with the corresponding p values (Student’s t test). 
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We then analysed the relative fold change of mean lipid droplet numbers per cell 
before and after oleic acid treatment. There were ~18-fold and ~14-fold increases in 
mean lipid droplet numbers per cell in parent and vector control cells, respectively, 
after 24 h oleic acid treatment (Figure 4.16B). In contrast, TPD52-expressing 3T3 
cells showed a ~4-fold increase (D52-1-12 and D52-2-1 cells), and a ~2-fold increase 
(D52-2-7 cells) in mean lipid droplet numbers per cell (Figure 4.16B). This meant that 
even though oleic acid-treated TPD52-expressing 3T3 cells formed more lipid 
droplets then controls (Figure 4.16A), parent and vector control cells showed 
significantly greater relative increases in lipid droplet numbers (Figure 4.16B).  
 
Under basal conditions, D52-2-7 cells showed the highest lipid droplet numbers per 
cell and also showed the highest TPD52 levels (Figure 4.16A and 4.17A). D52-2-7 
cells also showed the lowest relative fold increase in lipid droplet numbers per cell of 
any cell line examined (Figure 4.16B). Interestingly, while the relative increases in 
lipid droplet numbers varied between the 3 TPD52-expressing 3T3 cell lines, they all 
showed very similar lipid droplet numbers per cell after oleic acid treatment (Figure 
4.16A). 
 
Increased lipid droplet numbers per cell after 24 h oleic acid treatment were 
accompanied by increased lipid droplet diameters and areas (Figure 4.16C and 
4.16E). The apparent increase in lipid droplet diameter and area might be due to lipid 
droplets being in clusters (Fig 4.9), and this will be discussed further (Section 4.3). 
An enlarged image of a D52-2-7 cell after 24 h oleic acid treatment showed that 
droplets were relatively uniform in size (Figure 4.15A, far right), and this is supported 
by the small error bars obtained from the analysis of mean lipid droplet diameter 
(Figure 4.16C). Although BODIPY quantitation revealed that there were significant 
increases in lipid droplet diameter and area in TPD52-expressing cells when 
compared to controls (Figure 4.16C and 4.16E), relative fold changes of these 
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parameters were similar in all 3T3 cell lines analysed (Figure 4.16D and 4.16F). The 
significant increases in lipid droplet diameter and size in TPD52-expressing cells 
were noted to be largely driven by D52-2-7 cells (Figure 4.16C and 4.16E). In 
summary, all cell lines showed larger lipid droplets following oleic acid treatment, and 
this was not primarily determined by TPD52 expression status. 
 
4.2.10 PAT protein, Fasn and TPD52 levels remained unchanged in TPD52-
expressing 3T3 cells after oleic acid treatment 
 
We wanted to determine whether oleic acid treatment could affect PAT protein and 
Fasn levels in 3T3 cell lines. Therefore, we harvested total protein lysates from these 
cell lines after 0 h, 6 h, and 24 h of 400 M oleic acid treatment (Figure 4.17A). 
Western blot and densitometry analyses revealed that Adrp levels were increased 
after 6 h and 24 h oleic acid treatment in all 3T3 cell lines (Figure 4.17A, data not 
shown), as expected (de Wilde et al., 2010; Fan et al., 2009; Masuda et al., 2006), 
with similar increases noted in all 3T3 cell lines. In contrast, Fasn, TPD52 and 
perilipin levels were not obviously affected by oleic acid treatment in any cell line 
(Figure 4.17, data not shown). Collectively, Western blot and densitometry results 
revealed no significant changes in perilipin, Fasn or TPD52 levels in TPD52-
expressing 3T3 cells after 400 M oleic acid treatment for 6 h or 24 h. 
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Figure 4.17 Adrp, Fasn, TPD52 and perilipin levels after oleic acid treatment of 
3T3 cell lines. Western blot analyses of (A) Adrp, Fasn and TPD52 levels (A) and (B) 
perilipin and TPD52 levels in total protein lysates from the indicated 3T3 cell lines 
treated with 400 µM oleic acid and harvested at 0 h, 6 h or 24 h. A representative 
Western blot image is shown from 3 independent experiments. Differentiated 3T3-L1 
adipocytes were used as a positive control for perilipin (B). Gapdh was used as a 
loading control. (*) Non-specific staining. Left, proteins analysed. Right, molecular 
weights of detected species.  
* * 
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4.2.11 TPD52 localization relative to that of Adrp, lipid droplets, and Pdi (ER 
marker) in TPD52-expressing 3T3 cells following oleic acid treatment 
 
In Section 4.2.3, we described altered Adrp distribution in TPD52-expressing 3T3 
cells. We therefore compared the localizations of TPD52, Adrp and lipid droplets in 
TPD52-expressing 3T3 cells compared with control cells after oleic acid treatment, 
using indirect immunofluorescence microscopy. Immunofluorescent staining revealed 
changes in TPD52 distribution in TPD52-expressing 3T3 cells after oleic acid 
treatment (Figure 4.18B), compared with TPD52 localization prior to treatment 
(Figure 4.18A). TPD52 staining increased within the perinuclear region, relative to 
untreated cells (Figure 4.18A and 4.18B). In addition, there were also more “spider-
web”-like projections within the perinuclear region that were revealed by TPD52 
staining (Figure 4.18B, inset). Lipid droplets were either detected between or in close 
proximity to these structures (Figure 4.18B).  
  
Immunofluorescent images of vector control cells showed more pronounced Adrp 
staining after oleic acid treatment (Figure 4.18G and 4.18H), in agreement with the 
results of Western blot analyses (Figure 4.17A). TPD52-expressing 3T3 cells also 
showed an increase in Adrp staining, in agreement with the results of Western blot 
analyses (Figure 4.17A) and increased Adrp-associated lipid droplets (Figure 4.18E 
and 4.18F). Adrp was detected near lipid droplets before and after oleic acid 
treatment in both cell lines (Figure 4.18E-4.18H). Limited co-localization of TPD52 
and Adrp was detected before or after oleic acid treatment of D52-2-7 cells (Figure 
4.18I-4.18J). Similarly, TPD52 showed limited co-localization with lipid droplets 
(Figure 4.18A and 4.18B).  
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Figure 4.18 TPD52 localization relative to that of Adrp and lipid droplets before 
and after oleic acid treatment. 3T3 cell lines were treated with media only (0 h) or 
with 400 M oleic acid, and harvested after 24 h. Immunofluorescent images of D52-
2-7 cells (A, B, E, F, I, J) and vector-3 control cells (C, D, G, H, K, L) triple stained 
with rabbit polyclonal TPD52 antisera (red or pseudo-coloured as green), guinea pig 
polyclonal ADRP antisera (green) and BODIPY 493/503 (pseudo-coloured as 
magenta), and analyzed with confocal microscopy using a X63 objective. Cells were 
also treated with DAPI (blue) to stain the nuclei, shown in combined images on the 
right (merge). Below images of D52-2-7 cells (A, B, E, F, I, J) are enlarged images of 
boxed regions showing co-localization between TPD52, Adrp and/or lipid droplets 
(small arrowheads), a lack of co-localization between TPD52 and lipid droplets (A, B) 
or Adrp (I, J) within the perinuclear region, and enhanced TPD52 staining after oleic 
acid treatment (A, B, I, J; open arrowheads). Adrp and lipid droplets co-localized in 
D52-2-7 and vector-3 cells as anticipated (E, F, H; shown with arrows). Without oleic 
acid treatment, Adrp was detected in clusters in D52-2-7 cells (E) and showed a 
more diffuse cytoplasmic distribution in vector control cells (G). A single experiment 
was performed. BODIPY staining in (A, E, I, C, G, K) was also shown in Figure 4.10. 
Images in (A, B, C, D) are repeated in (E, F, G, H) respectively. TPD52 staining 
shown in (A, B, C, D) is repeated in (I, J, K, L), respectively. Adrp staining shown in 
(E, F, G, H) is repeated in (I, J, K, L) respectively. Scale bar = 20 m.  
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Studies have reported that lipid droplets can be formed by budding from the 
endoplasmic reticulum (ER) membrane and have been demonstrated to be in close 
proximity with the ER membrane (Blanchette-Mackie et al., 1995; Ozeki et al., 2005; 
Tauchi-Sato et al., 2002; Wan et al., 2007). Since we noticed perinuclear projections 
stained for TPD52 in D52-2-7 cells after 24 h 400 M oleic acid treatment (Figure 
4.18A, 4.18B, 4.18I, 4.18J), we examined whether these structures could be 
associated with the ER. Protein disulfide isomerise (PDI) protein was previously used 
as an ER marker which stains the ER membrane in a lace-like pattern (Ohsaki et al., 
2008), and we therefore compared this with TPD52 in D52-2-7 cells. Pdi staining was 
detected throughout the cytoplasm in both D52-2-7 and vector control cells, before 
and after 24 h 400 M oleic acid treatment (Figure 4.19). TPD52 and Pdi did not 
obviously co-localize in D52-2-7 cells, either before or after oleic acid treatment 
(Figure 4.19A and 4.19B). The perinuclear TPD52 projections noted following 24 h 
400 M oleic acid treatment therefore did not co-localize with the ER marker Pdi 
(Figure 4.19B).  
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Figure 4.19 TPD52 localization relative to that of Pdi in TPD52-expressing 3T3 
cells. 3T3 cell lines were treated (A, C) with media only (0 h) or (B, D) with 400 M 
oleic acid and harvested after 24 h. (A, B) D52-2-7 and (C, D) vector control cells 
were stained with mouse monoclonal TPD52 antibody (red) and rabbit polyclonal PDI 
antisera (green) and analyzed by confocal microscopy using a X63 objective. 
Combined images are shown on the right (merge). Below images of D52-2-7 cells (A, 
B) are enlarged images of boxed regions showing the lack of co-localization between 
TPD52 and Pdi (arrows) in cells treated or not treated with oleic acid. A single 
experiment was performed. Scale bar = 20 m.  
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4.3 Discussion  
 
The work in this chapter explored a novel function for TPD52 in the regulation of lipid 
storage. Previous studies suggest TPD52 as a potential oncogene (Adler et al., 2006; 
Balleine et al., 2000; Byrne et al., 2012; Liu et al., 2007b; Shehata et al., 2008a). 
However, the underlying mechanisms are still elusive. Data presented in this chapter 
suggest that TPD52 may promote tumorigenesis via regulation of lipid storage, 
possibly through interactions with PAT proteins (Yamaguchi et al., 2006; Zhang et al., 
2007b). The increase in intracellular lipid droplets produced in response to TPD52 
expression may assist to meet the high energy demands of tumor cells. 
 
4.3.1 A lipogenic phenotype in TPD52-expressing 3T3 cells 
 
To date, a number of studies have suggested links between TPD52 and lipid droplet 
regulation (Ashrafi et al., 2003; Yamaguchi et al., 2006; Zhang et al., 2007b). For the 
first time, data presented in this chapter revealed that TPD52 expression increased 
lipid droplet numbers in 3T3 cells. This was based on the analyses of images of 
BODIPY stained lipid droplets (Figures 4.5 and 4.6), supported by electron 
microscopy images (Appendix 1). In addition, increased lipid content, specifically 
triacylglyceride in TPD52-expressing 3T3 cells has been recently confirmed by Dr. 
Alvin Kamili detected using an enzymatic triacylglyceride assay (A. Kamili, 
unpublished results). A similar result was obtained when mouse Adrp was 
overexpressed in 3T3 cell lines, resulting in increased lipid droplets as revealed by 
Oil Red O staining, without induction of other adipocyte-specific or lipogenic genes 
(Imamura et al., 2002).  
 
TPD52 expression in 3T3 cells led to increased proliferation and anchorage-
independent growth which are characteristic of transformed cells (Shehata et al., 
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2008a). The increased proliferation of TPD52-expressing 3T3 cells might indicate an 
increase in energy demand which subsequently might increase utilization of lipids 
from lipid storage through the -oxidation pathway. As mentioned before, increased 
-oxidation has been reported to occur in prostate cancer and glioblastoma cells 
(Section 1.4.3.1.3). Therefore, it would be of interest for future studies to investigate 
the rate of -oxidation as well as the levels and activities of the enzymes involved, 
such as carnithine palmitoyl (CPT) and acetyl-CoA oxidase (ACO). 
 
TPD52-expressing cell lines showed increased lipid droplet numbers per cell, with a 
mean diameter of ~ 1 μm (Figure 4.6). Most lipid droplets in non-adipocytes are 
smaller than those in adipocytes (Suzuki et al., 2011). Lipid droplets are usually ~1 
μm or smaller in non-adipocytes, compared with ~100 μm in size for adipocytes. 
Therefore, in TPD52-expressing 3T3 cells the greater increase in lipid droplet 
numbers, as opposed to size, suggests that TPD52 regulates lipid droplet formation 
as opposed to the growth and/or fusion of lipid droplets. This observation was also 
reported in Drosophila S2 cells, which upon oleic acid treatment, formed numerous 
clusters of lipid droplets which were smaller in size than the large lipid droplets seen 
in mature adipocytes (Guo et al., 2008).  
 
Analyses of TPD52 expression in a human cell line model may be more informative 
in terms of understanding the role of TPD52 in human cancer pathogenesis. 
Therefore, we provided preliminary results of increased lipid droplets in exogenously 
TPD52-expressing MDA-MB-231 breast cancer cell lines (Figure 4.7). It will be 
important to repeat the lipid droplet staining using both TPD52- and TPD52L1-
expressing MDA-MB-231 breast cancer cell lines for further confirmation. Overall, 
these results provide the first direct evidence that TPD52 expression produces 
increased lipid droplet numbers in fibroblasts (Figure 4.5) and the breast cancer cell 
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line MDA-MB-231 (Figure 4.7). Ideally, these findings should be confirmed upon 
transient TPD52 overexpression to exclude aberrant lipid metabolism due to cell 
selection following stable and constitutive TPD52 overexpression. However, 
preliminary findings of transient TPD52 expression (for 72 h) in breast cell lines (BT-
474, 2 experiments; MCF-7, HS-578T, and MCF-10A, a single experiment each) 
showed that FASN levels remained unchanged. 
 
Following oleic acid treatment, TPD52 expression allowed 3T3 cells to form more 
lipid droplets than either vector control or parental cells (Figure 4.15). However, 
TPD52-expressing 3T3 cells showed lesser relative increases in lipid droplet 
numbers relative to either vector control or parental cells (Figure 4.16A). The fact that 
the three TPD52-expressing 3T3 cell lines showed very similar mean lipid droplet 
numbers per cell after oleic acid treatment might indicate that these cells had 
reached a maximal capacity to store lipid. Vector control and parental cells also 
demonstrated very similar lipid droplet numbers per cell after oleic acid treatment. 
Further investigations such as more prolonged incubations with oleic acid, as well as 
investigating the cell proliferation effects of oleic acid treatment would extend the 
findings of this study. Nevertheless, the fact that parental and vector control cell lines 
showed greater relative increases in lipid droplet numbers than TPD52-expressing 
cells might suggest that TPD52 does not function primarily by regulating lipid uptake 
(Figure 4.16B). Radiolabelled fatty acids could be used as a more accurate way to 
measure the level and rate of fatty acid uptake in future studies.  
 
We acknowledge that there were limitations with the software used to quantitate 
BODIPY stained lipid droplets, which may have led to an underestimation of lipid 
droplet numbers. This was most likely in TPD52-expressing 3T3 cells after oleic acid 
treatment which showed many lipid droplets clustered together (Figure 4.15). Lipid 
droplets could be distinguished as individuals visually (Figure 4.15A), but this was not 
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always possible using Image ProPlus 5.1 software. Therefore, numbers of individual 
lipid droplets in TPD52 expressing 3T3 cells after 24 h oleic acid treatment might 
actually be higher than presented (Figure 4.16A). However, these analyses still 
demonstrated a significant increase in lipid droplet numbers in TPD52-expressing 
3T3 cell lines compared to parent and vector controls, both at baseline and after 24 h 
oleic acid treatment (Figure 4.16A). Other approaches are required to confirm this 
result, and currently this is on-going, by measuring total lipid content in these cell 
lines using an enzymatic triacylglyceride assay. We are also optimizing conditions for 
further analysing the lipid content and specifically identifying lipid species using mass 
spectrometry. 
 
In non-adipocytes, ADRP is known to coat lipid droplets and to be the major PAT 
protein regulating their formation (Brasaemle et al., 1997) and lipolysis (Listenberger 
et al., 2007). ADRP has been found to surround smaller lipid droplets in 3T3-L1 pre-
adipocytes and during early adipocyte differentiation, but not in mature adipocytes 
where larger lipid droplets are surrounded by perilipin (Brasaemle et al., 1997). The 
uniform size of lipid droplets seen post oleic acid treatment was increased in TPD52-
expressing 3T3 cells, compared to parental and vector control cells (Figure 4.16C 
and 4.16E). However, the relative fold change in lipid droplet size was comparable 
for all cells (Figure 4.16D and 4.16F). This suggests that lipid droplets in these cells 
were commonly restricted in their capacity to increase in size, following oleic acid 
treatment. Furthermore, this could possibly be attributed to Adrp and not perilipin, 
being the major PAT protein expressed in these 3T3 cells which also co-localized 
with lipid droplets (Figure 4.18E, F, H). As mentioned previously, Adrp has been 
shown to be involved in lipolysis (Listenberger et al., 2007), where Adrp 
overexpression was shown to reduce the association of ATGL and TIP47 with lipid 
droplets. Therefore, in our 3T3 cells, once the lipid droplets have reached their 
maximal storage capacity, Adrp might also activate lipolysis and this will increase the 
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intracellular free fatty acid content. In response to this, the cells will then activate lipid 
droplet formation in order to prevent lipotoxicity due to intracellular free fatty acids. 
However, these are only assumptions that warrant further investigations. The smaller 
size lipid droplets in most non-adipocytes are assumed to be more efficient as an 
intracellular energy source (Suzuki et al., 2011).  
 
Electron microscopy results processed and imaged by our collaborator Dr. Dongwei 
Wang (Appendix 1), further confirmed our BODIPY staining results, which showed 
more lipid droplets in D52-2-7 cells (Appendix 1B) when compared with vector 
controls (Appendix 1A). Lipid droplets were noted to be in close proximity as well as 
attached to the ER (Appendix 1B). Lipid droplet formation from the ER has been 
proposed by numerous investigators (Brasaemle et al., 2004; Liu et al., 2004; Murphy 
and Vance, 1999; Robenek et al., 2006; Wan et al., 2007). Interestingly, we also 
noted numerous whorled, laminated structures in D52-2-7 cells (Appendix 1B) when 
compared to vector controls. These structures resembled phospholipid inclusions 
(O'Farrell et al., 2001) although this would need further confirmation. Alternatively, 
these structures may be lysosome intermediates, possibly caused by lipid overload 
(Sathasivam et al., 2003). This is interesting as exogenous TPD52 expression using 
Chinese Hamster ovary (CHO-K1) cells was shown to co-localize with lysosome-like 
secretory organelles and with Rab27, vesicle-associated membrane protein 7 
(VAMP7) and lysosomal-associated membrane protein LAMP1 (Thomas et al., 
2009). Recently, we also detected partial TPD52 co-localization with LAMP1 in 
TPD52-expressing 3T3 cells (data not shown). Therefore, it will be interesting to 
determine whether TPD52 localization with lysosomes reflects phospholipid 
inclusions within the TPD52-expressing 3T3 cells.  
 
Electron microscopy results also indicated that the ER of D52-2-7 cells was swollen 
compared to vector control cells (Appendix 1). Studies have shown that ER stress 
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plays an important role in regulating lipid metabolism and homeostasis (Fu et al., 
2011; Gentile et al., 2011; Guo et al., 2007; Wei et al., 2006). ER-stress-dependent 
dysregulation of lipid metabolism has been reported to cause diseases such as 
dyslipidemia, insulin resistance, cardiovascular disease, type 2 diabetes, and obesity 
(Basseri and Austin, 2012). Saturated fatty acids such as palmitate and stearate are 
known to induce ER stress in various cell types, as well as modulating intracellular 
signaling such as survival and apoptosis (Guo et al., 2007; Wei et al., 2006). These 
preliminary electron microscopy observations suggest that ER stress could be 
occurring in TPD52-overexpressing 3T3 cells, due to the accumulation of lipids. This 
could be futher investigated using ER stress markers such as Grp78 (glucose-
regulated protein-78), Grp94 (glucose-regulated protein-94), calreticulin, and CHOP 
(CAAT/enhancer binding protein (C/EBP) homologous protein) (Samali et al., 2010).  
 
We are currently optimizing conditions for electron immunogold labelling of TPD52 in 
3T3 cell lines, which has never been achieved previously. This would give more 
detailed information as to where exactly TPD52 is localizing within the cell. 
Previously, EM images have revealed that labelling of endogenous TPD52 localized 
to vesicular structures in pancreatic acinar cells (Thomas et al., 2004). This result 
was further confirmed with EM images showing dual labelling of TPD52 and EEA-1 
(an early endosomal marker) in these acinar cells. However it is not known whether 
these cells also show a lipogenic phenotype, and so the localization of TPD52 in 
pancreatic acinar cells may not resemble that of TPD52 when expressed in 3T3 cells.  
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4.3.2 How the lipogenic phenotype in TPD52-expressing 3T3 cell lines may be 
produced 
 
4.3.2.1 Fatty acid synthase – FASN 
  
As explained previously, high levels of FASN have been found in breast cancer cell 
lines (Kumar-Sinha et al., 2003; Zhang et al., 2005) which also showed high 
intracellular lipid content (Kourtidis et al., 2010; Kourtidis et al., 2009). Although we 
observed the focal co-localization of TPD52 and FASN proteins towards the plasma 
membrane of SK-BR-3 cells (Figure 4.13B), there was no significant correlation 
between TPD52 and FASN levels in breast cell lines, but this needs to be confirmed 
in a larger cell line cohort. Nevertheless, Fasn/FASN levels were comparable in both 
TPD52-expressing 3T3 and MDA-MB-231 cells, compared to relevant vector control 
cells (Figure 4.11B and 4.12B). Hence, these results indicate that TPD52 may not 
directly affect FASN expression, and may instead affect other enzymes involved in 
de novo fatty acid synthesis. The precursor for de novo fatty acid synthesis is acetyl-
CoA, which can be obtained through glycolysis or glutaminolysis (Section 1.4.2.1). 
Cancer cells have been reported to have high glycolysis rates leading to high 
intracellular lipid content from de novo fatty acid synthesis (Lunt and Vander Heiden, 
2011). Thus, it would be worth comparing the levels of enzymes in glycolytic and 
glutaminolytic pathways, which provide the precursor for de novo fatty acid synthesis.  
 
4.3.2.2 PAT proteins – Perilipin, Adipophilin and TIP47 
 
Initially, TPD52 has been found in the lipid droplet fraction of Drosophila (Cermelli S. 
et al, 2006). However, to date, there is no biochemical evidence showing direct 
interactions between TPD52 and lipid droplets. However, previous results 
(Yamaguchi et al., 2006; Zhang et al., 2007b) and those presented in this chapter 
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suggest that TPD52 might regulate lipid storage via associating with PAT proteins, 
specifically ADRP and TIP47. Interactions between TPD52 with TIP47 and ADRP 
were also supported by direct interaction testing in the yeast-two-hybrid system (S. 
Frost, unpublished results). 
 
Immunofluorescent staining showed altered Adrp distribution in TPD52-expressing 
3T3 cells relative to controls, with Adrp surrounding lipid droplets in TPD52-
expressing 3T3 cells (Figure 4.8 and 4.10C). Ectopic Adrp expression is known to 
stimulate lipid droplet formation and accumulation (Imamura et al., 2002). As Adrp 
levels remained unchanged in both TPD52-expressing and vector control 3T3 cells 
(Figure 4.11A), TPD52 may not regulate Adrp levels, and instead Adrp could re-
locate to lipid droplets as a consequence of increased lipid droplet formation. It would 
be valuable to analyze ADRP expression in the panel of breast cell lines used in this 
study, but the available ADRP antisera did not detect human ADRP (Figure 4.12).  
 
4.3.2.3 Prominent perinuclear TPD52 staining post oleic acid treatment of 3T3 
cells 
 
We noted more prominent and enhanced staining of TPD52 at the perinuclear region 
after oleic acid treatment of TPD52-expressing 3T3 cells. That this staining had a 
spider-web-like appearance in some cells suggested that this might reveal the ER. 
Lipid droplets have been proposed to be synthesized in and bud off from the ER 
(Murphy and Vance, 1999). However, the ER marker Pdi did not co-localize with 
TPD52, including within the perinuclear region (Figure 4.19A and 4.19B). It was 
nonetheless interesting to note that TPD52 was detected in close proximity to and/or 
surrounding lipid droplets, although their co-localization was not frequently noted. 
Knowing TPD52’s involvement with vesicular trafficking (Thomas et al., 2010; 
Thomas et al., 2002; Thomas et al., 2009; Thomas et al., 2004) and its interaction 
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with TIP47 (S. Frost, unpublished results), the TPD52-positive structures might 
function as passages for lipid transfer/trafficking/delivery. Lipid droplets are also 
known to be transported on microtubules (Welte et al., 1998), therefore co-staining 
3T3 cells with TPD52 and with microtubule markers such as dynein (Bostrom et al., 
2005) would also be worth considering. These structures could also be associated 
with the Golgi apparatus, which has been shown to be involved in lipid trafficking 
(Surma et al., 2012). Regardless of the underlying mechanism, the re-distribution of 
TPD52 after oleic acid treatment warrants further investigation. 
 
4.3.3 Increased lipid storage is an isoform-specific function of TPD52 
 
As described in Chapter 1, TPD52L1 is 52% identical/66% conserved with respect to 
TPD52 at the amino acid level (Byrne et al., 1996), which includes differences in 
alternatively spliced regions (Byrne et al., 1998b). However, Y2H and other studies 
have found both TPD52 and TPD52L1 to have common binding partners (Byrne et 
al., 1998b; Shahheydari, 2013; Wilson et al., 2001). The results presented in this 
chapter highlight the possibility of a novel, isoform-specific function for TPD52 in 
regulating lipid storage, potentially mediated via interactions with PAT proteins.  
 
Unlike TPD52, TPD52L1 did not promote proliferation and anchorage-dependent 
growth in 3T3 cells, and transient TPD52L1 knock down did not induce apoptotic cell 
death in SK-BR-3 cells (Shehata et al 2008a). Using 3T3 cells as a model, we 
discovered that TPD52 but not TPD52L1 expression led to increased intracellular 
lipid droplets (Figure 4.5). TPD52L1-expressing 3T3 cells also showed similar Adrp 
staining patterns as parent and vector control cells (Figure 4.9). Similarly, TIP47 and 
ADRP were found to interact with TPD52 but not TPD52L1 in the yeast-two-hybrid 
system respectively (S. Frost, unpublished results). The differential interaction of 
TPD52 and TPD52L1 with TIP47/ADRP could therefore for the first time provide a 
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molecular explanation for the isoform-specific oncogenic functions of TPD52. TPD52 
has been proposed to represent a signaling intermediate and regulator of vesicle 
trafficking (Thomas et al., 2009; Thomas et al., 2004). Thus, TPD52 may also 
function as an adaptor protein that works in parallel with TIP47 in trafficking lipids 
throughout the cytoplasm.  
 
4.4 Summary and conclusions 
 
In summary, results from this chapter demonstrate that TPD52 expression led to 
markedly increased lipid droplet numbers in 3T3 cells. In contrast, this was not 
observed in TPD52L1-expressing 3T3 cells. In addition, after oleic acid treatment, 
TPD52-expressing cells formed increased numbers of lipid droplets, although these 
relative increases were less than those measured in vector control cells. The 
mechanisms whereby TPD52-expressing cells form or accumulate more lipid 
droplets need further investigation. These may be underpinned by interactions with 
lipid droplet-associated protein, such as TIP47 and ADRP which may account for the 
isoform-specific oncogenic functions of TPD52. Taken together, the results in this 
chapter highlight the importance of TPD52 in regulating intracellular lipid storage, and 
identify a potentially important functional difference between TPD52 and TPD52L1.  
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Chapter 5 
General Discussion 
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5.1 Introduction 
 
Despite the increasing recognition of the significance of TPD52 overexpression in 
various cancer types, including breast, prostate, ovarian, lung and colorectal cancers 
(discussed in Chapter 1, Section 1.6.3), little is known about how increased TPD52 
expression advantages cancer cells. Studies of TPD52-transfected fibroblasts 
revealed TPD52 regulation of cell proliferation and anchorage-independent growth in 
vitro (Shehata et al., 2008a) as well as formation of subcutaneous tumors and lung 
metastases in vivo (Lewis et al., 2007). However, the molecular functions of TPD52 
and related proteins remain obscure. The current project aimed to understand the 
molecular basis of TPD52 oncogenic functions. Data presented in this thesis 
demonstrate TPD52 as a survival factor in ERBB2-amplified breast cancer cell lines 
(Chapter 3) and propose a novel function for TPD52 in regulating lipid storage 
(Chapter 4). 
 
5.2 TPD52 promotes the survival of ERBB2-positive cancer cells 
 
Findings from Shehata et al. (2008a) and others (Ummanni et al., 2008; Zhang et al., 
2011; Zhang et al., 2007a) reported that reduced TPD52 expression in vitro leads to 
cell death. Combined with frequent reports of TPD52 amplification and 
overexpression in various cancers, this suggested that TPD52-amplified cancer cell 
lines may be more sensitive to reduced TPD52 expression, which would in turn 
highlight TPD52 as a potential therapeutic target in TPD52-amplifed cancers. 
Reports of TPD52 and ERBB2 co-expression in cancers (Chapter 1, Section 1.6.3.1) 
also led us to hypothesise that TPD52 may co-operate with ERBB2 in cancer 
pathogenesis and that TPD52 could represent a potential therapeutic target in 
ERBB2-positive cancers. Through RNA interference approaches, we sought to 
examine the transient and long-term effects of reduced TPD52 expression. To date, 
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no study had directly characterised TPD52 expression status in breast cancer cell 
lines, and no-long term study of TPD52 knock-down had been performed in breast 
cancer cell lines. 
 
Firstly, our breast cell line cohort showed that TPD52 and ERBB2 were significantly 
co-expressed, and this was supported by RT-PCR data from breast cancer patient 
samples (Roslan et al., 2013; Appendix 2). Secondly, we showed that transient 
reduction of TPD52 in two ERBB2-amplified cell lines did not affect pERBB2 and 
pAkt or pMAPK levels, but still induced significant cell death. Hence, TPD52 may act 
independently of Akt and MAPK signaling in regulating cell survival and TPD52 and 
ERBB2 may function independently of each other. Thirdly, long-term depletion of 
TPD52 in a TPD52- and ERBB2-amplified cell line revealed an inverse relationship 
between TPD52 and pERBB2 levels, and that cells may compensate for reduced 
TPD52 levels by increasing ERBB2 signaling to maintain cell survival. A more 
detailed understanding of changes in stably TPD52-depleted SK-BR-3 cell lines 
could be pursued at the genetic level, by performing expression microarray analysis. 
This might help to identify key genes and signaling pathways altered in response to 
long-term TPD52 knock-down.    
 
Knock-down of oncogenes has been reported to affect phenotypes other than cell 
proliferation or survival. Knock-down of  human pituitary tumor-transforming gene 1 
(PTTG1), an oncogenic transcription factor,  did not affect cell proliferation but 
reduced breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA 
signaling (Liao et al., 2012). Knock-down of a new amplification target SMURF1 also 
did not affect cell proliferation, but reduced invasion in pancreatic cancer cells (Kwei 
et al., 2011). Data from our group have shown that TPD52 overexpression in 3T3 
fibroblasts led to increased migration and invasion (Della Franca, 2012). Therefore, 
future experiments could investigate the migration and invasion capability of stably 
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TPD52-depleted SK-BR-3 cells. Additionally, it would be worth assessing cell 
migration and/or invasion upon Lapatinib treatment or ERBB2 siRNA knock-down. 
Due to time constraints, these experiments were not able to be performed.  
 
It is important to understand the effects of reduced TPD52 expression both in the 
short and long-term, as this will be valuable for the future development of chemical 
inhibitors of TPD52. The in vitro approach of reducing TPD52 expression provided in 
this thesis will be valuable for comparison with TpD52 knock-out mice or similar in 
vivo approaches which are yet to be delivered. Based on the results in Chapter 3, 
TPD52 inhibition may be less successful in patients with ERBB2-positive cancers, 
unless TPD52 and ERBB2 were inhibited together. Given the emerging possibility 
that TPD52 function is important in the context of ERBB2 expression, it seems 
important to examine the effects of TPD52 knock-down in TPD52-amplified cell lines 
that are not also ERBB2-amplified. Although attempts have been made, we are yet to 
identify a TPD52-amplified cell line that does not also detectably express ERBB2. As 
TPD52 is known to be amplified and overexpressed in various cancer types, it would 
be worth identifying TPD52-amplified cell lines from cancer types other than breast 
cancer, and this is being investigated. We are currently assembling a larger cohort of 
cancer cell lines predicted to be TPD52-amplified using online database tools 
(canSAR, cBioPortal), and are examining whether these cell lines are or are not 
ERBB2-amplified. Once cell lines are identified, long-term knock-down models in a 
carefully chosen subset will be derived, to compare these results with those obtained 
for SK-BR-3. Additionally, future work could also examine if TPD52 levels are 
upregulated in stably ERBB2-depleted SK-BR-3 cells.  
 
Collectively, the findings presented in Chapter 3 could have implications for future 
therapeutic strategies, as both TPD52 and ERBB2 expression have been associated 
with poor patient outcomes (Adler et al., 2006; Borg et al., 1991; Choschzick et al., 
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2010; Guerin et al., 1988; Liu et al., 2007b; Ross-Innes et al., 2012; Shehata et al., 
2008a; Slamon et al., 1987; Varley et al., 1987). The poorer metastasis-free survival 
of patients with breast tumors with high level TPD52 expression, both in the overall 
cohort and the HR+/ERBB2+ subgroup, suggests that TPD52 overexpression is 
clinically significant in ERBB2-positive cancers (Roslan et al., 2013; Appendix 2). 
TPD52 overexpression could possibly promote tumor resistance towards ERBB2-
targetted therapies, since TPD52 was indicated to regulate cell survival 
independently of ERBB2 expression. That SK-BR-3 cells may at least partially 
escape the effects of reduced TPD52 levels by increasing signaling through the 
amplified oncogene ERBB2 shows complementary functions for these genes, 
although different signaling mechanisms likely underpin these. These results might 
also suggest that pathways regulated by highly amplified oncogenes such as ERBB2 
and TPD52 might represent obvious escape routes from the effects of a given 
targeted therapy, and tumors with many highly amplified genes may be afforded 
more escape choices. Further research into oncogene co-amplification may therefore 
help to understand these escape mechanisms, and to translate such results to the 
clinic. 
 
5.3 TPD52 involvement in regulating lipid storage 
 
Known TPD52 binding partners are not able to fully explain TPD52’s oncogenicity, 
and TPD52 reports of binding partners are not exclusive for TPD52, but also bind 
other TPD52-related proteins such as TPD52L1 (Byrne et al., 1998b). We addressed 
this issue by proposing a novel function for TPD52 in Chapter 4.  
 
We revealed for the first time that ectopic TPD52 but not TPD52L1 expression in 
mouse 3T3 fibroblasts led to increased lipid droplets, with droplets numbers being 
more significantly increased than size. This provided direct evidence for TPD52 
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involvement in regulating lipid storage, as well as evidence of an isoform-specific 
function for TPD52 which might explain TPD52’s oncogenicity. However, it remains 
uncertain whether the lipogenic phenotype observed in TPD52-expressing 3T3 cells 
is due to TPD52 increasing the uptake and/or synthesis of free fatty acids, and/or the 
inhibition of fatty acid export from lipid droplets. Upon oleic acid treatment, TPD52-
expressing 3T3 cells formed more lipid droplets, but to lesser relative extent 
compared to control cells. It is also unknown how TPD52 overexpression leads to 
increased lipid droplet formation. As discussed earlier (Section 4.3), there are many 
signaling pathways and proteins involved in regulating lipid metabolism, and TPD52’s 
role in this regulation is currently being pursued by other group members. Future 
studies could also examine whether TPD52 amplification is broadly associated with 
increased lipid storage/lipogenesis, by identifying other TPD52-amplified cancer cell 
lines, beyond SK-BR-3 and AU-565 breast cancer cell lines. 
 
Our results support TPD52 regulating lipid storage via interactions with PAT proteins 
such as TIP47 and/or ADRP, possibly by acting as a lipid carrier. TPD52 has been 
previously localized to vesicular structures, and to interact with membrane trafficking 
proteins such as EEA-1, LAMP1 and RAB5 (Shahheydari, 2013; Thomas et al., 
2009; Thomas et al., 2004). Lipid droplets also contain trafficking proteins such as 
RAB proteins (Liu et al., 2007a; Martin et al., 2005; Ozeki et al., 2005). Therefore, 
TPD52 could be associating with these trafficking proteins for transporting lipids 
between membrane compartments. Additionally, it will also be of interest to 
determine whether TPD52 is associated with PAT protein expression in clinical 
cancer samples. If so, TPD52 could be useful as a biomarker for cancers with a 
lipogenic phenotype.  
   
Another interesting future direction would be to determine whether TPD52 expression 
could protect cells from lipotoxicity. The current study used oleic acid, a 
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monounsaturated fatty acid known to be non-toxic to cells (Hardy et al., 2000; 
Listenberger et al., 2003). In future experiments, palmitate could be used, since it has 
been shown to be toxic to various cell types such as human endothelial cells (Zhang 
et al., 1992), human skin fibroblasts (Rosenthal, 1981), rat cardiomyocytes (de Vries 
et al., 1997) and CHO cells (Listenberger et al., 2003). Kourtidis et al. (2009) have 
revealed that using breast cancer cell lines, MCF-7 cells (ERBB2-negative, low 
intracellular lipid content) are resistant to high doses of palmitate supplementation, 
whereas exogenous administration of palmitate was toxic to ERBB2-positive BT-474 
cells which contained high intracellular lipid content (Kourtidis et al., 2009). 
Therefore, it would be interesting to examine the effects of palmitate treatment in 
TPD52-amplified cancer cells. As we have shown that TPD52-expressing 3T3 cells 
contain high intracellular lipid content, TPD52 inhibitors might also be useful in 
targeting TPD52-overexpressing cancers by reducing lipid storage, which might then 
lead to reduced cell proliferation and cell death. Hence, TPD52 could be useful as a 
biomarker for cancers sensitive to drugs targeting lipid storage. 
 
5.4 Significance of lipid metabolism and cancer  
 
ERBB2-overexpressing cancer cells have been shown to display a lipogenic 
phenotype, supported by enhanced activation (direct or indirect) of metabolic 
signaling (Kourtidis et al., 2010; Kumar-Sinha et al., 2003; Zhang et al., 2005). As 
high levels of intracellular free fatty acids lead to cytotoxicity and cell death (Kourtidis 
et al., 2009; Listenberger et al., 2003), interference with lipid storage may therefore 
be a potent means of killing cancers that are dependent upon high lipid levels for 
survival, through gene amplification and/or overexpression of ERBB2. This highlights 
the potential for novel metabolic signaling strategies to target ERBB2-positive 
cancers (Menendez and Lupu, 2007).  
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We have shown that TPD52 promotes the survival of ERBB2-positive cancer cells, 
which is supported by persistent associations between TPD52 and ERBB2 
expression (Chen et al., 2010; Kourtidis et al., 2010; Landis et al., 2006; Landis et al., 
2005; Whiteaker et al., 2007; Wilson et al., 2002). Our collective observations 
suggest that TPD52 may co-operate indirectly with ERBB2, through increasing lipid 
storage, possibly mediated by associations with PAT proteins. This suggests that 
TPD52 represents a potential therapeutic target in ERBB2-positive cancers. Since 
reduced TPD52 expression did not induce significant cell death in breast cancer cell 
lines other than ERBB2-amplified cell lines, inhibiting TPD52 function in normal 
tissues may not provoke widespread toxicity. Unlike agents targeting more broadly 
expressed lipogenic proteins, TPD52-targetted cancer therapies may also avoid the 
limiting anorexic side effects of agents such as cerulenin targeting FASN (Menendez 
and Lupu, 2007). The data presented in this thesis, supports inhibiting TPD52 
function or expression as a potential method for treating lipogenic cancers. In 
addition, the differential expression of TPD52 in obese versus non-obese adipose 
tissue (Clement et al., 2004; Keller et al., 2008; Nadler et al., 2000) also suggests 
that TPD52 inhibitors could be applied to treat obesity.  
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5.5 Final conclusions  
 
TPD52 is a known amplification target in various cancer types. The data presented in 
this thesis have revealed that TPD52 is important for the survival of ERBB2-positive 
breast cancer cells, and that TPD52 may co-operate with ERBB2 in promoting 
tumorigenesis and/or progression. However, TPD52 appears to regulate cell survival 
independently of ERBB2 signaling. We also revealed for the first time that ectopic 
TPD52 expression in mouse fibroblast cells leads to increased lipid droplets, and 
therefore proposed a novel function for TPD52 in regulating intracellular lipid storage. 
This lipogenic phenotype was only observed in TPD52-expressing but not TPD52L1-
expressing cells, which may partially explain the isoform-specific oncogenic function 
of TPD52. TPD52 may co-operate indirectly with ERBB2 by regulating lipid storage, 
possibly via associations with PAT proteins, but this requires further validation.  
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Appendix 1 
D52-2-7 vector-3 
Appendix 1. Electron microscopy confirmed increased lipid droplets in TPD52-
expressing 3T3 cells compared with vector controls. Ultrastructural analysis using 
electron microscopy (CM12 BioTwin transmission electron microscope, Philips; 
X135000 objective) of (A) vector-3 cells compared with (B) D52-2-7 cells. Lipid 
droplets are indicated by red dots and in some cases, red arrows. Endoplasmic 
reticulum (ER) membranes are indicated by blue arrows, phopholipid inclusions are 
indicated by black arrows and lipid droplet-associated-ER structures are indicated by 
yellow arrows. Images were derived from one experiment. Cells were provided by 
Nuruliza Roslan, which were fixed, embeded, sectioned and stained for electron 
microscopy and imaged by Dr. Dongwei Wang, Kids Research Institute, Westmead.  
Scale bar = 2µm.  
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MOLECULAR CARCINOGENESIS
TPD52 Represents a Survival Factor in
ERBB2-Ampliﬁed Breast Cancer Cells
Nuruliza Roslan,1,2 Ivan Bièche,3,4 Robert K. Bright,5 Rosette Lidereau,4 Yuyan Chen,1 and
Jennifer A. Byrne1,2*
1Molecular Oncology Laboratory, Children’s Cancer Research Unit, Kids Research Institute, The Children’s Hospital at
Westmead, Westmead, NSW, Australia
2The University of Sydney Discipline of Paediatrics and Child Health, The Children’s Hospital atWestmead,Westmead, NSW,
Australia
3Laboratoire d’Oncogenetique, Institut Curie - Hoˆpital Rene Huguenin, FNCLCC, Saint-Cloud, France
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Descartes, Paris, France
5Department of Immunology and Molecular Microbiology and TTUHSC Cancer Center, Texas Tech University Health Sciences
Center, Lubbock, Texas
TPD52 and ERBB2 co-expression has been persistently reported in human breast cancer and animal models of this
disease, but the signiﬁcance of this is unknown.We identiﬁed signiﬁcant positive associations between relative TPD52 and
ERBB2 transcript levels in human diagnostic breast cancer samples, andmaximal TPD52 expression in the hormone receptor
(HR)- and ERBB2-positive sub-group. High-level TPD52 expressionwas associatedwith signiﬁcantly reducedmetastasis-free
survival, within the overall cohort (log rank test, P ¼ 8.6  104, n ¼ 375) where this was an independent predictor of
metastasis-free survival (hazard ratio, 2.69, 95% conﬁdence interval 1.59–4.54, P ¼ 2.2  104, n ¼ 359), and the HR-
and ERBB2-positive sub-group (log rank test, P ¼ 0.035, n ¼ 47). Transient TPD52 knock-down in the ERBB2-ampliﬁed
breast cancer cell lines SK-BR-3 and BT-474 produced signiﬁcant apoptosis, both singly and in combination with transient
ERBB2 knock-down. Unlike ERBB2 knock-down, transient TPD52 knock-down produced no reduction in pAKT levels in SK-
BR-3 or BT-474 cells. We then derived multiple SK-BR-3 cell lines in which TPD52 levels were stably reduced, and measured
signiﬁcant inverse correlations between pERBB2 and TPD52 levels in viable TPD52-depleted and control cell lines, all of
which showed similar proliferative capacities. Our results therefore identify TPD52 as a survival factor in ERBB2-ampliﬁed
breast cancer cells, and suggest complementary cellular functions for TPD52 and ERBB2. © 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Targeted therapies are increasingly employed for
cancer treatment, yet predicting patient response
remains problematic. This situation is exemplified by
considering the oncogene ERBB2 (human epidermal
growth factor-2, Neu or HER2), whose amplification
occurs in approximately 15% of breast cancer cases
[1]. The association between ERRB2 amplification
and/or overexpression and poor prognosis led to the
development of ERBB2-targetted therapies for the
treatment of breast and other cancers [2,3]. However,
not all patients with ERBB2-positive disease respond
to ERBB2-targetted therapies, and many develop
resistance [2,3]. Understanding the functions of
proteins co-expressed with ERBB2 may identify
co-operating factors which promote or enhance
tumor cell phenotypes, and which may contribute
to primary or secondary resistance to ERBB2-targetted
therapies.
A gene/protein that has been persistently linked
with ERBB2 expression is the chromosome 8q21.13
oncogene and adaptor protein TPD52. TPD52 was
originally identified from an ERBB2-expressing breast
tumor [4]. TPD52 transcript levels were subsequently
found to be increased in ERBB2-positive breast cancer
cell lines [5], followed by reports thatTpd52 transcript
or protein levels were increased in mammary tissues
from Erbb2 transgenic animals [6–9]. Kourtidis et al.
[10] also identified increased TPD52 levels in ERBB2-
Abbreviations SBR, Scarff Bloom Richardson; HR, hormone receptor;
ERa, estrogen receptor a; RT, room temperature; siRNA, small
interfering RNA; shRNA, short hairpin RNA; MTT, 3-(4,5-dimethylthia-
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positive human breast cancers and cell lines, through
a meta-analysis of 22 human expression studies. Like
ERBB2, TPD52 is amplified or gained in breast cancer
[11], and associations between gene copy number and
expression support TPD52 representing a gene ampli-
fication target in breast andother cancers [12,13]. This
was recently underscored by a large-scale genomic
study identifying focal amplification of TPD52 and
three neighboring chromosome 8q21.13 genes in
breast cancer [14]. Chromosome 8q21 amplification
has been significantly associated with both ERBB2
amplification and poor patient outcome in breast
cancer [15], and increased TPD52 immunohistochem-
ical staining was associated with reduced overall
survival in breast cancer patients, where this was an
independent prognostic factor [16]. TPD52 has
similarly been included in gene expression [17–19]
or copy number [20] signatures associated with poor
prognosis in breast cancer patients. Thus ERBB2 and
TPD52 are both amplified genes whose overexpres-
sion is reproducibly associated with poor patient
outcomes in breast cancer. The present study exam-
ined the significance of TPD52 and ERBB2 co-
expression, by defining the expression of TPD52
relative to ERBB2 in primary breast cancer samples
and breast cell lines, and the effects of depleting
TPD52 and ERBB2 levels in breast cancer cell lines
with differing TPD52 and ERBB2 gene amplification
and/or expression status.
MATERIALS AND METHODS
Patients and Samples
Samples of 375 primary invasive breast tumors
excised from women managed at Institut Curie—
Hoˆpital Rene Huguenin (Saint-Cloud, France) from
1978 to 2008 were immediately stored in liquid
nitrogen until RNA extraction. All patients who
entered the institution before 2007 were informed
that their tumor samples might be used for scientific
purposes and had the opportunity to decline. Since
2007, patients entering the institution have given
their approval by signed informed consent. This study
was approved by the local ethics committee (Breast
Group of Hoˆpital Rene Huguenin). Tumor samples
were included if the proportion of tumor cells
exceeded 70%. Normal breast tissue from women
undergoing cosmetic breast surgery (n ¼ 8) were used
as a source of control RNA. Breast cancer patients
(mean age 62.5 yr, range 31–91 yr) met the following
criteria: primary unilateral non-metastatic breast
carcinoma for which complete clinical, histological
and biological data were available; no radiotherapy or
chemotherapy before surgery; and full follow-up at
Institut Curie—Hoˆpital Rene Huguenin. The histo-
logical type, number of positive axillary nodes and
macroscopic tumor size (Table 1) were established at
the time of surgery. The malignancy of infiltrating
carcinomas was scored according to Scarff Bloom
Richardson’s (SBR) histoprognostic system (Table 1).
Treatment consisted of modified radical mastectomy
(253 cases, 67.4%) and breast conserving surgery plus
locoregional radiotherapy (122 cases, 32.6%). Patients
had a physical examination and routine chest
radiography every 3 mo for 2 yr, then annually.
Mammogramswere done annually. Adjuvant therapy
was administered to 298 patients, consisting of
chemotherapy alone in 73 cases, hormone therapy
alone in 168 cases, and both treatments in 57 cases.
During amedian follow-up of 7.9 yr (range 6mo to 29
yr), 157 patients developed distant metastasis.
Hormone receptor (HR), estrogen receptor a (ERa),
progesterone receptor (PR), and ERBB2 status were
determined at the protein level using biochemical
methods (dextran-coated charcoal method, enzyme
immunoassay, or immunohistochemistry) and con-
firmed by real-time quantitative RT-PCR assays
[21,22]. The population was divided into groups
according to HR (ERa and PR) and ERBB2 status:
two luminal subtypes [HRþ (ERaþ or PR þ)/ERBB2þ
(n ¼ 47)] and [HRþ (ERaþ or PR þ)/ERBB2
(n ¼ 224)]; an ERBB2þ subtype [HR (ERa and
PR)/ERBB2þ (n ¼ 46)]; and a triple-negative subtype
[HR (ERa and PR)/ERBB2 (n ¼ 58)].
Cell Lines and Cell Culture
Breast cancer cell lines AU-565, BT-483, MDA-MB-
175, HS-578T, MDA-MB-157,MDA-MB-134, DU4475,
MDA-MB-468, ZR-75-30were kindly provided by Prof.
Roger Daly (Garvan Institute, Australia). SK-BR-3, BT-
474, MCF-7, T-47D, MDA-MB-231, and MCF-10A cell
lines were obtained from the American Type Culture
Collection (Rockville, MD). All cell line identities
were confirmed through short tandem repeat profil-
ing by CellBank Australia (Westmead, Australia). Cell
lines were cultured in a humidified incubator at
378C/5% CO2 in RPMI media (Life Technologies, Inc.
Ltd, Paisley, UK) supplemented with 10% fetal bovine
serum (FBS, Life Technologies) and 3% L-glutamine
(Life Technologies), except for MCF-7 cells, where
the above media were supplemented with 10 mg/mL
insulin (Sigma–Aldrich, St. Louis, MO), andMCF-10A
cells, which were cultured as described [23].
Total RNA and Genomic DNA Extraction, cDNA Synthesis
and Real-Time (Reverse-Transcriptase) PCR
Total RNAwas extracted from breast tumor samples
by using acid–phenol guanidium, as described [24].
RNA quality was determined by electrophoresis
through agarose gels and staining with ethidium
bromide. Real time RT-PCR analyses were performed
as described [25]. Briefly, reactions were performed
using an ABI Prism 7900 Sequence Detection System
using the SYBRR Green PCR Core Reagents kit
(Perkin–Elmer Applied Biosystems, Carlsbad, CA).
Thermal cycling conditions comprised an initial
denaturation step at 958C for 10 min and 50 cycles
at 958C for 15 s and 658C for 1 min. Quantitative
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values were obtained fromCt values using the Perkin–
Elmer Biosystems analysis software, according to the
manufacturer’s instructions. Results were expressed
as fold differences in TPD52 expression relative to
the endogenous RNA control TBP. Gene expression
values were then expressed relative to the median
value obtained in normal breast samples, which was
set at 1.0.
Genomic DNA was extracted from cultured cells
using the phenol/chloroform method. TPD52 PCR
primer sequences were sense: 5’-CAG TTT AGA GCC
CAGGGAAA-3’ and antisense: 5’-CGATCATCCAAC
GTA GCA TG-3’. Quantitative real-time PCR was
performed using the Corbett Rotor-Gene 6000
(Qiagen, Valencia, CA) using the KAPA SYBRR FAST
Universal qPCR kit (Kapa Biosystems, Inc., Woburn,
MS). Thermal cycling conditions comprised an initial
denaturation step of 958C for 10 min and 40 cycles at
958C for 15 s, 578C for 30 s and 728C for 30 s. Relative
DNA copy numbers were calculated by normalizing
raw data for each cell line against MCF-10A.
Total RNAwas extracted from breast cell lines using
Trizol LS reagent (Life Technologies) according to the
manufacturer’s protocol. One microgram of RNA was
subjected to cDNA synthesis using the SuperScript III
First Strand Synthesis System for RT-PCR kit (Life
Technologies), according to the manufacturer’s
instructions. TPD52 RT-PCR primer sequences were
sense: 5’-GGA AGA GGA GCA GGA AGA GC-3’ and
antisense 5’-GAT GAC TGA GCC AAC AGA CG-3’.
Quantitative real-time RT-PCR was performed using
the Corbett Rotor-Gene 6000 (Qiagen) using the
KAPA SYBRR FAST Universal qPCR kit (Kapa Bio-
systems). Thermal cycling conditions comprised an
initial denaturation step of 958C for 10 min and 40
cycles at 958C for 15 s, 608C for 30 s and 728C for 30 s.
Relative gene transcript levels were calculated by
normalizing raw data obtained for each cell line
against that obtained for MCF-10A.
Western Blot Analyses
Cells were lysed in 3% SDS lysis buffer as described
[26]. 12–18 mg total protein extracts were resolved
using SDS–PAGE on 12.5% polyacrylamide gels or
4–12% gradient gels (Life Technologies) and electro-
transferred to nitrocellulose PVDF membranes (Milli-
pore, Billerica, MA). Membranes were blocked
overnight at 48C in 5% skim milk powder in 0.1%
Tween 20 in TBS, washed twicewith 0.1%Tween 20 in
TBS and incubated with one or more of the following
primary antibodies: affinity-purified rabbit polyclonal
TPD52 antisera (1:100) [11], rabbit monoclonal
Table 1. Characteristics of the 375 Primary Breast Cancers Analyzed
Number of patients
n ¼ 375
Number of metastases (%)
n ¼ 157 (41.9) P-valuea
Age
50 74 35 (47.3) NSa (0.15)
>50 301 122 (40.5)
SBR histological gradeb
I 37 7 (18.9)
II 190 82 (43.2) 0.011
III 139 65 (46.8)
Lymph node status
0 103 35 (34)
1–3 186 67 (36) 0.0000018
>3 85 55 (64.7)
Macroscopic tumor size
25 mm 166 53 (31.9) 0.00024
>25 mm 202 103 (51)
ERa
Neg 105 49 (46.7) 0.027
Pos 270 108 (40)
PR
Neg 179 82 (45.8) 0.024
Pos 196 75 (38.3)
ERBB2
Neg 282 117 (41.5) NS (0.39)
Pos 93 40 (43)
HR/ERBB2
HRþ/ERBB2þ 47 17 (36.2)
HRþ/ERBB2 224 92 (41.1) NS (0.093)
HR/ERBB2þ 46 23 (50)
HR/ERBB2 58 25 (43.1)
aLog-rank test. NS, not significant.bScarff Bloom Richardson classification.
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ERBB2 (1:1000, Cell Signalling Technology, Inc.,
Beverly, MA); rabbit monoclonal pERBB2(Tyr1221/
1222) (1:1000, Cell Signalling); rabbit monoclonal
Pan-AKT (1:1000, Cell Signalling); rabbit monoclonal
pAKT(Ser473; 1:1000, Cell Signalling); rabbit poly-
clonal cleaved PARP-1 (1:1000, Cell Signalling); rabbit
monoclonal pMAPK(44/42) (1:1000, Cell Signalling);
mouse monoclonal a-tubulin (1:1000; Sigma–Al-
drich); mouse monoclonal glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH; 1:5000; Ambion,
Austin, TX). Primary antibody incubations were
performed in 0.1% Tween 20 in TBS for 1–2 h at
room temperature (RT) or overnight at 48C. Mem-
branes were washed three times and then incubated
with a horseradish peroxidase-conjugated donkey
anti-rabbit or anti-mouse secondary antibody
(1:10 000 or 1:5000 respectively; GE Healthcare,
Uppsala, Sweden) for 1 h at RT. Membranes were
then washed and visualized by Western Lightening
chemiluminescent reagent (Perkin Elmer Life Science,
Boston, MA). Densitometry analysis using ImageJ
1.45s software was used to quantitate fold changes in
protein levels relative to loading controls.
Indirect Immunofluorescence Analyses
Cells were plated onto glass coverslips, cultured
overnight, washed twice with PBS, fixed in 2%
paraformaldehyde/PBS for 15 min, washed twice,
permeabilized with cold acetone:methanol (1:1) for
15 min, washed twice, and incubated with TPD52
mouse monoclonal antibody (1:10) [27] and ERBB2
rabbit monoclonal (1:400, Cell Signalling Technolo-
gy) in 3% bovine serum albumin in PBS overnight at
48C. Cells were washed twice and incubated
with secondary Alexa488 anti-mouse (1:1000, Life
Technologies) and Cy3-conjugated anti-rabbit
(1:1000; Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA) antibodies in 3% bovine serum
album in PBS for 1 h in the dark at RT. After washing,
cells were mounted in FluorSave mounting medium
(Calbiochem, San Diego, CA) and visualized using a
TCS SP2 confocal laser scanning upright microscope
(Leica, Heidelberg, Germany), using a 63 objective
lens.
Transient Small Interfering RNA Transfections
TPD52 small interfering RNA (siRNA) duplexes [16]
and an ON-TARGETplus siRNA pool targeting ERBB2
(5’-TGG AAG AGA TCA CAG GTT A-3’, 5’-GAG ACC
CGCTGAACAATAC-3’, 5’-GGAGGAATGCCGAGT
ACT G-3’ and 5’-GCT CAT CGC TCA CAA CCA A-3’)
were obtained from Dharmacon (Lafayett, CO),
whereas non-targeting siRNA (siControl) was ob-
tained from Qiagen. Cells were seeded at 2  104
cells/well into 24-well plates. After 24 h, cells were
transfected with 50 nmol/L siRNA duplexes using
TransIT-TKO transfection reagent (Mirus Bio, Madi-
son, WI) in complete media following the manufac-
turer’s instructions. After 24 h, transfection media
were removed and replaced with complete media.
Cells were harvested for analysis 48 h later.
Generation of Stably TPD52-Depleted SK-BR-3 Cell Lines
Two Hush 29 mer short hairpin RNA (shRNA)
constructs (shD52-2: 5’-AAT TCG GCT GCA AAT
GCTAGTGCCACCAC-3’; and shD52-3: 5’-ATCCAG
ACT CTG TCT CAA GTG TTA GCA GC-3’) and a non-
targeting control in the pGFP-V-RS vector were
obtained from OriGene Technologies (Rockville,
MD). SK-BR-3 cells were seeded at 60% confluence
in 10 cm dishes and transfected 24 h later with 3 mg
plasmid DNA with TransIT-LT1 transfection reagent
(Mirus) in serum-free media. After 3 d, cells were
seeded into nine 10 cm dishes, and 2 mg/mL puro-
mycin (Sigma–Aldrich) was added 24 h later. Puro-
mycin selection continued for 2 wk, after which
selected resistant clones were screened usingWestern
blot analyses. Four cell lines stably depleted of TPD52
and two control cell lines were maintained under
1 mg/mL puromycin selection.
Cell Death Detection Assay
DNA fragmentation was quantified using the Cell
Death ELISAPLUS kit according to the manufacturer’s
instructions (Roche, Vilvoorde, Belgium), with color
development measured at 405 nm using a Multiskan
Ascent plate reader (Thermo Scientific, Waltham,
MA). Samples were analysed in duplicate in three
independent experiments. Doxorubicin treatment
(Sigma–Aldrich) for 72 h (SK-BR-3 cells, 500 nM, BT-
474 cells, 1 mM) was used as a positive control. The
enrichment factor of mono- and oligonucleosomes
released into the cytoplasm of cell lysates was
calculated relative to the control value for cells treated
with transfection reagent only, which was set as 1.0.
Cell Proliferation (MTT) Assay
Untreated, non-target control or stably TPD52-
depleted SK-BR-3 cells were plated in triplicate in
96-well plates (3  103 cells/well), cultured for 24 h
and then 50 ml 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) reagent (Sigma–
Aldrich) was added either immediately (0 h) or at the
designated number of days post-seeding. MTT reac-
tions were incubated at 378C in the presence of 5%
CO2 for 4 h. To stop each reaction, media were
replaced with 100 mL DMSO (Sigma–Aldrich) per
well. Absorbances at 540 nm were read using a
Multiskan Ascent plate reader. Means of triplicate
wells from three independent experiments were used
to generate data points and SE values.
Statistical Analysis
The SPSS for Windows package (version 19; SPSS)
was used in most cell line analyses. Spearman rank
correlation was used for correlation tests between
samples. The Mann–Whitney U test was used to
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compare relative transcript and protein levels and
other variables. Results of all cell death detection and
proliferation assays were expressed as means  SE of
three independent experiments. Comparisons be-
tween groups were made using two-tailed, unequal
variance Student’s t test calculated using Excel
(Microsoft, Redmond, WA).
Relationships between transcript levels of different
genes, and transcript levels and clinical parameters
were identified by using chi-square, Mann–Whitney
U test, and Spearman rank correlation tests. Metastasis-
free survival was determined as the interval between
initial diagnosis and detection of the first metastasis.
To visualize the efficacy of amolecularmarker (TPD52
level) to discriminate two populations (patients that
developed/did not developmetastases) in the absence
of an arbitrary cut-off value, data were summarized in
an ROC (receiver operating characteristic) curve [28].
The AUC (area under curve) was calculated as a single
measure for discriminate efficacy. Survival distribu-
tions were estimated by the Kaplan–Meier method,
and significance of differences between survival rates
was ascertained with the log-rank test. Best-fitting
multiple Cox proportional hazards models with
backward step-wise selection were used to identify
independent predictors of survival from potential risk
factors [29].
RESULTS
TPD52 Expression Relative to ERBB2 in Primary Breast
Cancer Tissues
Quantitative RT-PCRwas employed to study TPD52
expression in 375 invasive breast carcinomas
(Table 1), relative to eight normal breast samples.
TPD52 was overexpressed more than threefold,
relative to normal breast, in 311/375 (82.9%) of breast
carcinomas, andmore than 10-fold in 65/375 (17.3%)
cases (Table 2). The tumor cohort was divided into 4
subgroups based upon HR and ERBB2 status. TPD52
was significantly differentially expressed in the
four subgroups compared (Mann–Whitney test,
P < 1  107, n ¼ 375), withTPD52 expression being
highest in HRþ/ERBB2þ cases (Table 2, Table 3).
TPD52 was significantly differentially expressed
according to ERa, PR, and ERBB2 status, but not
according to patient age, SBR histological grade,
lymph node status, macroscopic tumor size, PIK3CA
mutation status, or KI67 transcript levels (Table 3). A
significant positive correlation between relative
TPD52 and ERBB2 levels (Spearman rank correlation,
rs ¼ 0.273, P ¼ 5.3  108, n ¼ 375) contrasted with
a significant inverse correlation between TPD52 and
EGFR levels (Table 3).
Area under the curve analyses were performed to
identify a cut-point bywhich to divide the cohort into
relevant TPD52 expression subgroups. We therefore
compared tumors with relative TPD52 expression
16.68 (n ¼ 353, 94.1%), with those with relative Ta
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TPD52 expression>16.68 (n ¼ 22, 5.9%). Interesting-
ly, the percentage of cases in the high TPD52
expression group is very similar to the percentages
of breast cancer cases estimated to be TPD52-ampli-
fied from TCGA cohorts (5.8% of 484 cases, 6.2% of
482 cases [14], data available through the cBio Cancer
Genomics Portal, http://www.cbioportal.org/public-
portal/). A significantly greater proportion of patients
with tumors in the high TPD52 expression group
relapsed with metastases (16/22 cases, 72.7%), com-
pared with patients with tumors in the lower TPD52
expression group (141/353 cases, 39.9%; chi-square
test, P ¼ 0.0025, n ¼ 375). Metastasis-free survival
was significantly poorer for patients with tumors with
highTPD52 expression, in the overall cohort (log rank
test, P ¼ 8.6  104, n ¼ 375; Figure 1A), the HRþ/
ERBB2þ subgroup (log rank test, P ¼ 0.035, n ¼ 47;
Figure 1B) and the HRþ/ERBB2 subgroup (log rank
test, P ¼ 0.0059, n ¼ 224), whereas the HR/ERBB2
(n ¼ 58) and HR/ERBB2þ (n ¼ 46) subgroups in-
cluded only one or two tumors in the high TPD52
expression category, respectively. Multivariate analy-
ses indicated that high TPD52 levels were an
independent predictor of metastasis-free survival
(hazard ratio, 2.69, 95% confidence interval 1.59–
4.54, P ¼ 2.2  104, n ¼ 359), following adjustment
for lymph node, tumor size, SBR, ERa, and PR status
(Table 4).
Table 3. Characteristics of the 375 Breast Cancers, According to Relative TPD52 Transcript Levels
Number of patients (%)
TPD52 transcript levels,
relative to normal breast median (range) P-valuea
Total 375 (100) 5.20 (0.73–115)
Age
50 74 (19.7) 4.79 (1.07–36.9) 0.098 (NS)
>50 301 (80.3) 5.26 (0.73–115)
SBR histological gradeb
I 37 (10.1) 4.78 (1.64–15.1) 0.14 (NS)
II 190 (51.9) 5.35 (1.20–81.8)
III 139 (38) 4.93 (0.73–115)
Lymph node statusc
0 103 (27.5) 4.89 (0.73–81.8) 0.30 (NS)
1–3 186 (49.7) 5.15 (1.07–87.6)
>3 85 (22.7) 5.40 (1.45–115)
Macroscopic tumor sized
25 mm 166 (45.1) 5.07 (1.07–36.9) 0.67 (NS)
>25 mm 202 (54.9) 5.26 (0.73–115)
ERa status
Negative 105 (28) 3.92 (0.73–36.9) 0.00000024
Positive 270 (72) 5.64 (1.20–115)
PR status
Negative 178 (47.5) 4.92 (0.73–81.8) 0.012
Positive 197 (52.5) 5.34 (1.20–115)
ERBB2 status
Negative 282 (75.2) 4.79 (0.73–115) 0.013
Positive 93 (24.8) 5.48 (1.40–87.6)
Molecular subtypes
HR-/ERBB2- 58 (15.5) 3.49 (0.73–21.5) <0.0000001
HR-/ERBB2þ 46 (12.3) 5.14 (1.40–36.9)
HRþ/ERBB2- 224 (59.7) 5.34 (1.20–115)
HRþ/ERBB2þ 47 (12.5) 7.40 (2.0–87.6)
PIK3CA mutation status
Wild type 259 (69.1) 5.26 (1.07–115) 0.51 (NS)
Mutated 116 (30.9) 4.91 (0.73–87.6)
KI67 mRNA expression rs ¼ 0.038
P ¼ 0.47 (NS)e
EGFR mRNA expression rs ¼ 0.264
P ¼ 0.0000012e
aMann–Whitney U-Test.
bScarff Bloom Richardson classification, information available for 366 patients.
cInformation available for 374 patients.
dInformation available for 368 patients.
eSpearman rank correlation.
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TPD52 and ERBB2 Expression in Breast Cancer Cell Lines
We selected a panel of 14 breast cancer cell lines
according to their predicted TPD52 amplification
status [30–33], assessed via the ROCK database
(http://rock.icr.ac.uk/), and MCF-10A cells as a non-
tumorigenic breast cell line, to compare TPD52 and
ERBB2 expression in cell lines with varying TPD52
levels, and select cell lines for further analysis. Real-
time (RT-) PCR and Western blot analyses revealed
differences in relative TPD52 copy number, transcript
and protein levels between the 15 breast cell lines
(Figure 2). Although the cell line cohort was small for
statistical analyses, four ERBB2-amplified cell lines
(SK-BR-3, AU-565, BT-474, ZR-75-30) showed signifi-
cantly higher relative TPD52 transcript and protein
Figure 1. Associations between TPD52 expression status and
metastasis-free survival of primary breast cancer patients. Kaplan–
Meier plots comparing metastasis-free patient survival (X axis, in
months) according to relative TPD52 expression status in (A) the overall
breast carcinoma cohort (n ¼ 375) and (B) the HRþ/ERBB2þ subgroup
(n ¼ 47). High relative TPD52 expression (shown in blue) was deﬁned
as more than 16.68-fold higher than median TPD52 expression in
normal breast tissue, set at 1.0. All other cases (low relative TPD52
expression) are represented in black. The numbers of patients
compared in each arm, and associated P-values (log rank tests) are
indicated.
Table 4. Multivariate Cox Analysis of Metastasis-Free
Survival in Breast Cancer Patients
Variables
Metastasis-free survival
HR (95% CI)a P-value
Lymph node status
0 1
1–3 1.58 (1.25–1.99) 0.00013
>3 2.49 (1.56–3.98)
Relative TPD52 expression
16.68 1
>16.68 2.69 (1.59–4.54) 0.00022
Macroscopic tumor size
25 mm 1
>25 mm 1.58 (1.13–2.21) 0.007
Progesterone receptor
negative 1
positive 0.71 (0.51–0.97) 0.032
aHazard ratio (HR) and 95% confidence interval (CI).
Figure 2. TPD52 copy number and expression status in breast cell
lines. Breast cell lines were subjected to quantitative real-time (RT)-PCR
to determine relative (A) TPD52 DNA copy number and (B) TPD52
transcript levels, both normalized against levels in MCF-10A cells.
Results shown are the means  SE from three independent experi-
ments performed in triplicate. (C) Representative Western Blot analysis
demonstrating TPD52 and ERBB2 levels. Left, proteins analysed. Right,
molecular weights of detected species. Results shown are representa-
tive of those obtained in at least three independent experiments. (D)
Densitometric analysis of TPD52 and ERBB2 levels in breast cell lines
from three independent experiments, as shown in (C). Mean intensities
(relative to GAPDH) of TPD52 (gray bars) or ERBB2 (black bars) are
plotted on the Y axis (SD), with breast cell lines shown on the X axis.
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levels than non-ERBB2-amplified cell lines (n ¼ 11;
Mann–Whitney test, P ¼ 0.006, n ¼ 15, TPD52 tran-
script levels; P ¼ 0.037, n ¼ 15, TPD52 protein levels;
Figure 2B–D), and significant or borderline positive
correlations were measured between ERBB2 protein
and TPD52 transcript or protein levels, respectively
(Spearman test, rs ¼ 0.681; P ¼ 0.005; n ¼ 15, TPD52
transcript levels; rs ¼ 0.513; P ¼ 0.051; n ¼ 15,
TPD52 protein levels). These associations were likely
driven by the inclusion of the TPD52-amplified
SK-BR-3 and AU-565 cell lines within this cohort.
Transient TPD52 and ERBB2 Depletion in Breast Cell Lines
We previously reported that transient TPD52
knock-down using three siRNA targets produced
significantly increased apoptotic cell death in SK-
BR-3 cells, but notMCF-7 cells [16]. SK-BR-3 cells show
high TPD52 copy number and expression, relative to
MCF-7 cells (Figure 2).We subsequently examined the
effects of transient TPD52 knock-down in the non-
TPD52-amplified cell lines MDA-MB-231 and MCF-
10A (Figure 2), using two TPD52 siRNAs previously
employed [16]. TPD52 depletion was not associated
with significantly increased apoptosis in either cell
line (data not shown).
As themajority of cell lines indicated to be sensitive
to the effects of TPD52 knock-down were either
ERBB2-amplified or positive for ERBB2 expression
[10,16], we directly compared the effects of TPD52
and ERBB2 knock-down, alone or in combination, in
the ERBB2-amplified and overexpressing cell lines
BT-474 and SK-BR-3, the latter cell line also being
TPD52-amplified (Figure 2A) [34]. Both SK-BR-3 and
BT-474 cells showed increased apoptosis following
ERBB2 knock-down, relative to non-targeting siRNA-
transfected cells (Figure 3). Quantitative apoptosis
assays and detection of cleaved PARP-1 indicated that
higher levels of apoptosis were produced by ERBB2
knock-down in BT-474 than SK-BR-3 cells (Figure 3),
which agrees with the reported effects of ERBB2
knock-down on the viability of these cell lines [10].
SK-BR-3 and BT-474 cells showed similar significant
increases in apoptosis following TPD52 knock-down
(Figure 3), despite their differing TPD52 levels
Figure 3. Transient TPD52 and ERBB2 knock-down in ERBB2-
ampliﬁed cell lines. SK-BR-3 (A) or BT-474 cells (B) were treated with
TPD52 (siD52-1) and/or ERBB2 siRNA (siERBB2) or non-targeting siRNA
(siControl) for 72 h, and harvested for apoptosis assays and Western
blot analyses. Doxorubicin treatment of BT-474 (1 mM, 72 h; Dox) was
used as a positive apoptosis control. The effects of siRNA treatment
were assessed after 72 h using a Cell Death Detection ELISAPLUS kit
(Roche). Results were expressed as enrichment factors normalized
against TKO results, and means  SE are presented for three
independent experiments done in duplicate. Signiﬁcant differences
between the mean enrichment factors measured following TPD52
and/or ERBB2 knock-down versus other treatments are indicated
(P < 0.05, P < 0.001, n.s., not signiﬁcant, Student's t-test). TPD52,
pERBB2, ERBB2, cleaved PARP-1, pAKT, and pMAPK levels were
determined using Western blot analyses. Images shown are represen-
tative of those obtained in three independent experiments. Left,
proteins analysed. Right, molecular weights of detected species.
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(Figure 2C). SK-BR-3 cells showed similar sensitivity to
both TPD52 and ERBB2 knock-down, and knock-
down of both genes produced significantly higher
levels of apoptosis, comparedwith the knock-down of
either gene alone (Figure 3A). Transient TPD52 knock-
downdid not reproducibly alter total or pERBB2 levels
in either cell line, and similarly ERBB2 knock-down
did not alter TPD52 levels (Figure 3).
Overexpression of TPD52 isoforms in LnCaP pros-
tate cancer cells has been reported to result in
increased pAKT (pSer473) [35–37]. While ERBB2
knock-down was associated with reduced pAKT levels
in both BT-474 and SK-BR-3 cells as anticipated [38],
pAKT levels were unchanged by TPD52 knock-down
(Figure 3). There were similarly no changes to
pMAPK44/42 levels upon transient TPD52 knock-
down (Figure 3).
Subcellular Distributions of TPD52 and ERBB2 in SK-BR-3
Cells
To further investigate the significance of TPD52 and
ERBB2 co-expression in SK-BR-3 cells, we compared
the distributions of both proteins using indirect
immunofluorescence analyses. Detection of both
proteins reproduced their expected subcellular dis-
tributions [11,39], with TPD52 and ERBB2 co-locali-
zation being focally limited towards the cell
membrane (Figure 4). The lack of substantial co-
localization of TPD52 and ERBB2 in SK-BR-3 cells
supports the non-overlapping signaling effects of
TPD52 and ERBB2 knock-down in ERBB2-amplified
cell lines (Figure 3).
Generation and Analysis of Stably TPD52-Depleted SK-BR-
3 Cell Lines
As transient TPD52 and ERBB2 knock-down had
comparable effects in SK-BR-3 cells, we investigated
the long-term effects of TPD52 depletion in this cell
line using TPD52 shRNA targets (Additional file 1).
Cell lines were harvested during early propagation in
24 wells (termed early passage cells, Figure 5A) and re-
harvested at passage 10 (Additional file 1, Figure 5B).
Immunofluorescence (Additional file 1, data not
shown) and Western blot analyses (Additional file 1,
Figure 5A and B, data not shown) confirmed reduced
TPD52 expression in shRNA-D52-2 and shRNA-D52-
3-transfected cell lines, compared with non-targeting
control and parental cells. shRNA-D52-3 transfected
cells reproducibly showed greater, more temporally
stable reductions in TPD52 expression than shRNA-
D52-2 transfected cells (Additional file 1, Figure 5A
and B, data not shown). Increased cleaved PARP-1
levels were detected in early passage TPD52-depleted
cells (Figure 5A), in accordance with the results of
transient TPD52 knock-down in SK-BR-3 cells
(Figure 3A).
Depletion of TPD52 by 40–90% in early passage
cells was associated with increased pERBB2 but not
Figure 4. Limited co-localization of TPD52 and ERBB2 in SK-BR-3
cells. Immunoﬂuorescence images of SK-BR-3 cells co-stained with
TPD52 monoclonal antibody (red) and ERBB2 polyclonal antisera
(green) and combined images on the right (Merge). Representative
images are shown from the top and middle sections of the same cell
groups.White arrows show co-localization between TPD52 and ERBB2.
Images were taken using a TCS SP2 confocal laser scanning upright
microscope (Leica Technologies) using a 63X objective.
Figure 5. Analysis of stably TPD52-depleted SK-BR-3 cell lines.
Western blot analyses of total protein extracts from untreated SK-BR-3
cells and SK-BR-3 cell lines stably transfected with non-targeting
control, shRNA-D52-2 (cell line A) or shRNA-D52-3 shRNAs (cell lines
B–D) and harvested at early passage (A) or at passage 10 (B). Images
shown are representative of those obtained in three independent
experiments. Left, proteins analysed. Right, molecular weights of
detected species. (C) Scatter plot comparing mean TPD52 (X axis) and
pERBB2 levels (Y axis) measured in untreated, non-target control and
stably TPD52-depleted SK-BR-3 cell lines. Open circles represent values
obtained for early passage cells, whereas black circles represent values
obtained for cell lines at passage 10. Densitometric values were
obtained through the analysis of three replicate Western blots,
normalized to the loading control GAPDH, and then to levels measured
in untreated cells, set at 1.0.
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total ERBB2 levels, relative to controls (Figure 5A and
C). At passage 10, TPD52 levels remained reduced by
50–90% in TPD52-depleted cell lines, and pERBB2
expression remained increased by 2-fold (Figure 5B
and C). Passage 10 cell lines with lower TPD52 levels
showed higher pERBB2 levels (Figure 5B, cell lines B
and D), whereas cell lines which had partially
recovered TPD52 expression showed lower pERBB2
levels (Figure 5B, cell lines A and C). Overall,
significant inverse correlations were measured be-
tween mean TPD52 and pERBB2 levels, relative to
levels measured in untreated cells, both in early
passage and passage 10 cells, and in these groups
combined (Spearman test, rs ¼ 0.886, P ¼ 0.019,
n ¼ 6, early passage; rs ¼ 0.943, P ¼ 0.005, n ¼ 6,
passage 10, rs ¼ 0.846, P ¼ 0.001, n ¼ 12, combined
groups; Figure 5C). While no changes in pAKT or
pMAPK levels were noted in early passage cell lines
(Figure 5A), increased pERBB2 levels were accompa-
nied by 2–4-fold increased pAKT but not pMAPK
levels in 3/4 TPD52-depleted cell lines harvested at
passage 10 (Figure 5B). Previously, stably reduced
TPD52 in C4-2 prostate cancer cells was associated
with reduced cell proliferation [37]. In contrast, MTT
assays performed over 3 d revealed that all stably
TPD52-depleted SK-BR-3 cell lines proliferated at
similar rates as untreated or non-targeting control
cells (Figure 6).
DISCUSSION
The oncogene addiction hypothesis predicts that
tumors bearing amplification of a given oncogenewill
be usually sensitive to the removal of that gene’s
expression or function [40]. Demonstrating that this
is the case identifies an oncogene as a driver of
tumorigenesis, whose disruption might play a major
role in stabilizing or removing disease. However,
the experimental study of amplification targets is
complicated by the fact that many genes may be
co-amplified, mutated or otherwise inactivated with-
in a given tumor system [1], and thus a single gene’s
effects may be enhanced or diluted by the presence of
other alterations. It seems clear that these factors
could also influence responses to targeted therapies,
but how this occurs is only beginning to be explored.
Numerous studies have reported co-expression of
TPD52 and ERBB2 [5–10], two gene amplification
targets in breast cancer. in the present study, we
demonstrate that TPD52 and ERBB2 co-expression is
both functionally and clinically significant. Firstly,
ERBB2-positive diagnostic breast tumors expressed
significantly higher TPD52 levels than ERBB2-nega-
tive tumors, and high-level TPD52 expression was
associated with significantly poorer metastasis-free
survival, both in the overall cohort, the large HR þ /
ERBB2 sub-group, and the smaller HR þ /ERBB2þ
subgroup in which TPD52 expression was highest.
Secondly, acute TPD52 knock-down produced signif-
icant cell death in cell lines amplified for ERBB2 via a
mechanism independent of AKT signaling. Finally,
stable TPD52 depletion in TPD52- and ERBB2-ampli-
fied SK-BR-3 cell lines was associated with significant
inverse correlations between TPD52 and pERBB2
levels, indicating that ERBB2-amplified cells may
compensate for reduced TPD52 levels by increasing
ERBB2 signaling. These combined results indicate
that TPD52may co-operate with ERBB2 in promoting
tumorigenesis and/or progression, by enhancing
breast cancer cell survival.
Cancer cells have previously shown differing
sensitivities to TPD52 knock-down, although the
reasons for this have not been directly examined
[10,16]. In the present study, the ERBB2-amplified SK-
BR-3 and BT-474 cell lines showed very similar
increases in apoptosis in response to reduced TPD52
expression, despite theirmarked differences in TPD52
expression and relative TPD52 copy numbers. This
indicates that cellular responses to TPD52 knock-
down may be partly determined by ERBB2 status.
Transient TPD52 isoform knock-down also produced
increased cell death in LnCaP prostate cancer cells
[36], and in the androgen-independent derivative cell
line C4-2 [35,37]. As both LnCaP and C4-2 cells
express ERBB2 [41–43] the consequences of TPD52
knock-down in these cell lines are consistent with
TPD52 promoting the survival of ERBB2-positive
cancer cells. However, Kourtidis et al. [10] also
reported that the ERBB2-negative breast cancer cell
line MDA-MB-468 showed similar reductions in
viability to TPD52 knock-down as ERBB2-amplified
and/or -expressing cell lines. Thus it would appear
that ERBB2 amplification or expression, and other
factors yet to be determined, confer sensitivity to
TPD52 depletion in cancer cells.
Other consequences of TPD52 knock-down were
different from those which would have been pre-
dicted by previous results. TPD52 isoform overex-
pression in LnCaP prostate cancer cells resulted in
Figure 6. Proliferation of stably TPD52-depleted SK-BR-3 cell lines.
Cell proliferation was quantiﬁed using MTT assays, in SK-BR-3 cells
stably depleted of TPD52 (using shRNA-D52-2 or shRNA-D52-3
shRNAs), and in untreated or non-targeting (non-target) control cells.
Values plotted are means  SE for three independent experiments
done in triplicate.
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increased pAKT levels [35–37] and reduced TPD52
expression in C4-2 cells led to reduced pAKT levels
[37]. However, in the present study, transient TPD52
knock-down did not alter pAKT levels in SK-BR-3 or
BT-474 cells. The siRNA targets employed in both the
present study and that of Zhang et al. [37] bind
sequences that are common to PrLZ and TPD52
transcripts, and therefore the different results ob-
tained are unlikely to reflect differential targeting of
PrLZ versus TPD52. These could however highlight
functional differences between PrLZ and TPD52 in
prostate versus breast cancer cells, or other differences
between the particular cell lines examined. The fact
that ERBB2 but not TPD52 knock-down resulted in
reduced pAKT levels indicates that TPD52 regulates
cell survival independently of AKT signaling in
ERBB2-amplified breast cancer cells.
Longer term gene knock-down experiments can
highlight whether and how cells adapt to reduced
gene function. We examined the longer term effects
of TPD52 knock-down in SK-BR-3 cells, as these cells
have similar TPD52 and ERBB2 copy numbers [34],
and were similarly sensitive to transient TPD52 and
ERBB2 knock-down. While TPD52 depletion led to
increased cell death in the short term, TPD52-
depleted cell lines that remained viable over 10
passages showed increased ERBB2 signaling, with
most also showing increased pAKT levels. As TPD52-
depleted cell lines showed very similar proliferation to
controls, increased pERBB2 and pAKT levels likely
represent compensatory mechanisms to escape the
consequences of reduced TPD52 levels. It seems
unlikely that PrLZ upregulation occurred in response
to TPD52 depletion, as the shRNA targets employed
bind sequences common to PrLZ and TPD52 tran-
scripts, and the TPD52 antisera employed detect an
epitope shared by TPD52 and PrLZ [44]. This contrasts
with the reported effects of stably reducing PrLZ/
TPD52 expression in C4-2 cells, which was associated
with reduced cell proliferation and colony-forming
capacity [37]. Given the many differences between
SK-BR-3 andC4-2 cells, it is not unexpected that stable
TPD52 depletion produced different responses in
these cell lines over time. It is possible that reducing
TPD52 levels in SK-BR-3 cells requires adaptive
changes for cells to remain viable, and/or that
ERBB2 amplification may allow SK-BR-3 cells to
more readily adapt to reduced TPD52 levels. Sequenc-
ing of the SK-BR-3 genome revealed that 3 regions of
chromosome 8q, one of which includes TPD52, are
co-amplified with chromosome 17q [45], in agree-
ment with the similar copy numbers reported for
TPD52 and ERBB2 in SK-BR-3 cells using next-
generation sequencing [34]. Co-amplification of
TPD52 and ERBB2 in SK-BR-3 cells may partially
explain the similar effects of transient TPD52 or
ERBB2 knock down in this cell line, and is consistent
with SK-BR-3 cells relying upon both proteins for
survival. It will be important to examine the effects of
stable TPD52 depletion in a broader range of TPD52-
amplified cancer cell lines with and without ERBB2
amplification, but these need to be identified for such
work to proceed.
It is tempting to speculate as to how TPD52 and
ERBB2 co-operate in cancer cells, although the
current poor understanding of TPD52’s molecular
functions renders this difficult. The significant posi-
tive correlation between relative TPD52 and ERBB2
levels in breast cancer samples measured in the
present study, combined with previous reports of
TPD52 and ERBB2 co-expression [5–10], suggest that
TPD52 might regulate ERBB2 expression, or vice
versa. However, neither transient nor stable TPD52
depletion reproducibly altered total ERBB2 levels, and
transient ERBB2 knock-down did not measurably
affect TPD52 levels in BT-474 or SK-BR-3 cells.
Similarly, there was no evidence that short-term
TPD52 depletion altered pERBB2 levels, indicating
that TPD52 does not directly regulate ERBB2 signal-
ing, although an inverse relationship between TPD52
and pERBB2 levels emerged in stably TPD52-depleted
versus control SK-BR-3 cell lines. The latter associa-
tion, combined with the lack of substatial co-
localization between TPD52 and ERBB2 in SK-BR-3
cells, and the different signaling consequences of
transient TPD52 and ERBB2 knock-down, suggest that
TPD52 and ERBB2 co-operation occurs indirectly.
ERBB2 is a powerful oncogene on account of its
pleiotrophic effects on cellular proliferation and
survival [3]. It is therefore likely that TPD52 promotes
similar phenotypes through independent mecha-
nisms, which are yet to be identified.
Increased TPD52 immunohistochemical staining
has been associated with reduced overall survival in
breast cancer patients [16], and TPD52 has been
included in gene expression signatures associated
with poor prognosis [17–19]. In the present study, a
>16.68 relativeTPD52 expression cut-pointmaximal-
ly discriminated patients that did or did not develop
metastases, identifying a 5.9% subgroup with high-
level TPD52 expression and reduced metastasis-free
survival. This proportion of patients is very similar to
the 5.8–6.2% of breast cancers in TCGA cohorts that
are TPD52-amplified (http://www.cbioportal.org/
public-portal/). This suggests that TPD52-amplified
breast cancers may be a clinically relevant subgroup
which show reducedmetastasis-free survival, which is
also supported by TPD52 gain being included in a
copy number signature that identified breast cancer
patients with increased probability of distant metas-
tasis [20]. The poorer metastasis-free survival of
patients with tumors with high-level TPD52 expres-
sion, combined with the demonstration that ERBB2-
amplified cell lines rely upon TPD52 for survival,
indicates that TPD52 overexpression could conceiv-
ably promote tumor resistance towards ERBB2-target-
ted therapies, particularly as TPD52 was indicated to
regulate cell survival independently of ERBB2. In a
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broader sense, our results also suggest that pathways
regulated by highly amplified oncogenes represent
obvious escape routes from the effects of targeted
therapies. Further research into oncogene co-
amplificationmay therefore help to understand these
escape mechanisms, and to translate such results to
the clinic.
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SUPPORTING INFORMATION
Additional supporting information may be found
in the online version of this article at the publisher’s
web-site.
Additional file 1 Generation of stably TPD52-
depleted SK-BR-3 cell lines. (A) Schematic dia-
gram of TPD52 coding region showing the positions
of shRNA targets (shRNA-D52-2 and shRNA-D52-3).
Numbers represent exons, with exons 1a, 1b, 5 and 6
being subject to alternative splicing. Exons 1a and 1b
are included in TPD52 and PrLZ transcripts, respec-
tively. (B) Immunofluorescence images of SK-BR-3
cells stably transfected with shRNA-D52 (shRNA-D52-
2-A or shRNA-D52-3-D) or non-target shRNA cultured
at passage 10. Cells were stained with human TPD52
monoclonal antibody (top row, red). shRNA contructs
were also GFP-tagged (bottom row, green). Images
were taken using a TCS SP2 confocal laser scanning
upright microscope (Leica Technologies) using a 63X
objective. (C) TPD52 levels in SK-BR-3 cell lines
stably transfected with shRNA-D52 (shRNA-D52-2-A
and shRNA-D52-3-D) and non-target shRNAs as
assessed by Western blot analyses at passage 10.
Left, proteins analysed. Right, molecular weights of
detected species.
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